MCID: ALC007
MIFTS: 65

Alcohol Dependence

Categories: Cancer diseases, Genetic diseases, Mental diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Alcohol Dependence

MalaCards integrated aliases for Alcohol Dependence:

Name: Alcohol Dependence 57 11 75 28 5 14 38 33
Alcoholism 57 11 53 14 33
Aerodigestive Tract Cancer, Squamous Cell, Alcohol-Related, Protection Against 57 5
Alcohol Dependence, Protection Against 57 12
Alcohol Dependence, Susceptibility to 57 5
Alcoholic Intoxication, Chronic 71
Alcoholism, Susceptibility to 5
Chronic Alcoholic Disease Nos 33
Alcoholic Disease Nos 33
Pharyngeal Neoplasms 71
Chronic Alcoholism 33
Ethanol Dependence 33
Chronic Ethanolism 33
Alcohol Addiction 33
Dipsomania 33
Alcoholic 33

Characteristics:


Inheritance:

Probably multifactorial genetically influenced 57

Classifications:



External Ids:

Disease Ontology 11 DOID:0050741
OMIM® 57 103780
SNOMED-CT 68 66590003
MedGen 40 C0001973
UMLS 71 C0001973 C0031347

Summaries for Alcohol Dependence

Disease Ontology: 11 A substance dependence that is characterized by tolerance, withdrawal symptoms, increasing use, persistent desire to decrease consumption, time spent obtaining or recovering from alcohol caused by a physical and psychological dependence on alcohol.

MalaCards based summary: Alcohol Dependence, also known as alcoholism, is related to alcohol use disorder and personality disorder. An important gene associated with Alcohol Dependence is GABRA2 (Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Metapathway biotransformation Phase I and II. The drugs Lenograstim and Alogliptin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and prefrontal cortex, and related phenotypes are alcoholism and no effect

Wikipedia: 75 Alcohol dependence is a previous (DSM-IV and ICD-10) psychiatric diagnosis in which an individual is... more...

More information from OMIM: 103780

Related Diseases for Alcohol Dependence

Diseases related to Alcohol Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1650)
# Related Disease Score Top Affiliating Genes
1 alcohol use disorder 33.9 SLC6A4 SLC6A3 OPRM1 MAOA GABRA2 DRD2
2 personality disorder 32.3 SLC6A4 SLC6A3 NRXN3 MAOA HTR2A DRD2
3 substance dependence 32.2 SLC6A4 SLC6A3 OPRM1 OPRK1 MAOA HTR2A
4 substance abuse 32.2 SLC6A4 SLC6A3 OPRM1 OPRK1 MAOA HTR2A
5 anxiety 32.2 SLC6A4 SLC6A3 OPRM1 OPRK1 MAOA HTR2A
6 post-traumatic stress disorder 32.1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
7 drug dependence 32.1 SLC6A4 SLC6A3 OPRM1 OPRK1 MAOA GABRA2
8 major depressive disorder 32.1 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A DRD2
9 tobacco addiction 32.1 TAS2R16 SLC6A4 SLC6A3 OPRM1 NRXN3 MAOA
10 bipolar disorder 32.0 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A GABRA2
11 withdrawal disorder 32.0 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
12 antisocial personality disorder 31.9 SLC6A4 SLC6A3 MAOA HTR2A GABRA2 DRD2
13 psychotic disorder 31.9 SLC6A4 SLC6A3 OPRM1 NRXN3 MAOA HTR2A
14 conduct disorder 31.9 SLC6A4 SLC6A3 MAOA GABRA2 DRD2 ALDH2
15 attention deficit-hyperactivity disorder 31.9 SLC6A4 SLC6A3 OPRM1 NRXN3 MAOA HTR2A
16 cocaine dependence 31.8 SLC6A4 SLC6A3 OPRM1 OPRK1 GABRA2 DRD2
17 mood disorder 31.8 SLC6A4 SLC6A3 MAOA HTR2A DRD2
18 opiate dependence 31.8 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
19 social phobia 31.7 SLC6A4 SLC6A3 MAOA HTR2A DRD2
20 schizophrenia 31.7 SLC6A4 SLC6A3 OPRM1 NRXN3 MAOA HTR2A
21 panic disorder 31.6 SLC6A4 SLC6A3 MAOA HTR2A DRD2
22 pathological gambling 31.5 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A DRD2
23 brunner syndrome 31.5 SLC6A4 MAOA HTR2A
24 liver cirrhosis 31.5 CYP2E1 ALDH2 ADH1C ADH1B
25 borderline personality disorder 31.5 SLC6A4 SLC6A3 NRXN3 MAOA HTR2A DRD2
26 generalized anxiety disorder 31.4 SLC6A4 MAOA HTR2A DRD2
27 sleep disorder 31.4 SLC6A4 SLC6A3 HTR2A
28 dysthymic disorder 31.4 SLC6A4 SLC6A3 MAOA HTR2A
29 agoraphobia 31.3 SLC6A4 MAOA HTR2A
30 acute stress disorder 31.3 SLC6A4 HTR2A
31 eating disorder 31.3 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2
32 bulimia nervosa 31.3 SLC6A4 SLC6A3 MAOA HTR2A DRD2
33 obsessive-compulsive disorder 31.2 SLC6A4 SLC6A3 MAOA HTR2A DRD2
34 alcoholic cardiomyopathy 31.2 CYP2E1 ALDH2 ADH7 ADH1B
35 hepatic encephalopathy 31.2 OPRM1 MAOA DRD2
36 alcoholic liver cirrhosis 31.2 CYP2E1 ALDH9A1 ALDH2 ADH1C ADH1B
37 alexithymia 31.2 SLC6A4 HTR2A DRD2
38 cocaine abuse 31.2 SLC6A4 SLC6A3 OPRM1 OPRK1 HTR2A DRD2
39 oppositional defiant disorder 31.2 SLC6A4 SLC6A3 MAOA HTR2A GABRA2 DRD2
40 disease of mental health 31.1 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A DRD2
41 alzheimer disease, familial, 1 31.1 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A DRD2
42 endogenous depression 31.1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
43 paranoid schizophrenia 31.1 SLC6A4 MAOA HTR2A DRD2
44 gilles de la tourette syndrome 31.1 SLC6A4 SLC6A3 NRXN3 MAOA HTR2A DRD2
45 bipolar i disorder 31.0 SLC6A4 HTR2A DRD2
46 heroin dependence 30.9 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A DRD2
47 anorexia nervosa 30.9 SLC6A4 MAOA HTR2A DRD2
48 fetal alcohol syndrome 30.9 CYP2E1 ALDH2 ADH7 ADH4 ADH1C ADH1B
49 narcolepsy 30.9 SLC6A3 MAOA HTR2A DRD2
50 tic disorder 30.9 SLC6A4 SLC6A3 NRXN3 MAOA HTR2A DRD2

Graphical network of the top 20 diseases related to Alcohol Dependence:



Diseases related to Alcohol Dependence

Symptoms & Phenotypes for Alcohol Dependence

Human phenotypes related to Alcohol Dependence:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 alcoholism 30 HP:0030955

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Neuro:
alcoholism

Misc:
25 to 50% lifetime risk for sons and brothers of severely alcoholic men

Clinical features from OMIM®:

103780 (Updated 24-Oct-2022)

GenomeRNAi Phenotypes related to Alcohol Dependence according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ADH1B ADH1C ADH4 ADH7 ALDH2 ALDH9A1
2 no effect GR00402-S-2 10.18 ADH1B ADH1C ADH4 ALDH2 CHRNA6 CYP2E1

MGI Mouse Phenotypes related to Alcohol Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 ADH7 ALDH2 CHRNA6 DRD2 GABRA2 LAMA2
2 behavior/neurological MP:0005386 9.4 ADH7 ALDH2 CYP2E1 DRD2 GABRA2 HTR2A

Drugs & Therapeutics for Alcohol Dependence

Drugs for Alcohol Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 642)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Alogliptin Approved Phase 4 850649-61-5 11450633
3
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
4
Ledipasvir Approved Phase 4 1256388-51-8 67505836
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Glycyrrhizic acid Approved, Experimental Phase 4 1405-86-3 3495 14982
7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
8
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
9
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Lorazepam Approved Phase 4 846-49-1 3958
12
Sodium oxybate Approved Phase 4 502-85-2 23663870
13
Oxazepam Approved Phase 4 604-75-1 4616
14
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
15
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
18
Ondansetron Approved Phase 4 99614-02-5 4595
19
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
20
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
21
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
22
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
23
Ribavirin Approved Phase 4 36791-04-5 37542
24
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
25
Benzyl alcohol Approved Phase 4 100-51-6 244
26
Chlorzoxazone Approved Phase 4 95-25-0 2733
27
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
28
Adenosine Approved, Investigational Phase 4 58-61-7 60961
29
Tocopherol Approved, Investigational Phase 4 1406-66-2
30
Povidone-iodine Approved Phase 4 25655-41-8
31
Gliclazide Approved Phase 4 21187-98-4 3475
32
Glimepiride Approved Phase 4 93479-97-1 3476
33
Montelukast Approved Phase 4 158966-92-8 5281040
34
Insulin detemir Approved Phase 4 169148-63-4 16137271
35
Insulin aspart Approved Phase 4 116094-23-6 16132418
36
Phentermine Approved, Illicit Phase 4 122-09-8 4771
37
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
38
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
39
Baclofen Approved Phase 4 1134-47-0 2284
40
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
41
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
42
Dapagliflozin Approved Phase 4 461432-26-8 9887712
43
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
44
Calcium carbonate Approved, Investigational Phase 4 471-34-1
45
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
46
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
47
Dulaglutide Approved, Investigational Phase 4 923950-08-7
48
Denosumab Approved Phase 4 615258-40-7
49
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
50
Nalmefene Approved, Investigational, Withdrawn Phase 4 55096-26-9 4422 5284594

Interventional clinical trials:

(showing 2614, show less)
# Name Status NCT ID Phase Drugs
1 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
2 The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
3 Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study Unknown status NCT01135602 Phase 4 Topiramate
4 Prospective Assessment of Valproate on Ethanol Withdrawal Unknown status NCT03235531 Phase 4 Valproate;Lorazepam
5 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4 antabuse (disulfiram)
6 Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study Unknown status NCT02596763 Phase 4 Baclofen
7 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
8 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
9 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Unknown status NCT04465032 Phase 4
10 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Unknown status NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
11 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
12 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
13 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
14 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline
15 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Unknown status NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
16 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
17 Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis Unknown status NCT03703674 Phase 4 GCSF
18 A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection Unknown status NCT02759861 Phase 4 harvoni
19 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
20 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
21 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis - a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
22 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
23 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
24 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
25 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
26 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
27 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Completed NCT01749215 Phase 4 Topiramate;placebo
28 Pharmacogenetic Response to Naltrexone for Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
29 Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
30 The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
31 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
32 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
33 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI): An Open Prospective Pilot Trial Completed NCT00453609 Phase 4 long-lasting injectable naltrexone
34 Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study Completed NCT00620750 Phase 4 Extended release injectable naltrexone (Vivitrol)
35 Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence Completed NCT00435435 Phase 4 Disulfiram;Acamprosate;Naltexone
36 Sertraline for Alcohol Dependence and Depression Completed NCT00004554 Phase 4 naltrexone (Revia);sertraline (Zoloft);Placebo
37 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
38 Etiology and Treatment of Alcohol Dependence Completed NCT00000442 Phase 4 naltrexone (Revia)
39 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
40 A Double-Blind Placebo-Controlled Trial of Prazosin for the Treatment of Alcohol Dependence Completed NCT00167687 Phase 4 prazosin
41 Double Blind Placebo Controlled Randomized Clinical Trial of Pregabalin for Alcohol Dependence Completed NCT02205879 Phase 4 Pregabalin;Placebo
42 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
43 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
44 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
45 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
46 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
47 Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study Completed NCT00381043 Phase 4 Acamprosate (Campral)
48 Nalmefene in Nicotine and Alcohol Dependence Completed NCT00000437 Phase 4 Naltrexone Tablet and Nicotine Patch;Naltrexone Tablet and Placebo Patch;Placebo Tablet and Nicotine Patch;Placebo Tablet and Placebo Patch
49 A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence Completed NCT01015586 Phase 4 Lamotrigine;Placebo
50 Primary Care Based Disease Management for Alcohol Dependence Completed NCT00419315 Phase 4
51 SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis Completed NCT02504931 Phase 4 Sertraline;Placebo
52 Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial Completed NCT00727103 Phase 4 Varenicline;Placebo
53 Placebo Controlled Pilot Study of Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
54 Identifying Multiple Mechanisms of Change in Alcoholism Treatment Completed NCT01168960 Phase 4
55 Multinational, Multicentre, Double-blind, Placebo-controlled Evaluation of the Efficacy of GHB in the Long-term Maintenance of Abstinence in Alcoholic Patients After the Initial Weaning Phase, Stratified by Lesch's Taxonomy (GATE 2) Completed NCT04648423 Phase 4 Sodium Oxybate;Placebo
56 The Effects of VIVITROL® on Alcohol-Related Cue-Induced Craving and BOLD [Blood Oxygen-level-dependent] Functional Magnetic Resolution Imaging (fMRI) Signal Activation Patterns Completed NCT00511836 Phase 4 VIVITROL 380 mg;Placebo
57 Combined Pharmacotherapy in Depressed Alcoholics Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
58 A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder Completed NCT00466661 Phase 4 Acamprosate;Placebo
59 A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
60 Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response Completed NCT00366626 Phase 4 Naltrexone;Placebo
61 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
62 Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder Completed NCT00006489 Phase 4 Naltrexone;Placebo
63 Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
64 Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment Completed NCT02197598 Phase 4 nalmefene
65 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
66 Comparison of Cognitive Behavioral Therapy and Motivational Enhancement Therapy Plus Naltrexone for Alcoholism Completed NCT00000456 Phase 4 naltrexone (Revia)
67 Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients and Its Effect on Quality of Life, Clinical and Psychosocial Features: A 12-Week Double-Blind Randomized Controlled Trial Completed NCT01002105 Phase 4 Baclofen
68 Randomized, Open-label Clinical Trial of Extended-Release vs. Oral Naltrexone for Alcohol Treatment in Primary Care. Completed NCT01893827 Phase 4 XR-NTX (Extended-Release Naltrexone);Oral Naltrexone (O-NTX)
69 Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life Completed NCT02445339 Phase 4 XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
70 Dutasteride Treatment for the Reduction of Heavy Drinking Completed NCT01758523 Phase 4 Dutasteride;sugar pill
71 Oral v. Injection Naltrexone in Hospital: Comparative Effectiveness for Alcoholism Completed NCT02478489 Phase 4 Oral naltrexone (PO-NTX);Extended-release injectable naltrexone (XR-NTX)
72 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
73 Field Study of Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
74 Nalmefene Maintenance Treatment of Alcoholism Completed NCT00000450 Phase 4 Naltrexone Tablet;Matched Placebo Tablet
75 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
76 Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism Completed NCT00368862 Phase 4 Ebixa (memantine hydrochloride);Cipralex (escitalopram)
77 Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism Completed NCT00115037 Phase 4 Naltrexone;placebo
78 Naltrexone Treatment for Alcoholism: Predicting Outcome Completed NCT00000438 Phase 4 naltrexone (Revia)
79 Individually Adapted Therapy of Alcoholism: Clinical Studies Completed NCT00317031 Phase 4 Acamprosate or Naltrexone
80 A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
81 Alcohol Detoxification in Primary Care Treatment (ADEPT) - a Feasibility Study of Conducting a Randomised Trial in Primary Care Comparing Two Pharmacological Regimens. Completed NCT00855699 Phase 4 Acamprosate
82 Defining an Endopheneotype for Alcohol Treatment With Naltrexone Completed NCT00817089 Phase 4 Placebo Oral Tablet;Naltrexone
83 The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects Completed NCT00329407 Phase 4 Topiramate (Topamax)
84 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
85 Combination Nicotine Replacement for Alcoholic Smokers Completed NCT00064844 Phase 4 Nicoderm CQ nicotine patch;Placebo gum;Nicotine gum - Nicorette®
86 Naltrexone, Craving, and Drinking: Ecological Assessment Completed NCT00006203 Phase 4 naltrexone (Revia)
87 Acamprosate and Integrative Behavior Therapy in the Outpatient Treatment of Alcohol Dependents Completed NCT00159107 Phase 4 Acamprosate;Placebo
88 Post-Treatment Effects of Naltrexone Completed NCT00006449 Phase 4 naltrexone (Revia)
89 Coping, Exposure, and Naltrexone Treatment With Alcoholics Completed NCT00000449 Phase 4 naltrexone (Revia)
90 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
91 Carbamazepine and Lorazepam in Outpatient Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
92 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
93 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
94 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
95 Mood Management Training for Alcohol Dependent Smokers Completed NCT00004551 Phase 4 nicotine replacement patch
96 The Effectiveness of Benfotiamine in Reducing Abusive Drinking Among Family History Positive and Negative Alcoholics Completed NCT00680121 Phase 4 Benfotiamine;Placebo
97 Targeted Naltrexone for Early Problem Drinkers Completed NCT00000455 Phase 4 naltrexone
98 Timing of Smoking Intervention in Alcohol Treatment Completed NCT00000444 Phase 4 nicotine replacement patch
99 The Effects of Levetiracetam on Alcohol Dependent Subjects Completed NCT00325182 Phase 4 Levetiracetam
100 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
101 The Treatment of Late Life Major Depression Complication by Alcohol Completed NCT00018824 Phase 4 NALTREXONE;Placebo
102 Behavioral/Pharmacological Treatments for Alcohol-Nicotine Dependence Completed NCT00000447 Phase 4 naltrexone (Revia);nicotine replacement patch
103 Effectiveness of Naltrexone in a Community Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
104 Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder Completed NCT01377168 Phase 4 oral naltrexone;Placebo pill
105 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed NCT02082678 Phase 4 Ondansetron;Placebo
106 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
107 Smoking Cessation in a Drug Treatment Program: A Randomized Trial of Varenicline Versus Placebo. Completed NCT01286584 Phase 4 varenicline;placebo
108 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial Completed NCT00190957 Phase 4 Atomoxetine;placebo
109 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
110 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
111 Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder Completed NCT02735577 Phase 4 Disulfiram
112 URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence Completed NCT03302299 Phase 4 Isoniazid 300 Mg ORAL TABLET;Pyridoxine 25 Mg Oral Tablet
113 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
114 Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST) Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
115 Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV Completed NCT01008280 Phase 4 baclofen;placebo
116 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. Completed NCT00223249 Phase 4 Quetiapine
117 Feasibility of Emergency Department Initiated Extended-Release Naltrexone and Case Management Services for the Treatment of Alcohol Use Disorder Completed NCT04094584 Phase 4 Vivitrol (Extended Release Naltrexone)
118 A Randomized Study to Compare the Efficacy of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Patients With Non-alcoholic Fatty Liver Disease Using (IL6 and CCL2) as a Predictors of Non-alcoholic Steatohepatitis Completed NCT04977661 Phase 4 Vitamin E;Ursodeoxycholic acid;Pentoxifylline
119 Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation Completed NCT01841242 Phase 4 alcoholic povidone iodine;alcoholic chlorhexidine
120 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Completed NCT01501162 Phase 4 hepatitis, alcohol, probiotics;alcohol, hepatitis, Placebo
121 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
122 Effectiveness of Pre-surgical Hand Washing in Reducing Bacterial Load, Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate Completed NCT04454619 Phase 4 Hand antisepsis with Clorhexidine and solution
123 A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases Completed NCT03910361 Phase 4 Evogliptin;Pioglitazone
124 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
125 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
126 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Completed NCT02649465 Phase 4 Tofogliflozin;Glimepiride
127 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
128 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
129 Assessment of Hepatic Function in Alcoholic Patients Administered Therapeutic Dosing of Acetaminophen- a Multicenter Study Completed NCT00402571 Phase 4 acetaminophen
130 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
131 Prevention of Central Venous Catheter Infections : Comparison of the Efficacy of Skin Disinfection With 5% Povidone Iodine in Alcoholic Solution Versus 0.25% Chlorhexidine, 0.025 Benzalkonium and 4% Benzylic Alcohol Completed NCT00259350 Phase 4 Skin disinfection
132 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
133 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
134 Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis Completed NCT02161653 Phase 4 Prednisone plus Metadoxine;Pentoxifylline plus Metadoxine
135 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
136 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
137 Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers Completed NCT00943696 Phase 4
138 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
139 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
140 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
141 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
142 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
143 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
144 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
145 Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients Completed NCT01413360 Phase 4 High dose vitamin C
146 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
147 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
148 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
149 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
150 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
151 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
152 Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation Completed NCT02859142 Phase 4 Chantix;NicodermCQ;Placebo
153 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;Vitamin E-placebo
154 Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release Formulation Recruiting NCT05028062 Phase 4 XR-NTX 380 mg, intramuscular injection;Placebo intramuscular injection
155 Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders Recruiting NCT02582905 Phase 4 Placebo;Citicoline;Pregnenolone
156 Baclofen Bij de Behandeling Van Acute Alcoholontwenning Recruiting NCT03293017 Phase 4 Diazepam 10 MG;Baclofen 30mg;Baclofen 60mg
157 Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome Recruiting NCT03818191 Phase 4 Acamprosate
158 Combined Active Treatment in Type 2 Diabetes With NASH Recruiting NCT04639414 Phase 4 Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector;Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide;Placebo matching empagliflozin and placebo pen injector matching semaglutide
159 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Recruiting NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
160 The Efficacy and Safety of Ornithine Aspartic Acid Granules in Non-Alcoholic Fatty Liver Disease Against Silymarin Capsules: a Randomized, Double-Blind, Multicenter Clinical Trial Recruiting NCT05042245 Phase 4 Ornithine aspartate granule;Silymarin capsule;Silymarin capsule simulant;Ornithine aspartate granule simulant
161 Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases: A Randomized Placebo-controlled Clinical Trial Recruiting NCT04475276 Phase 4 Placebo;Alphalipoic acid
162 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
163 Efficacy and Safety of Dapagliflozin Compared to Pioglitazone in Diabetic and Non-diabetic Patients With Non-alcoholic Steatohepatitis Recruiting NCT05254626 Phase 4 Dapagliflozin 10Mg Tab;Pioglitazone 30 mg
164 Quantitation of Hepatic Mitochondrial Fluxes in Humans With Nonalcoholic Fatty Liver Disease (NAFLD) Recruiting NCT05305287 Phase 4 Pioglitazone
165 The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD) Recruiting NCT05459701 Phase 4 Dapagliflozin 10mg Tab
166 Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial Recruiting NCT04976283 Phase 4 Pioglitazone;Empagliflozin;Pioglitazone + Empagliflozin
167 Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography Active, not recruiting NCT03314454 Phase 4 Beer
168 Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial Active, not recruiting NCT04642261 Phase 4 Empagliflozin 10 MG;Placebo pills
169 Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion Active, not recruiting NCT02500147 Phase 4 Metformin;Placebo
170 A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder Not yet recruiting NCT05408247 Phase 4 N-acetyl cysteine;Placebo
171 In Hospital Administration of Extended-Release Naltrexone for Alcohol Use Disorder: A Pilot Study of Feasibility and Acceptability Not yet recruiting NCT05087771 Phase 4 injectable naltrexone;oral naltrexone
172 Bridging ED to Outpatient AUD Therapy With Naltrexone Not yet recruiting NCT05228418 Phase 4 Naltrexone Pill
173 Effectiveness of Pre-surgical Hand Washing in Reducing Bacterial Load, Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate Not yet recruiting NCT04683146 Phase 4 Hand antisepsis with Propanolol- 1 60%.;Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
174 A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
175 Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Women With Postmenopausal Osteoporosis and Nonalcoholic Fatty Liver Disease Not yet recruiting NCT05493761 Phase 4 Denosumab;Alendronate Sodium
176 The GLP-1 Agonist Semaglutide for the Treatment of Metabolic Disease in Liver Transplant Recipients: A Phase IV, Randomized Trial Not yet recruiting NCT05195944 Phase 4 Semaglutide Treatment;Sitagliptin 100mg
177 Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics Suspended NCT00226109 Phase 4 spironolactone
178 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
179 Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care Terminated NCT02195817 Phase 4 Selincro® 18 mg with continuous psychosocial support: Cohort A
180 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Terminated NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
181 A Multi-site Study to Disseminate and Evaluate Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers Terminated NCT01638377 Phase 4 Naltrexone;Control
182 Pilot Study of Depot Naltrexone in Alcohol-Dependent, Homeless Veterans Terminated NCT01155869 Phase 4 Depot naltrexone;Oral Naltrexone
183 The Use of Acamprosate for Preventing Alcohol Relapse Among Alcohol Dependent Drug Treatment Court Participants Terminated NCT00249379 Phase 4 Acamprosate
184 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Terminated NCT00449007 Phase 4 fluoxetine;bupropion
185 Alcoholism and Schizophrenia: Effects of Clozapine Terminated NCT00169026 Phase 4 Clozapine versus typical (conventional) and atypical antipsychotic medications
186 Topiramate Treatment of Alcohol Use Disorder in African Americans Terminated NCT03018704 Phase 4 Topiramate;placebo
187 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis) Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
188 RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
189 Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients Terminated NCT00188045 Phase 4 Propranolol - Spironolactone
190 Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
191 A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
192 Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism: A Double-blind, Placebo-controlled, Randomized, Parallel Groups, Multi-center Study. Withdrawn NCT01211704 Phase 4 Paliperidone Palmitate;Placebo
193 Randomized Clinical Trial Comparing Propofol and Midazolam in Mechanically Ventilated Critically Ill Patients With Alcohol Use Disorders: An Open Label Pilot Study Withdrawn NCT00871039 Phase 4 Propofol;Midazolam
194 An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder Withdrawn NCT00221481 Phase 4 divalproex or olanzapine
195 Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters Withdrawn NCT02973295 Phase 4 Silymarin
196 Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
197 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
198 Pharmacotherapy for HIV Infected Patients With Alcohol Problems Withdrawn NCT00854230 Phase 4 Naltrexone
199 Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia Unknown status NCT03479086 Phase 3 Topiramate;Naltrexone
200 Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. Unknown status NCT02824354 Phase 3 Nalmefene (Selincro®) 18 mg tablet;placebo
201 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
202 Motivational Interviewing (MI) for ETOH+ Teens in the ER Unknown status NCT00246428 Phase 3
203 Naltrexone and CBT for Problem-Drinking MSM Unknown status NCT01115894 Phase 3 Naltrexone;Placebo
204 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
205 Enhanced MI With Alcohol Positive Trauma Patients Unknown status NCT00280488 Phase 3
206 Using Memantine in Treating Bipolar Disorder Comorbid With Alcoholism Unknown status NCT03043001 Phase 3 Memantine
207 1/2 - Pharmacogenetic Treatments for Alcoholism Unknown status NCT01591291 Phase 2, Phase 3 Ondansetron + Brief Behavioral Enhancement Treatment;Placebo + Brief Behavioral Enhancement Treatment
208 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Unknown status NCT02654665 Phase 3 Liraglutide
209 A Randomised Controlled Trial of Vitamin D Plus Plus Lifestyle Versus Lifestyle in Patients With Non-alcoholic Steatohepatitis:Effect on Liver Histology and Metabolic Parameters Unknown status NCT01623024 Phase 3 Vitamin D
210 Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD) Unknown status NCT00303537 Phase 2, Phase 3 metformin
211 Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis Unknown status NCT02485106 Phase 3 Rifaximin;Corticosteroid or pentoxifylline
212 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
213 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
214 A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (GLAZED Trial) Unknown status NCT02265276 Phase 3 Saroglitazar;Pioglitazone
215 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
216 Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence Completed NCT00812461 Phase 3 Placebo;Nalmefene
217 Alcohol Dependence: Study of the Possible Reduction of Compulsion by Association of Naltrexone With Poly-unsaturated Fatty Acids (PUFAs) Completed NCT01211769 Phase 3 Naltrexone;PUFAs;Placebo;Naltrexone + Placebo
218 Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence Completed NCT02557815 Phase 3
219 A New Pharmacotherapy for Alcohol Dependence: Olanzapine Completed NCT00746785 Phase 3 2.5 mg Olanzapine;5mg Olanzapine;placebo
220 The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD). Completed NCT00744055 Phase 3 Prazosin;Placebo
221 Gabapentin for Abstinence Initiation in Alcohol Dependence Completed NCT01141049 Phase 2, Phase 3 Gabapentin
222 A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence Completed NCT00811941 Phase 3 Placebo;Nalmefene
223 Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence Completed NCT00811720 Phase 3 Placebo;Nalmefene
224 Baclofen for the Treatment of Alcohol Dependence - BACLAD Completed NCT01266655 Phase 2, Phase 3 Baclofen;Placebo
225 International Multicentre Randomized Double-blind Placebo Controlled Phase III Clinical Study to Assess Efficacy and Safety of Odelepran, 125 mg, for the Use in Patient With Alcohol Dependence Completed NCT03663374 Phase 3 Odelepan;Placebo
226 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
227 Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder. Completed NCT00197951 Phase 3 Treatment of psychiatric symptoms associated to alcoholism
228 Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence Completed NCT00501631 Phase 3 VIVITROL 380 mg;Placebo for VIVITROL 380 mg
229 Modification of Cognitive Processing Therapy (CPT-C) for Posttraumatic Stress Disorder (PTSD) and Alcohol Dependence (AD) Completed NCT00639288 Phase 2, Phase 3
230 Phase IIIa Trial of Baclofen for Alcohol Dependence Completed NCT00877734 Phase 2, Phase 3 baclofen;placebo
231 Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence Completed NCT02196142 Phase 3 Cortisol 20mg;Placebo Mannitol
232 Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence Completed NCT00563797 Phase 3 Mecamylamine;Placebo
233 Progesterone Treatment in Reducing Trauma and Alcohol Induced Craving in Individuals Diagnoses With Alcohol Dependence (AD) and Post-tramatic Stress Disorder (PTSD). Completed NCT02187224 Phase 2, Phase 3 Progesterone;Placebo (for Progesterone)
234 A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder Completed NCT00114686 Phase 3 Quetiapine fumarate;lithium;divalproex
235 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
236 A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence Completed NCT02382276 Phase 3 Nalmefene hydrochloride
237 A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial) Completed NCT02364947 Phase 3 Nalmefene hydrochloride;Placebo
238 Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism Completed NCT02901041 Phase 3 Zonisamide;Placebo (for Zonisamide)
239 Efficacy of Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Randomized, Placebo-Controlled Trial Completed NCT01145677 Phase 2, Phase 3 Topiramate
240 Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease Completed NCT01711125 Phase 3 Baclofen 30mg/day;Baclofen 75mg/day;Placebo
241 Making Alcoholics Anonymous Easier: A Group TSF Approach Completed NCT01382316 Phase 3
242 A Multicenter Double-Blind Extension of Alkermes Study ALK21-003 to Evaluate the Long-Term Safety of Medisorb® Naltrexone Completed NCT01218971 Phase 3 Medisorb naltrexone 190 mg;Medisorb naltrexone 380 mg
243 Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients Completed NCT00758277 Phase 3 levetiracetam (Keppra);Placebo
244 A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients Completed NCT01738282 Phase 3 Baclofen;Placebo (for baclofen)
245 Varenicline Treatment for Active Alcoholic Smokers Completed NCT01347112 Phase 2, Phase 3 Varenicline;placebo
246 Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Completed NCT01342549 Phase 3 Valproate;Naltrexone
247 Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication Completed NCT01292057 Phase 3 Aripiprazole;Placebo
248 Linkage of Alcohol Abusers to Primary Care Completed NCT00278447 Phase 3
249 Gabapentin as an Adjunct to Naltrexone for Alcoholism Completed NCT00183196 Phase 3 Naltrexone;Naltrexone plus Gabapentin
250 Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Completed NCT00463346 Phase 3 Acamprosate;Placebo
251 Aripiprazole and Topiramate on Free-Choice Alcohol Use Completed NCT00884884 Phase 2, Phase 3 Double Placebo;Aripiprazole 15, placebo;Aripiprazole 7.5, Placebo;Topiramate 100, Placebo;Topiramate 200, Placebo;Topiramate 100, Aripiprazole 15;Topiramate 100, Aripiprazole 7.5;Topiramate 100, Aripiprazole 15mg;Topiramate 200, Aripiprazole 7.5mg;Topiramate 200, Aripiprazole 15
252 Pharmacological Treatment for Alcoholism Completed NCT00382642 Phase 3 Ondansetron + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
253 Hospital-based Brief Intervention for Alcohol Problems Completed NCT00183105 Phase 3
254 Transcranial Magnetic Stimulation in Alcohol Use Disorder: Effects on Dopamine Transporter and Alcohol Intake Completed NCT02862093 Phase 3
255 A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention Completed NCT00262639 Phase 2, Phase 3 Flumazenil and Gabapentin;Placebo
256 Effectiveness of Extended Telephone Monitoring Completed NCT00194103 Phase 3
257 Pharmacotherapeutic Intervention to Improve Treatment Engagement Among Alcohol-dependent Veterans After Hospital Discharge Completed NCT01856712 Phase 3 Naltrexone
258 The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use Completed NCT02539511 Phase 2, Phase 3 CI-581a;CI-581b
259 Validation of a Test System for Development of Medications for Alcoholism Completed NCT02652585 Phase 3 Naltrexone;Placebo
260 Combined Pharmacotherapies for Alcoholism Completed NCT00768508 Phase 3 Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy;Naltrexone 50 mg/day + Cognitive Behavioral Therapy;Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy
261 CBT And Venlafaxine Treatments For Anxiety In Alcoholism Completed NCT00248612 Phase 2, Phase 3 Venlafaxine
262 Acute and Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: A Prospective Randomized Parallel Group Placebo-controlled Trial Completed NCT02903251 Phase 3 intranasal oxytocin spray
263 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults Completed NCT01218958 Phase 3 Medisorb naltrexone 190 mg;Medisorb naltrexone 380 mg;Placebo matching Medisorb naltrexone 190 mg;Placebo matching Medisorb naltrexone 380 mg
264 A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone Completed NCT01218997 Phase 3 Medisorb naltrexone 380 mg;Oral naltrexone 50 mg
265 Naltrexone & SSRI in Alcoholics With Depression/PTSD Completed NCT00338962 Phase 3 paroxetine;desipramine;Naltrexone;Placebo
266 The Effects of Quetiapine on Sleep During Alcohol Abstinence Completed NCT00434876 Phase 3 Quetiapine XR;Placebo.
267 COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions Completed NCT00006206 Phase 3 naltrexone (Revia);acamprosate (Campral)
268 Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients Completed NCT00136617 Phase 3 chlordiazepoxide
269 A Double-Blind Study of Quetiapine Fumarate (Seroquel) for the Treatment of Type A vs.Type B Alcoholics. Completed NCT00124059 Phase 3 Seroquel;Placebo
270 Naltrexone and CBT for Problem-drinking MSM Completed NCT00444418 Phase 3 Naltrexone
271 Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed NCT00202514 Phase 2, Phase 3 divalproex sodium extended release
272 A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone Completed NCT00156923 Phase 3 Medisorb naltrexone 380 mg;Medisorb naltrexone 190 mg
273 Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial Completed NCT03339024 Phase 3 intranasal oxytocin spray
274 Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial Completed NCT02723383 Phase 3 BACLOFEN;PLACEBO
275 HIV & Drug Abuse Prevention for South African Men Completed NCT02358226 Phase 3
276 Alcohol Treatment: Pragmatic Therapeutic Trial Randomized, Double-blind for a Year in Ambulatory Care of Baclofen Versus Placebo. Completed NCT01604330 Phase 2, Phase 3 Baclofen;Placebo
277 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
278 Promoting Self-Change From Alcohol Problems: Mechanisms of Change in a Community-Based Intervention Completed NCT00732095 Phase 3
279 Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action Completed NCT02900352 Phase 3 Zonisamide;Placebo
280 Motivational Interviewing Delivered by Existing Prison Staff: A Randomized Controlled Study of Effectiveness on Substance Use After Release Completed NCT01184612 Phase 3
281 Brief Intervention for Heavy Drinkers - a Randomized Controlled Trial Completed NCT00728767 Phase 3
282 Web-based Ultra-brief Intervention for Heavy Drinkers - a Randomized Controlled Trial Comparing Personalized Normative Feedback With Self-help Material Completed NCT00751985 Phase 3
283 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
284 The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder Completed NCT04318639 Phase 2, Phase 3
285 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults With Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes Completed NCT04101227 Phase 3 AD04 (ondansetron);Matching placebo
286 Alcohol Screening and Brief Intervention in the Emergency Department Completed NCT00183183 Phase 3
287 "Primary Care Alcohol Intervention in College Students" Completed NCT00244049 Phase 3
288 Telephone and Mail Intervention for Alcohol Use Disorders Completed NCT00204854 Phase 3
289 Efficacy of Gabapentin in Alcohol Dependency Treatment: a Double-blinded Randomized Placebo-controlled Trial Completed NCT03274167 Phase 3 Gabapentin 300mg;Placebo oral capsule
290 Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study Completed NCT01908062 Phase 3 Extended Release Naltrexone
291 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
292 DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality. Completed NCT00359645 Phase 3
293 Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
294 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Completed NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
295 Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study. Completed NCT00863785 Phase 3 Corticoids plus N Acetyl Cysteine
296 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis Completed NCT02068339 Phase 3 Oltipraz 1 (90mg);Placebo;Oltipraz 2 (120mg)
297 Randomized, Clinical Trial to Evaluate the Effects of Aloe Vera Mouthwash in Comparison With Non-alcoholic Chlorhexidine on Periodontal Disease Completed NCT02560870 Phase 2, Phase 3 Active Comparator:Aloe Vera mouthwash;Active Comparator:Chlorhexidine mouthwash
298 Efficacy of Phosphatidylcholine in Addition to Behavior Therapy by Clinical Pharmacist in the Management of Non Alcoholic Fatty Liver (NAFLD) Completed NCT04411862 Phase 3
299 The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes Completed NCT02929901 Phase 2, Phase 3
300 The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease Completed NCT01277237 Phase 3 Omacor;lactose tablet
301 Safety and Efficacy of Resveratrol for the Treatment of Non-Alcoholic Fatty Liver Disease and Associated Insulin Resistance in Overweight and Obese Adolescents Completed NCT02216552 Phase 2, Phase 3
302 A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis Completed NCT01051219 Phase 3 Losartan
303 Effects of SAMe in Patients With Alcoholic Liver Disease Completed NCT00573313 Phase 3 S-adenosylmethionine;Placebo
304 Open-Label Study With Ademetionine (Heptral®) in Subjects With Intrahepatic Cholestasis (IHC) Associated With Alcoholic Liver Disease (ALD) Completed NCT02200029 Phase 3 Ademetionine IV+tablet;Ademetionine tablet
305 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
306 A Pilot Study of Varenicline for Tobacco Dependence Treatment in Recovering Alcoholic Smokers: the Clinical Trial Completed NCT01092702 Phase 2, Phase 3 Varenicline
307 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
308 N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial Completed NCT00962442 Phase 3 N-Acetylcysteine;placebo
309 A Randomized, Double-blind, Multicenter, 24-week Study of Subcutaneous Secukinumab to Assess Anti-interleukin-17A Treatment in Plaque Psoriasis Patients With Coexisting Non-alcoholic Fatty Liver Disease (pINPOINt) Completed NCT04237116 Phase 3
310 Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
311 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
312 Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease Completed NCT02303314 Phase 2, Phase 3 Trigonella Foenum-graecum Seed Extract;Drug: Placebo
313 Effect of Ginger Supplement on Non-alcoholic Fatty Liver Completed NCT02535195 Phase 2, Phase 3
314 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Completed NCT01471028 Phase 3
315 Efficacy and Tolerability of Vitamin D and Docosahexaenoic Acid (DHA) in Children With Biopsy Proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
316 The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
317 Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects Completed NCT02242149 Phase 3 Diacerein;Placebo
318 Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease Completed NCT01418027 Phase 3
319 The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
320 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz Completed NCT04142749 Phase 3 Oltipraz;Placebos
321 Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
322 The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
323 Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial Completed NCT02487225 Phase 3 Pentoxifylline;Placebo
324 Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study Completed NCT00820651 Phase 3
325 The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients Completed NCT02908152 Phase 2, Phase 3
326 Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes Completed NCT02132442 Phase 3
327 Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh) Completed NCT01529268 Phase 2, Phase 3 DR cysteamine bitartrate capsule
328 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo
329 Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
330 Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
331 Role of Exenatide in Treatment of NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
332 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study Completed NCT00509418 Phase 3
333 Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial Completed NCT00655018 Phase 2, Phase 3
334 The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH) Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
335 Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence (TEMACA) Recruiting NCT03634917 Phase 3 Acamprosate Calcium;Calcium Carbonate;Placebo;Placebo lead in
336 Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder - a Randomized Double-blind Placebo-controlled Parallel-group Trial Recruiting NCT05093296 Phase 2, Phase 3 Oxytocin nasal spray;Naltrexone Pill;Placebo
337 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder Recruiting NCT02918370 Phase 3 Aripiprazole;Placebo
338 Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking Recruiting NCT05181891 Phase 2, Phase 3
339 A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse Recruiting NCT03539887 Phase 3 Intranasal ketamine;Placebo
340 Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder Recruiting NCT05015881 Phase 2, Phase 3 FDG
341 Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Recruiting NCT04098302 Phase 2, Phase 3 Dutasteride Capsules;Placebo Capsules
342 Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Placebo-Controlled Clinical Trial Recruiting NCT04603781 Phase 2, Phase 3
343 Combining Topiramate and Prolonged Exposure for PTSD and Alcohol Use Disorder Recruiting NCT03176953 Phase 2, Phase 3 topiramate;placebo
344 Effects of Ketone Ester on Brain Function and Alcohol Consumption in Alcohol Use Disorder Recruiting NCT04616781 Phase 2, Phase 3 Isocaloric dextrose placebo
345 A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis Recruiting NCT04849728 Phase 3 IVA337;Placebo
346 The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis Recruiting NCT03069300 Phase 3 N-acetyl cysteine (NAC)
347 A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis Recruiting NCT05364931 Phase 2, Phase 3 Cotadutide;Placebo
348 The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis Recruiting NCT04822181 Phase 3 Semaglutide;Placebo
349 A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis Recruiting NCT04689152 Phase 3
350 A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES) Recruiting NCT05500222 Phase 3 Resmetirom;Placebo
351 Fecal Microbial Transplantation for Corticosteroids Non-responders and Non-eligible Patients With Severe Alcoholic Hepatitis Recruiting NCT04758806 Phase 3
352 A 52-Week, Phase 3, Open-Label Extension Study, With a Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Recruiting NCT04951219 Phase 3 Resmetirom
353 A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation Recruiting NCT03900429 Phase 3 MGL-3196;Placebo
354 An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH) Recruiting NCT04193982 Phase 3 Saroglitazar;Vitamin E;Combination drug
355 Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial Recruiting NCT03723252 Phase 3 Dapagliflozin;Placebo
356 Effect of N-acetyl Cysteine on Markers of Oxidative Stress and Insulin Resistance in Patients With Non-alcoholic Fatty Liver Disease Recruiting NCT05589584 Phase 3 N acetyl cysteine with weight reduction
357 Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial Recruiting NCT02473341 Phase 3 Bovine Colostrum;Placebo
358 Estrogen Administration for the Treatment of NASH in Postmenopausal Women Recruiting NCT04833140 Phase 3 Estradiol patch;Placebo
359 Development and Evaluation of the Effectiveness of Complex Therapy of Steatohepatitis of Various Aetiologies Based on Metabolomic Analysis With the Use of Innovative Medical Nutrition Products Recruiting NCT04308980 Phase 2, Phase 3
360 A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis Recruiting NCT04365868 Phase 2, Phase 3 belapectin;Placebo
361 A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease Recruiting NCT05308160 Phase 3 Dapagliflozin 10Mg Tab;Placebo
362 High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers Active, not recruiting NCT01182766 Phase 2, Phase 3 Topiramate with brief behavioral enhancement therapy;Placebo with brief behavioral enhancement therapy
363 EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents Active, not recruiting NCT02016378 Phase 3
364 Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD Active, not recruiting NCT02884908 Phase 3 Pregabalin plus BBCET
365 A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1) Active, not recruiting NCT04197479 Phase 3 Placebo;Resmetirom
366 A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis Active, not recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
367 Effectiveness and Safety of Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis Active, not recruiting NCT05284448 Phase 3 pentoxifylline (Trental SR®)
368 Efficacy of Simvastatin in Reducing Liver Fibrosis in Patients With Advanced Fibrosis Due to Alcohol: Randomized, Double-blind, Placebo-controlled Clinical Trial Not yet recruiting NCT04971577 Phase 2, Phase 3 Simvastatin 40mg
369 Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep: A Randomized, Double-Blind, Placebo- Controlled Study Not yet recruiting NCT05458609 Phase 3 Lemborexant 10 mg;Naltrexone
370 Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD) Not yet recruiting NCT05067621 Phase 3 Semaglutide Pen Injector;Placebo
371 MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1 Not yet recruiting NCT03970031 Phase 3 MSDC-0602K;Placebo
372 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Suspended NCT02541045 Phase 3 metadoxine
373 Study of the Efficacity of the Systemic Ketamine for the Improvement of Post-Operative Analgesia After ORL Carcinological Surgery at the Alcohol-Dependent Patient. Suspended NCT00329394 Phase 3 ketamine
374 A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) With Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol. The ARMOR Study Suspended NCT04104321 Phase 3 Aramchol;Placebo
375 A 24-week Open-Label Feasibility Trial of Varenicline for Alcoholic Cigarette Smokers Terminated NCT01169610 Phase 3 Varenicline
376 An Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of Medisorb® Naltrexone Terminated NCT00156936 Phase 3 Medisorb naltrexone 380 mg;Oral naltrexone to Medisorb naltrexone 380 mg
377 Efficacy of a Brief Alcohol Intervention for Non Dependant Alcohol-misusing Patients Undergoing a Scheduled Surgery: a Randomized Controlled Trial Terminated NCT01348113 Phase 3
378 Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans Terminated NCT02368431 Phase 3 Zonisamide;Placebo
379 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
380 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
381 Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study Terminated NCT02442180 Phase 3 G-CSF (Filgrastim injection);steroid;placebo
382 A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Terminated NCT02612428 Phase 3
383 Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures Terminated NCT00678587 Phase 3 Eltrombopag;Placebo
384 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Terminated NCT02704403 Phase 3 Elafibranor;Placebo
385 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Terminated NCT03053063 Phase 3 SEL;Placebo to match SEL 6 mg;Placebo to match SEL 18 mg
386 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Terminated NCT03053050 Phase 3 SEL;Placebo to match SEL 6 mg;Placebo to match SEL 18 mg
387 AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis Terminated NCT03028740 Phase 3 Placebo;Cenicriviroc
388 A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH). Terminated NCT00577148 Phase 3 Rimonabant;Placebo (for Rimonabant)
389 A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH) Terminated NCT00576667 Phase 3 Rimonabant;Placebo (for Rimonabant)
390 The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder Withdrawn NCT00571246 Phase 3 Topiramate;lamotrigine
391 Couples-based Behavioral Psychotherapy for Male Patients With Posttraumatic Stress Disorder and Alcohol Dependence Withdrawn NCT00622921 Phase 2, Phase 3
392 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
393 A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis Withdrawn NCT01384578 Phase 3 pentoxiphylline and Vitamin E;Vitamin E
394 The Efficacy and Neurobehavioural Mechanism of N-acetyl Cysteine for Alcohol Dependence: An Exploratory Pilot Study Unknown status NCT03879759 Phase 2 NAC 2400mg/day;Placebo
395 Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence Unknown status NCT01534494 Phase 2 Psilocybin
396 Investigation of the Efficacy and Safety of Varenicline in the Postacute Treatment of Alcohol Dependence - a Prospective, Double-blind, Placebo-controlled, Randomised Phase-II Study Unknown status NCT01071187 Phase 2 Varenicline;Placebo
397 RAP: Reaching Adolescents for Prevention - A Randomized Trial of a Brief Negotiated Interview and Active Referral to Reduce Alcohol Related Morbidity Among Youth and Young Adults in the Pediatric Emergency Department Unknown status NCT00183157 Phase 2
398 Combining Medications Treatment for Alcoholism Unknown status NCT00006205 Phase 2 ondansetron + cognitive behavioral therapy;topiramate + cognitive behavioral therapy;Placebo + cognitive behavioral therapy;ondansetron + topiramate + cognitive behavioral therapy
399 A Randomized, Double-Blind, Placebo-Controlled Trial of Vortioxetine for Depressive Mood and Alcohol Use in Adults With Major Depressive Disorder and Alcohol Use Disorder Unknown status NCT04498897 Phase 2 Vortioxetine;Acamprosate
400 Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse Unknown status NCT00437177 Phase 2 apomorphine;[(123)I] iodobenzamide
401 Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD) Unknown status NCT03137082 Phase 1, Phase 2 Guanfacine XR 3mgs/daily;Placebo (for guanfacine)
402 The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis Unknown status NCT01741090 Phase 2
403 Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study Unknown status NCT02116556 Phase 2 Prednisone;Rifaximin
404 A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis Unknown status NCT02912260 Phase 2 MGL-3196;Placebo
405 A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of HEPAR-P Capsule for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Unknown status NCT01680003 Phase 2 Hepar-P;Placebo for Hepar-P
406 A Phase 2, Randomised, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) Unknown status NCT04330326 Phase 2 Metabolic Cofactor Supplementation;Sorbitol
407 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis Unknown status NCT03205345 Phase 2 Emricasan (25 mg);Emricasan (5 mg);Placebo
408 Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH) Unknown status NCT01617772 Phase 2 Atorvastatin;L-Carnitine;Placebo
409 Impact of n-3 Fatty Acid Supplementation on the Metabolic Abnormalities in Children With NAFLD Unknown status NCT02201160 Phase 1, Phase 2
410 A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis Unknown status NCT02574325 Phase 2 Placebo;ARI-3037MO
411 Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial Unknown status NCT00699036 Phase 2 avandia;metformin;losartan
412 A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence Completed NCT02061293 Phase 2 Psilocybin;Diphenhydramine
413 A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence Completed NCT00805441 Phase 2 LY686017;Placebo
414 Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence Completed NCT02120365 Phase 1, Phase 2 Perampanel;Placebo
415 Doxazosin an a1 Antagonist for Alcohol Dependence Completed NCT01437046 Phase 2 Doxazosin;Placebo
416 A Phase 2 Study of LY2196044 Compared With Placebo in the Treatment of Alcohol Dependence Completed NCT00804570 Phase 2 LY2196044;placebo
417 A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence Completed NCT00777062 Phase 2 VIVITROL (Naltrexone extended-release injectable suspension);Placebo
418 A Placebo-Controlled Trial of Prazosin in Individuals With Co-occurring Alcohol Dependence and PTSD Seeking Abstinence Completed NCT01518972 Phase 2 Prazosin;Placebo medication
419 Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence Completed NCT00762710 Phase 2 Prazosin medication;Placebo medication
420 A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy of Varenicline Tartrate for Alcohol Dependence in Very Heavy Drinkers Completed NCT01146613 Phase 2 Varenicline;Placebo
421 N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence Completed NCT01214083 Phase 2 N-acetylcysteine + high-dose naltrexone (150 mg);High-dose naltrexone (150 mg) alone;Low-dose naltrexone (50 mg) alone
422 A Phase II, Randomised, Double-blind, Placebo- Controlled, Multi-site, Parallel Group Clinical Trial to Examine Ketamine as a Pharmacological Treatment for Alcohol Dependence in an Alcohol Dependent Population Completed NCT02649231 Phase 2 Ketamine;Placebo
423 Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial Completed NCT02251912 Phase 2 Intranasal Oxytocin;Placebo
424 Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence Completed NCT01847469 Phase 2 Zonisamide;Placebo
425 A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers. Completed NCT00498628 Phase 2 Quetiapine fumarate
426 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence Completed NCT00210925 Phase 2 topiramate
427 Duloxetine Versus Pregabalin for Alcohol Dependence Completed NCT00929344 Phase 2 Pregabalin;Duloxetine;Placebo
428 An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence Completed NCT00667875 Phase 2 Placebo;Naltrexone;Naltrexone + Aripiprazole
429 The Effects of Zonisamide on Alcohol Dependence Completed NCT00406692 Phase 2 Zonisamide
430 Combined Treatment for Cocaine-Alcohol Dependence Completed NCT00218569 Phase 2 Naltrexone;Placebo
431 Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives Completed NCT00000451 Phase 2 sertraline;naltrexone
432 Efficacy and Safety of High Dose Baclofen for Alcohol Dependence Completed NCT01980706 Phase 2 Baclofen;Placebo
433 New Medications to Treat Alcohol Dependence Completed NCT00223639 Phase 2 Topiramate
434 A Phase II, Randomized, Double-Blind Pilot Trial of Varenicline (Chantix™) for the Treatment of Alcohol Dependence Completed NCT00705523 Phase 2 varenicline;placebo
435 A Therapeutic Workplace for Alcohol Dependence Completed NCT00183144 Phase 2
436 A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence Completed NCT00142818 Phase 2 Naltrexone;Modafinil;Placebo
437 Pilot Trial of Levetiracetam in the Treatment of Alcohol Dependence With Comorbid Anxiety Completed NCT00141115 Phase 2 levetiracetam
438 Etiology and Treatment of Alcohol Dependence Completed NCT00004552 Phase 2 acamprosate (Campral)
439 Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence Completed NCT01055171 Phase 2 Propranolol;Placebo
440 N-acetylcysteine in Alcohol Dependence Completed NCT00568087 Phase 1, Phase 2 N-acetylcysteine;Placebo
441 Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial Completed NCT00678457 Phase 2 Ondansetron;Olanzapine;Placebo
442 Gabapentin Treatment of Alcohol Dependence Completed NCT00391716 Phase 2 Gabapentin 900mg;placebo;gabapentin 1800mg
443 A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults With Alcohol Dependence Completed NCT00981617 Phase 2 ALKS33 (RDC-0313) (1 mg);ALKS33 (RDC-0313) (2.5 mg);ALKS33 (RDC-0313) (10 mg);Placebo
444 Initiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence. Completed NCT00360594 Phase 2 Acamprosate;Placebo
445 Medications Development for Alcohol Abuse: NMDA Agents -- A Placebo-Controlled Trial of Memantine for Alcohol Dependence Completed NCT00246415 Phase 2 Memantine
446 Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence Completed NCT00142844 Phase 2 Naltrexone;Disulfiram;Placebo
447 Therapeutic IVR to Augment CBT in Alcohol Dependence Completed NCT00132795 Phase 2
448 Harm Reduction With Pharmacotherapy for Homeless Adults With Alcohol Dependence Completed NCT01932801 Phase 2 XR-NTX+HRC
449 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence Completed NCT01798303 Phase 2 LY2940094;Placebo
450 A Phase 2, Double-Blind, Randomized, Placebo Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence Completed NCT01613014 Phase 2 ABT-436;Matched Placebo - Sugar Pill
451 Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence? Completed NCT03232112 Phase 2 Exenatide 2 MG Injection;BD PosiFlush (saline)
452 Carisbamate as a Potential Treatment for Alcohol Dependence Completed NCT02435381 Phase 1, Phase 2 Carisbamate;Placebo
453 Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial Completed NCT02275611 Phase 2 intranasal oxytocin spray;Intranasal Placebo Spray
454 Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs Completed NCT01128140 Phase 2
455 Ondansetron Pharmacotherapy for Hazardous Drinking in HIV+, African-American Women Completed NCT01254877 Phase 2 ondansetron;placebo ondansetron;Ondansetron
456 Behavioral Treatment for Alcohol Dependent Women With Co-occurring Depression Completed NCT00851669 Phase 2
457 CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component Completed NCT00842036 Phase 2
458 Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving Completed NCT01176591 Phase 2 Placebo session 1, Aprepitant session 2;Placebo session 1, Placebo session 2
459 Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals? Completed NCT00846859 Phase 2 varenicline (Champix/Chantix);placebo for varenicline
460 Topiramate to Aid Smoking Cessation in Recovering Alcohol Dependent Men Completed NCT00802412 Phase 2 Topiramate;Placebo
461 Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving Completed NCT01151813 Phase 2 Varenicline;Placebo
462 Advancing Tobacco and Cancer Control: Reducing Alcohol Use to Promote Smoking Cessation Completed NCT01120080 Phase 1, Phase 2
463 Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics Completed NCT01227980 Phase 2 Pexacerfont;Placebo
464 Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study Completed NCT01187511 Phase 2 GSK561679;Placebo
465 An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers Completed NCT01165541 Phase 2 Mirtazapine;Quetiapine fumarate extended release (Quetiapine XR)
466 Screening and Brief Intervention in the ED Among Mexican-origin Young Adults Completed NCT02056535 Phase 2
467 Remote Brief Intervention and Referrals to Treatment Service for Alcohol Completed NCT02622984 Phase 2
468 A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects Completed NCT01842503 Phase 1, Phase 2 GET 73;inactive ingredients capsule
469 Alcoholism Treatment by Cognitive Neuromodulation Produced by Repeated Transcranial Direct Current Stimulation Over the Left Dorsolateral Prefrontal Cortex Completed NCT01330394 Phase 2
470 Sweet Preference and Alcohol Craving Predict Naltrexone Response in Alcoholism Completed NCT01296646 Phase 2 Naltrexone;Placebo
471 Glucocorticoid Antagonist Treatment of Alcohol Use Disorder Completed NCT02179749 Phase 2 Mifepristone 1200 mg daily;Placebo
472 The Use of Acamprosate in Alcohol-Dependent Individuals With Bipolar Disorder Completed NCT00330486 Phase 1, Phase 2 Acamprosate
473 Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal Completed NCT00106106 Phase 2 Oral acamprosate
474 NK1 Receptor Antagonism for Treatment of Anxiety and Craving in Anxious Alcohol Dependent Subjects During Early Abstinence Completed NCT00310427 Phase 2 LY686017;Placebo
475 Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual Completed NCT00300742 Phase 2 Topiramate
476 Optimizing Pharmacotherapy for Bipolar Alcoholics Completed NCT00302133 Phase 1, Phase 2 Naltrexone hydrochloride
477 The Effects of Mirtazapine vs Placebo on Alcohol Consumption in Male Alcohol High Consumers; a Randomized Controlled Trial Completed NCT00874003 Phase 2 mirtazapine;placebo
478 Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Completed NCT00585780 Phase 1, Phase 2 Prazosin Tablet;Placebo Tablet
479 Alcohol Research Center Grant. Component #1. COMBINING MEDICATIONS: ALCOHOL REACTIVITY AND CONSUMPTION Completed NCT00183222 Phase 2 naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
480 Internet Screening and Brief Intervention for Hazardous Drinking in College Students: A Pilot Study Completed NCT00183131 Phase 2
481 HIV Prevention Partnership in Russian Alcohol Treatment Completed NCT00183118 Phase 1, Phase 2
482 Mindfulness Meditation For Alcohol Relapse Prevention Completed NCT01056484 Phase 2
483 Implementing Early Intervention for Alcohol Use Disorders in the General Hospital Completed NCT00423904 Phase 2
484 Effectiveness of Aripiprazole to Reduce Craving for Alcohol and Drinking Under Natural Observation, During Cue Induced Brain Imaging, and During a Motivated Free Choice Drinking Procedure Compared to Placebo Completed NCT00183235 Phase 2 aripiprazole (up to 15 mg/day) for 8 days
485 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed NCT02210195 Phase 2 aprepitant;Placebo
486 Posttreatment Effects of Naltrexone Completed NCT00523133 Phase 2 naltrexone
487 The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD Completed NCT00896038 Phase 2 Aprepitant;Placebo
488 10 Days of Medial Prefrontal Cortex Theta Burst Stimulation (MPFC cTBS) as a Tool to Improve Clinical Outcomes and Decrease Frontal-striatal Reactivity to Cues Among Treatment-engaged Cocaine and Alcohol Users Completed NCT03238859 Phase 2
489 A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics Completed NCT01751386 Phase 2 Baclofen
490 Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin Completed NCT02989493 Phase 2 Doxazosin
491 Alcoholism and Schizophrenia: A Translational Approach to Treatment Completed NCT01411085 Phase 2 Risperidone + Desipramine
492 Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity and Pavlovian-to-Instrumental Transfer (PIT) Completed NCT01585168 Phase 2 Memantine;Placebo
493 Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists Completed NCT01548417 Phase 2 Korlym (mifepristone);Sugar Pill
494 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo Completed NCT04466215 Phase 2 CORT118335;Placebo oral tablet
495 A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease Completed NCT01504295 Phase 2 Metadoxine
496 Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment Completed NCT02966340 Phase 1, Phase 2 Prazosin;Placebo
497 Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron) Completed NCT00027079 Phase 2 ondansetron (Zofran);naltrexone (ReVia)
498 Sertraline Treatment in Comorbid Post-Traumatic Stress Disorder and Alcoholism Completed NCT00000446 Phase 2 sertraline (Zoloft)
499 Pharmacological Treatment for Alcoholism Completed NCT00000443 Phase 2 ondansetron (Zofran)
500 Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone Completed NCT00656630 Phase 2 Acamprosate;Naltrexone;Placebo
501 Medication Development in Alcoholism: Investigating PPAR Agonists Completed NCT02158273 Phase 2 Sugar Pill;TRICOR (fenofibrate)
502 Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism Completed NCT00338598 Phase 2 Glycine;placebo
503 Tailored Tobacco Cessation Program for Rural Veterans With Comorbid Depression, Alcoholism or Obesity Completed NCT01592695 Phase 2 Nicotine replacement therapy - transdermal nicotine patch;Nicotine replacement therapy - nicotine gum;Nicotine replacement therapy - nicotine lozenge;Bupropion Sustained Release;Varenicline;Combination pharmacotherapy - transdermal nicotine patch + nicotine gum;Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge;Combination pharmacotherapy - transdermal nicotine patch + bupropion
504 Medication Development for Protracted Abstinence in Alcoholism: Apremilast Versus Placebo Completed NCT03175549 Phase 2 Apremilast;Placebo
505 Pharmacotherapy for Hazardous Drinking in HIV Infected Women: Randomized Trial Completed NCT01245647 Phase 2 Naltrexone, 50mg, once per day for 4 months
506 1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers Completed NCT01553136 Phase 2 Varenicline
507 Venue-Based Recruitment and HIV Prevention for Alcohol and Other Drug (AOD) Using Couples in South Africa Completed NCT01121692 Phase 2
508 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home Completed NCT02885311 Phase 1, Phase 2 Naltrexone
509 A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking Completed NCT01076283 Phase 2 Baclofen;Cyproheptadine
510 12-step Facilitation for the Dually Diagnosed Completed NCT00583440 Phase 1, Phase 2
511 Trazodone for Sleep Disturbance - Early Alcohol Recovery Completed NCT00027053 Phase 2 Trazodone;Placebo
512 Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study Completed NCT00561587 Phase 2 Seroquel®
513 A Phase II Double-blind, Placebo-controlled Trial of Quetiapine for Frequent, Heavy Drinkers (Seroquel2) Completed NCT00674765 Phase 2 Seroquel;Placebo
514 Pharmacologic Relapse Prevention for Alcoholic Smokers Completed NCT00000457 Phase 2 bupropion (Wellbutrin);Placebo
515 Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics Completed NCT00605904 Phase 2 Acamprosate;Yohimbine;mCPP;Saline
516 Predicting Alcoholics' Treatment Responses to an SSRI Completed NCT00249405 Phase 2 Citalopram + MI
517 Alcohol Research Center - Treatment and Implications Completed NCT00011297 Phase 2 gabapentin (Neurontin);lorazepam (Ativan)
518 Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients Completed NCT00342563 Phase 2 mecamylamine;Placebo
519 Pharmacological Intervention Project (Fluoxetine) Completed NCT00027378 Phase 2 fluoxetine (Prozac);Placebo plus Treatment As Usual
520 Efficacy of Valproate Maintenance in Bipolar Alcoholics Completed NCT00000439 Phase 2 sodium valproate
521 Reinforcement of Abstinence and Attendance in Substance Abuse Treatment Completed NCT00288886 Phase 2
522 A Phase II, Randomized, Double-blind, Placebo-Controlled, Pilot Trial of Topiramate for Alcohol and Comorbid Cocaine Dependence Completed NCT00167245 Phase 2 Topiramate;placebo
523 Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment Completed NCT00147576 Phase 2 CP-866,087
524 Sertraline and Cognitive Therapy in Depressed Alcoholics Completed NCT00000458 Phase 2 sertraline (Zoloft)
525 Sertraline and Naltrexone for Alcohol Dependents Completed NCT00000440 Phase 2 naltrexone (Revia);sertraline (Zoloft)
526 A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers Completed NCT00970814 Phase 2 Levetiracetam XR;Sugar Pill
527 Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers Completed NCT01779024 Phase 2 Ghrelin;Placebo;Alcohol
528 Integrated Alcohol Disorder and PTSD Treatment Completed NCT01601067 Phase 2
529 A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers Completed NCT02371889 Phase 2 Topiramate;Inactive Placebo
530 Behavioral Couples Group Therapy for Alcholic Patients: Clinical and Cost Outcomes Completed NCT01659957 Phase 2
531 Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder Completed NCT04502589 Phase 1, Phase 2 Perampanel Tablet;Disulfiram
532 Glial Regulators for Treating Comorbid Posttraumatic Stress Disorder and Substance Use Disorders Completed NCT02911285 Phase 2 N-acetylcysteine;Placebo
533 A Randomized Control Trial of Brief Intervention for Problem Drinking and Partner Violence Completed NCT01207258 Phase 2
534 Optimizing Naltrexone for Individuals of East Asian Descent Completed NCT02026011 Phase 2 Naltrexone;Placebo
535 Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction Completed NCT02698215 Phase 2 Varenicline;Varenicline plus Naltrexone
536 Puerarin (NPI-031G) Effects on Alcohol Drinking - A Natural Settings Study Completed NCT00854724 Phase 2 Puerarin, Placebo
537 The Dynamic Assessment and Referral System for Substance Abuse: Evaluation Completed NCT01153373 Phase 2
538 Human Laboratory Study of Varenicline for Alcohol Use Disorder Completed NCT03035708 Phase 1, Phase 2 Varenicline;Placebo oral capsule
539 Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study Completed NCT03034408 Phase 2 Nalmefene;Baclofen;Placebo Oral Capsule
540 PARTNER: The Underage Drinking: Building Health Care System Research Completed NCT00735956 Phase 1, Phase 2
541 A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking Completed NCT02243709 Phase 1, Phase 2 Mifepristone 600-mg/day or placebo for a week
542 Repositioning Ivermectin for the Treatment of Alcohol Use Disorders Completed NCT02046200 Phase 1, Phase 2 Ivermectin;Placebo;Alcohol
543 Impact of Oxytocin on Neurobiologic Substrates of Social Stress in Individuals With Alcohol Use Disorder Completed NCT03610633 Phase 2 Oxytocin;Placebo
544 Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder Completed NCT03489850 Phase 2 Ibudilast
545 Evaluating Alternative Aftercare Models for Ex-offenders Completed NCT01586689 Phase 2
546 Alkontrol-herbal (Isoflavone) Effects on Alcohol Drinking in an Outpatient Setting Completed NCT03099590 Phase 2
547 Delivering Treatment in DUI Programs to Reduce Alcohol-Related Disparities Completed NCT02588703 Phase 2
548 Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control Completed NCT02949934 Phase 2 Tolcapone;Placebo
549 Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder Completed NCT02252536 Phase 2 gabapentin enacarbil;Placebo
550 Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder Completed NCT03658330 Phase 2 Ketamine + Naltrexone
551 A Pilot Placebo-controlled Human Laboratory Feasibility Study of Lacosamide Effects in Alcohol Use Disorder Completed NCT03897348 Phase 2 Placebo;Lacosamide 100 mg;Lacosamide 200 mg
552 Remote Alcohol Monitoring to Facilitate Abstinence Reinforcement: Feasibility Completed NCT03507075 Phase 1, Phase 2
553 Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial Completed NCT02646449 Phase 2 Mirtazapine;Placebo
554 SBIR-PhaseII, "Adaptive Goal-Directed Adherence Tracking and Enhancement" Completed NCT01349985 Phase 2
555 Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD. Completed NCT02185131 Phase 2 Mirtazapine;Placebo
556 Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse Completed NCT00145678 Phase 2
557 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress Completed NCT02742532 Phase 2 Oxytocin;Placebo
558 A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder Completed NCT04249882 Phase 2 Placebo;Naltrexone;Varenicline
559 A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder Completed NCT02161718 Phase 2 Samidorphan + olanzapine (ALKS 3831);Placebo + olanzapine
560 Brief Alcohol Interventions by Counselor vs Computer Completed NCT00289965 Phase 2
561 Combined Treatment for Alcohol-Dependent Individuals With PTSD Completed NCT00262223 Phase 2 Sertraline;Pill placebo
562 Disulfiram for Cocaine-Alcohol Abuse Completed NCT00000278 Phase 2 Disulfiram
563 Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder Completed NCT04108104 Phase 2 Cyproheptadine;Alpress LP
564 Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders Completed NCT01000987 Phase 2 varenicline;placebo
565 Examining Alcohol Consumption, Perceptions, and User Experience of Alcohol Moderation Strategies Completed NCT04286867 Phase 1, Phase 2
566 Cognitive Behavioral Treatment by Phone to Promote Use of Alcohol Related Care and Reduce Drinking Completed NCT03758274 Phase 2
567 N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI Completed NCT02791945 Phase 2 N-acetylcysteine;Placebo
568 Double Blinded Placebo Controlled Trial of Protandim for Individuals With a History of Alcohol Abuse Completed NCT00936000 Phase 2
569 Psychosocial Research to Improve Drug Treatment in Pregnancy (PRIDE-P) Completed NCT00227903 Phase 2
570 PPARγ Agonist Treatment for Cocaine Dependence Completed NCT02774343 Phase 1, Phase 2 Pioglitazone;Placebo
571 Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers Completed NCT02740582 Phase 2 Tolcapone;Placebo
572 Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use Completed NCT00907309 Phase 1, Phase 2
573 Maintenance of Treatment Gains in Adolescents With Alcohol Related Disorders Completed NCT00561041 Phase 2
574 Modafinil for the Treatment of Alcohol Use Disorders: Targeting Impaired Response Inhibition Completed NCT03424681 Phase 2 Modafinil
575 Cannabidiol as a Treatment for Alcohol Use Disorder Comorbid With Posttraumatic Stress Disorder Completed NCT03248167 Phase 1, Phase 2 Cannabidiol;Placebos
576 Effect of Prazosin and Naltrexone on Personalized Script-Induced Alcohol Craving in Individuals With Alcohol Use Disorders With and Without Comorbid PTSD Completed NCT02322047 Phase 2 Prazosin;Naltrexone;Placebo (Prazosin);Placebo (Naltrexone)
577 An Open-Label Pilot Study of Pregabalin as Treatment for Alcohol Use Disorder Completed NCT03256253 Phase 2 Pregabalin
578 CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders Completed NCT02500602 Phase 2 doxazosin;placebo
579 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder Completed NCT02354703 Phase 2 Ondansetron;Placebo
580 Effects of Cannabidiol in Alcohol Use Disorder Completed NCT03252756 Phase 1, Phase 2 Phytocannabinoid cannabidiol (CBD)
581 Efficacy and Safety of the Melanocortin Activator Bupropion in Treating Binge Drinking Completed NCT03169244 Phase 2 Bupropion;Placebo Oral Tablet
582 Medication Development for Opioid and Alcohol Abuse: Laboratory Study in Humans Completed NCT03205423 Phase 2 Gabapentin
583 A Multisite Randomized Clinical Trial Evaluating BP1.3656 Vs Placebo For Alcohol Use Disorder Treatment Completed NCT03424824 Phase 2 BP1.3656 low dose;BP1.3656 intermediate dose;Placebo;BP1.3656 high dose
584 Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects Completed NCT02349477 Phase 2 Gabapentin;Placebo
585 Effect of GET73 on Magnetic Resonance Spectroscopy Measures of Central Glutamate and GABA and Alcohol Cue-elicited Brain Activation in Recently Abstinent Non-treatment Seeking Individuals With Alcohol Use Disorder. Completed NCT03418623 Phase 2 GET73
586 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder Completed NCT02511886 Phase 2 Arbaclofen Placarbil;Placebo
587 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
588 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Completed NCT03067610 Phase 2 chemotherapy
589 Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
590 Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer Completed NCT02849327 Phase 1, Phase 2
591 Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
592 The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) Completed NCT04198805 Phase 2
593 A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis Completed NCT02019056 Phase 2 Placebo /bid P.O;MG-1;MG-2 : MG1000mg, Placebo /bid P.O;metadoxine
594 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Completed NCT02927314 Phase 2 CF102;Placebo
595 Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH) Completed NCT00794716 Phase 2 NRL972
596 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH) Completed NCT04019561 Phase 2 MEDI0382 high dose;Placebo for MEDI0382 high dose;MEDI0382 low dose;Placebo for MEDI0382 low dose
597 An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia Completed NCT02681055 Phase 2 MN-001
598 A Pilot Study to Determine the Effect of Omega-3 Polyunsaturated Fatty Acids From Fish Oil on Patients With Non-Alcoholic Steatohepatitis (NASH) Completed NCT01056133 Phase 2
599 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™) Completed NCT02784444 Phase 2 MSDC-0602K;Placebo
600 Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial Completed NCT00851981 Phase 2
601 Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study Completed NCT01547910 Phase 2
602 A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man. Completed NCT00856869 Phase 1, Phase 2 NRL972
603 A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed NCT00799578 Phase 1, Phase 2 Cysteamine
604 Effect of N-acetyl Cysteine on Non Alcoholic Fatty Liver Disease in Obese Children Completed NCT02117700 Phase 1, Phase 2
605 The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Completed NCT01712711 Phase 2 H.pylori eradication
606 Evaluation of Efficacy and Safety of Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients Completed NCT03850886 Phase 2 Antidiabetic
607 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension Completed NCT02960204 Phase 2 Emricasan;Placebo
608 An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis Completed NCT03432260 Phase 2 DUR-928
609 A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis Completed NCT02686762 Phase 2 Emricasan (5 mg);Emricasan (50 mg);Placebo
610 An Exploratory Study of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) (Placebo-Controlled Double-Blind Study) Completed NCT02923154 Phase 2 MT-3995;Placebo
611 A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH). Completed NCT01694849 Phase 2 GFT505 80mg;GFT505 120mg;Placebo
612 This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis Completed NCT02970942 Phase 2 Semaglutide;Placebo
613 A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis) Completed NCT01373554 Phase 2 Placebo;Oltipraz
614 Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D Completed NCT01571063 Phase 2 Vitamin D3;Placebo
615 Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study. Completed NCT02265328 Phase 2
616 A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases Completed NCT02077374 Phase 2 IDN-6556
617 A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Completed NCT01999101 Phase 2 Px-104
618 An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis Completed NCT02655510 Phase 1, Phase 2 F-652
619 The Effect of n-3 Polyunsaturated Fatty Acid Supplementation in Patients With Non-alcoholic Fatty Liver Disease Completed NCT00819338 Phase 2
620 A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) Completed NCT00740610 Phase 2 GS-9450;GS-9450 Placebo
621 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Completed NCT02927184 Phase 2 VK2809;Placebo
622 A Randomised, Double-blind, Placebo-controlled, Phase II, Single-centre Study to Assess the Safety and Efficacy of Silymarin 700 mg Capsules TID for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT02006498 Phase 2 Sillymarin;Placebo
623 Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis Completed NCT02126306 Phase 1, Phase 2 Beta Glucosylceramide;Placebo
624 A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 2 mg and 4 mg in Patients With Non-alcoholic Steatohepatitis Completed NCT03863574 Phase 2 Saroglitazar Magnesium 2mg;Saroglitazar Magnesium 4mg;Placebos
625 Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E Completed NCT01792115 Phase 2 Vitamin E 200 IU/d;Vitamin E 400 IU/d;Vitamin E 800 IU/d
626 The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial Completed NCT01278056 Phase 1, Phase 2 Exjade
627 Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH) Completed NCT03963921 Phase 1, Phase 2 HepaStem
628 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED DAILY FOR 16 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS ON METFORMIN Completed NCT03969719 Phase 2 Placebo;PF-06835919
629 A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease Completed NCT01811472 Phase 2 LCQ908;placebo
630 A Phase 2, Multi-Center, Single-Blind, Randomized, Placebo-Controlled Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (FASCINATE-1) Completed NCT03938246 Phase 2 TVB-2640
631 Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis Completed NCT03987451 Phase 2 Semaglutide;Placebo (semaglutide)
632 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) Completed NCT04328077 Phase 2 TERN-101
633 A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet Consortium Completed NCT04072822 Phase 2 Anakinra and Zinc;Prednisone;Placebos
634 Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Completed NCT03829683 Phase 2 Vitamin C;Dextrose 5% in water
635 A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Completed NCT03776175 Phase 2 PF-05221304 Monotherapy;PF-06865571 Monotherapy;Placebo;PF-05221304 and PF-06865571 Combination
636 Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus Completed NCT00633282 Phase 2 pioglitazone;berberine
637 Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis Completed NCT00470171 Phase 2 Ursodesoxycholic acid
638 A Single-center, Single-blinded, Placebo-controlled Pilot Study of IdB 1016 (Siliphos) in Adult Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00443079 Phase 2 IdB 1016 (Siliphos);Matched placebo
639 A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis Completed NCT01968382 Phase 2 IMM 124-E (Hyperimmune Bovine Colostrum);Placebo (High protein milk powder)
640 Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH) Completed NCT00668070 Phase 2 ASP9831;Placebo
641 Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus Completed NCT00323414 Phase 2 Polyunsaturated fatty acid (Opti-EPA);Placebo
642 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis Completed NCT02776059 Phase 2 Standard of care + pegfiltrastim;Standard of care
643 Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease Completed NCT01016418 Phase 1, Phase 2
644 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study to Explore the Safety and Efficacy of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT04342793 Phase 2 Placebo oral tablet;ALS-L1023 1,200mg;ALS-L1023 1,800mg
645 Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH) Completed NCT00666016 Phase 2 TRO19622
646 A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis Completed NCT00492700 Phase 2 rosiglitazone
647 Iron Depletion Therapy for Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Completed NCT00230087 Phase 2
648 Naltrexone as an Adjunct in Alcoholic Cocaine Dependent Patients Completed NCT00000307 Phase 2 Naltrexone
649 A Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Orally Administered Silymarin Preparation (Legalon®) for the Treatment of Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Completed NCT00680407 Phase 2 Silymarin 700 mg;Silymarin 420 mg
650 Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study Completed NCT00525252 Phase 1, Phase 2 Baclofen;placebo
651 The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT04080947 Phase 1, Phase 2 Control group;Montelukast group
652 A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
653 Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial Completed NCT00990639 Phase 1, Phase 2 candesartan for hepatic fibrosis
654 Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease Completed NCT01963845 Phase 2 Sitagliptin;Placebo
655 Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis Completed NCT01919294 Phase 2 testosterone undecanoate
656 A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis Completed NCT01903798 Phase 2 Mycophenolate mofetil;Prednisolone;Rilonacept
657 The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-alcoholic Fatty Liver Disease Completed NCT01876108 Phase 2 H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
658 Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient. Completed NCT01875081 Phase 2
659 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed NCT01766713 Phase 2 Ezetimibe
660 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis Completed NCT03400163 Phase 2 BMS-986036;Placebo
661 A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT03205150 Phase 2 LIK066;Placebo
662 ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT02330549 Phase 2 Cenicriviroc 150 mg;Placebo
663 A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study Completed NCT02279524 Phase 2 Aramchol
664 The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-diabetic Subjects With Non-alcoholic Fatty Liver Disease Completed NCT01654549 Phase 2 H.pylori eradication
665 A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis Completed NCT01591200 Phase 2
666 A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients Completed NCT02546609 Phase 2 Leu-Met-Sil 0.5;Leu-Met-Sil 1.0;Placebo
667 Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients Completed NCT02491905 Phase 2 HL tablet;Placebo
668 The Effect of Helicobacter Pylori Eradication on Liver Function Tests in Subjects With Non-alcoholic Fatty Liver Disease Completed NCT01759628 Phase 2 H.pylori eradication
669 The Effect of Pentoxifylline on Liver Function Tests in Non-alcoholic Fatty Liver Disease Patients Refereed to Sina Hospital Gastroenterology Clinic Completed NCT02283710 Phase 2 Pentoxifylline
670 Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease Completed NCT02496390 Phase 1, Phase 2
671 A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis. Completed NCT02316717 Phase 2
672 A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed NCT03421431 Phase 2 EDP-305 Dose 1;EDP-305 Dose 2;Placebo
673 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis Completed NCT02413372 Phase 2 BMS-986036;Placebo
674 Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases Completed NCT02314026 Phase 2
675 An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH) Completed NCT02653300 Phase 2
676 A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients. Completed NCT02941549 Phase 2 Epeleuton
677 A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis Completed NCT03517540 Phase 2 Tropifexor (LJN452);Cenicriviroc (CVC)
678 A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Completed NCT03061721 Phase 2 Saroglitazar magnesium 1 mg;Saroglitazar magnesium 2 mg;Saroglitazar magnesium 4 mg;Placebos
679 A Monocentric, Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Nitazoxanide at 500mg Twice Daily on Collagen Turnover in Plasma in NASH Patients With Fibrosis Stage 2 or 3 Completed NCT03656068 Phase 2 Nitazoxanide 500mg BID
680 A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT03008070 Phase 2 IVA337;Placebo
681 Serine Supplementation in Nonalcoholic Fatty Liver Disease Completed NCT02599038 Phase 1, Phase 2
682 Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD Completed NCT01553500 Phase 2
683 The Sleep, Liver Evaluation and Effective Pressure Study (SLEEP) Completed NCT01482065 Phase 2
684 A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH Completed NCT01094158 Phase 2 Aramchol;Placebo
685 Residual Effects of Intoxication on Student Performance Completed NCT00183170 Phase 2 Alcohol
686 Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics Completed NCT01975935 Phase 2 Amlexanox;Placebo
687 A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Diet Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease Completed NCT00230113 Phase 2
688 Motivation and Skills for THC/ETOH+ Teens in Jail Completed NCT00227890 Phase 2
689 A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis Completed NCT03812029 Phase 2 EYP001a
690 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease. Completed NCT03350165 Phase 2 K-877;Placebo
691 A Multi-center, Randomized, Double-blind, Dose-increasing, Placebo-controlled,Multi-dose, 28-day Continuous Administration Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, Efficacy, and PK of ZSP1601 in Patients With Nonalcoholic Steatohepatitis Completed NCT04140123 Phase 1, Phase 2 ZSP1601;ZSP1601 Placebo
692 A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 Completed NCT02466516 Phase 2 SEL
693 Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH) Completed NCT02366052 Phase 2
694 A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH. Completed NCT03166735 Phase 2 BI 1467335;Placebo
695 A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II Completed NCT02279407 Phase 2 placebo;Omega-3 carboxylic acids;Dapagliflozin;Placebo
696 A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I Completed NCT02354976 Phase 2 Placebo;Omega-3 carboxylic acid;Fenofibrate 200mg
697 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE Completed NCT03256526 Phase 2 Placebo;PF-06835919 Low Dose;PF-06835919 High Dose
698 A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis Completed NCT03486912 Phase 2 BMS-986036
699 A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Completed NCT03486899 Phase 2 BMS-986036
700 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy Completed NCT02654977 Phase 2 Metreleptin
701 Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study Completed NCT01399645 Phase 2 Liraglutide-metformin vs insulin-metformin
702 48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes Completed NCT01237119 Phase 2 Liraglutide
703 Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial Completed NCT01205087 Phase 2 OKT3
704 An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD) Completed NCT03508687 Phase 1, Phase 2 300mg Gemcabene;600mg Gemcabene
705 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM Completed NCT03656744 Phase 2 HTD1801;Placebo
706 A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) Completed NCT03912532 Phase 2
707 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Completed NCT03449446 Phase 2 SEL;FIR;CILO;Placebo to match FIR;Placebo to match CILO;Placebo to match SEL
708 Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial Completed NCT02684591 Phase 2 Aramchol;Placebo
709 A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis Completed NCT02633956 Phase 2 Obeticholic Acid;Atorvastatin;Placebo
710 A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH) Completed NCT04399538 Phase 2 PF-06865571;PF-05221304;Placebo
711 A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2) Completed NCT04874233 Phase 2 HU6;Placebo
712 AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects Completed NCT04480710 Phase 2 CRV431 75mg;Placebo (1 softgel);CRV431 225mg;Placebo (3 softgels)
713 The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study Completed NCT01147523 Phase 2 Spironolactone/Vitamin E
714 The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial Completed NCT01265498 Phase 2 obeticholic acid;placebo
715 A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH Completed NCT01154985 Phase 2 Placebo capsule;EPA-E 300 mg capsule
716 Anti-LPS Antibody in Pediatric Nonalcoholic Fatty Liver Disease Completed NCT03042767 Phase 2
717 A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT03987074 Phase 2 Semaglutide;Firsocostat;Cilofexor
718 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT03976401 Phase 2 EFX;Placebo
719 Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial. Completed NCT04235205 Phase 2 Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g);Elobixibat 10mg + cholestyramine powder placebo;Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g);Elobixibat placebo + cholestyramine powder placebo
720 Long-Term Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00062764 Phase 2 Actos (Pioglitazone)
721 A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients Completed NCT04321343 Phase 2 PXL065;Placebo oral tablet
722 CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis Completed NCT02217475 Phase 2 Cenicriviroc;Placebo
723 Treatment Efficacy of Pentoxifylline in Patients With Nonalcoholic Steatohepatitis: A Double-blind Randomized Placebo Controlled Trial Completed NCT00590161 Phase 2 pentoxifylline (PTX);placebo
724 Weight Management in Nonalcoholic Steatohepatitis (NASH) Completed NCT00266019 Phase 2
725 A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT04134091 Phase 2 LPCN 1144 Formulation A;LPCN 1144 Formulation B;Placebo
726 Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease Completed NCT01084486 Phase 1, Phase 2 Metformin
727 A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00586911 Phase 2 Cystadane;Identical Placebo
728 Nonalcoholic Steatohepatitis: is Leptin an Etiological Factor (Phase 2). Completed NCT00596934 Phase 2 metreleptin
729 A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD Completed NCT03763877 Phase 2 PXL770;Placebo Oral Capsule
730 Acute and Residual Effects of Beer VS. Caffeinated Beer On Simulated Driving Completed NCT00515294 Phase 1, Phase 2 Caffeinated Alcoholic Beer;Caffeinated Non-Alcoholic Beer
731 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis Completed NCT02856555 Phase 2 Firsocostat;Placebo
732 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Completed NCT01066364 Phase 2 Colesevelam Hcl
733 A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis Completed NCT01068444 Phase 2 Pioglitazone;placebo
734 A Randomized, Double-blind, Placebo Controlled Trial (RCT) of Varenicline to Reduce Alcohol Consumption in Heavy Drinkers Completed NCT00695500 Phase 1, Phase 2 Varenicline;Placebo
735 Improving Smoking Cessation Outcomes in Heavy Drinkers Completed NCT00107575 Phase 2
736 Treatment of Nonalcoholic Steatohepatitis With Pioglitazone Completed NCT00013598 Phase 2 Pioglitazone
737 A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) Completed NCT04006145 Phase 2 Elobixibat;Placebo oral tablet
738 Treatment of Nonalcoholic Steatohepatitis With Metformin Completed NCT00063232 Phase 2 Metformin
739 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT02854605 Phase 2 GS-9674;Placebo to match GS-9674
740 A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT02781584 Phase 2 SEL;FIR;CILO;FENO;VAS
741 Study of Efficacy and Tolerability of Docosahexaenoic Acid (DHA) on Children Affected by Nonalcoholic Fatty Liver Disease (NAFLD). Completed NCT00885313 Phase 1, Phase 2 DHA250;DHA500;PLACEBO
742 A Pilot Study of Losartan in the Treatment of Pediatric NAFLD Completed NCT01913470 Phase 2 Losartan
743 A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT04618744 Phase 2 ORMD-0801 (Insulin) capsule 8 mg BD
744 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Completed NCT01679197 Phase 2 Metreleptin
745 An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis Completed NCT02510599 Phase 2 solithromycin
746 A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) Completed NCT02442687 Phase 2 JKB-121: 5 mg twice daily;JKB-121: 10 mg twice daily;Placebo
747 An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT04616014 Phase 2 ORMD-0801 QD;ORMD-0801 BD
748 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE Completed NCT03248882 Phase 2 Placebo;PF-05221304
749 Treatment of NAFLD With Two Different Diets Completed NCT03118310 Phase 2
750 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT03371355 Phase 2 Placebo;ISIS 703802 40 mg;ISIS 703802 80 mg;ISIS 703802 20 mg
751 A Phase II, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of Nonalcoholic Steatohepatitis (NASH) Completed NCT05343780 Phase 2 Heptex
752 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) Completed NCT02443116 Phase 2
753 Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Completed NCT02421094 Phase 2 GR-MD-02;Placebo
754 Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Pilot Study (CRAVR-Pilot) Recruiting NCT04990765 Phase 2
755 Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence: A Randomized Controlled Trial (CRAVR) Recruiting NCT05042180 Phase 2
756 A Placebo-controlled, Double -Blind Randomised Trial of Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence Recruiting NCT03897062 Phase 2 Suvorexant 20 mg
757 The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence: An Exploratory Pilot Study Recruiting NCT05387148 Phase 2 Cannabidiol (CBD);Placebo
758 A Randomized, Double-blind, Placebo-controlled Multicenter Trial on the Efficacy of Varenicline and Bupropion in Combination and Alone, for Treatment of Alcohol Use Disorder Recruiting NCT04167306 Phase 2 Varenicline Tartrate 1 mg b.i.d;Bupropion Hydrochloride 150 mg b.i.d
759 Medication Development for Protracted Abstinence in Alcoholism: Suvorexant Versus Placebo Recruiting NCT04229095 Phase 2 Suvorexant 20 mg;Placebo oral tablet
760 The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder Recruiting NCT02122562 Phase 2 Ketamine
761 Transcranial Alternating Current Stimulation to Boost the Efficacy of Motivational Interviewing Recruiting NCT04770025 Phase 2
762 Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder Recruiting NCT03896516 Phase 1, Phase 2 GLWL-01
763 Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder (AUD) and Comorbid Post-Traumatic Stress Disorder (PTSD) Recruiting NCT03852628 Phase 2 2mg Buprenex and 380mg Vivitrol;Placebo (SL pill qd, IM injection q4weeks)
764 Tolerability and Efficacy of Hemp-Derived CBD for the Treatment of Alcohol Use Disorder Recruiting NCT04873453 Phase 2 Cannabidiol;Placebo
765 Prazosin Treatment for Alcohol Use Disorder With Alcohol Withdrawal Symptoms Recruiting NCT04793685 Phase 1, Phase 2 Prazosin
766 COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder Recruiting NCT03904498 Phase 2 Tolcapone;Placebo
767 Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II Recruiting NCT02652195 Phase 2 Placebo;Oxytocin
768 Role of BP1.3656 on Alcohol Responses Recruiting NCT04727086 Phase 2 BP1.3656;Placebo
769 Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework Recruiting NCT05134857 Phase 2 Zonisamide;Placebo
770 Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With Post Traumatic Stress Disorder Recruiting NCT03667846 Phase 2 Topiramate
771 A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder Recruiting NCT03594435 Phase 2 Ibudilast;Placebo oral capsule
772 Human Laboratory Study of ASP8062 for Alcohol Use Disorder Recruiting NCT05096117 Phase 2 ASP8062;Placebo
773 Effects of a Novel mGluR5 Negative Allosteric Modulator on Alcohol Drinking, Neurochemistry, and Brain Reactivity to Alcohol Cues in Alcohol Use Disorder Recruiting NCT04831684 Phase 1, Phase 2 Placebo;GET73
774 Proof-of-Concept Clinical Trial of Lamotrigine as a Candidate Pharmacotherapy for Adolescent Alcohol Use Disorder Recruiting NCT04770493 Phase 2 Lamotrigine;Placebo
775 Randomized, Double Blind, Placebo-Controlled Trial of the Efficacy of Intranasal Oxytocin for the Treatment of Alcohol Use Disorder Recruiting NCT03878316 Phase 2 Instranasal Oxytocin
776 Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT) Recruiting NCT03846505 Phase 2 Oxytocin
777 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving Recruiting NCT05107765 Phase 1, Phase 2 Pioglitazone;Placebo
778 The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder Recruiting NCT05042102 Phase 2
779 An Inflammatory Challenge Using Endotoxin Recruiting NCT04310423 Phase 2 Placebo
780 A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder Recruiting NCT03707951 Phase 2 N-acetylcysteine;Placebo oral capsule
781 A-HACK Project: Addressing Heavy Alcohol Use Consumption With Kudzu Recruiting NCT03709043 Phase 2 Standardized kudzu
782 Neural Target Identification for Functional Disability Associated With Alcohol Related Characteristics Among Veterans With Co-occurring Alcohol Use Disorder and Traumatic Brain Injury Recruiting NCT04043442 Phase 2
783 Revolutionizing Normative Re-education: Delivering Enhanced PNF Within a Social Media Inspired Game About College Life Recruiting NCT04356261 Phase 2
784 A Double-blind, Placebo-Controlled Trial of Pregabalin for the Treatment of Alcohol Use Disorder Recruiting NCT04322305 Phase 2 Pregabalin
785 A Pharmacogenetic Human Laboratory Investigation of Brexpiprazole in Alcohol Use Disorder Recruiting NCT04066192 Phase 2 Brexpiprazole;Placebo
786 Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders Recruiting NCT03764098 Phase 2 Guanfacine ER
787 Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder Recruiting NCT04141501 Phase 2 Psilocybin;Placebo oral capsule
788 A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD Recruiting NCT04135846 Phase 2 Doxazosin;Placebo
789 The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking: a Randomized, Controlled Trial Recruiting NCT04084860 Phase 2 CI-581a;CI-581b
790 Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder Recruiting NCT04620759 Phase 2 Psilocybin;Placebo
791 Does Endotoxin Administration Increase Alcohol Consumption in Individuals With AUD? Recruiting NCT04527185 Phase 2 Endotoxin
792 Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Recruiting NCT03220776 Phase 2 N-Acetylcysteine;Gabapentin;Placebo Oral Tablet
793 Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD Recruiting NCT04523922 Phase 2 40 IU Intranasal Oxytocin;Placebo
794 Human Laboratory Screening of Semaglutide for Alcohol Use Disorder Recruiting NCT05520775 Phase 2 Semaglutide;Sham/placebo
795 Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine Recruiting NCT04565288 Phase 2 Atomoxetine;Placebo
796 Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism Recruiting NCT05312008 Phase 2 Intranasal oxytocin;Intranasal placebo
797 Ketamine for The Rapid Treatment of Major Depression and Alcohol Use Disorder Recruiting NCT02461927 Phase 1, Phase 2 Ketamine + Naltrexone;Ketamine + Placebo;Placebo (psychoactive placebo midazolam) + Placebo
798 A Phase II, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Subjects With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT05462353 Phase 2 2mg of ASC41;4mg of ASC41 (2 tablets of 2 mg ASC41);Placebo
799 Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) Recruiting NCT03884075 Phase 2 Semaglutide
800 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MN-001 in Patients Diagnosed With Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia Recruiting NCT05464784 Phase 2 MN-001;MN-001 placebo
801 SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Recruiting NCT03867487 Phase 2 Empagliflozin 10 MG;Placebo Oral Tablet
802 Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial Recruiting NCT05016882 Phase 2 NNC0194 0499 50 mg/mL;Placebo (NNC0194-0499);Semaglutide 3 mg/mL;Semaglutide placebo;NNC0174 0833 10 mg/mL;NNC0174 0833 placebo
803 Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH) Recruiting NCT05083390 Phase 2 norUrsodeoxycholic acid
804 Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis. Recruiting NCT04771273 Phase 2 BI 456906;Placebo
805 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH) Recruiting NCT04679376 Phase 2 Atorvastatin (40 mg daily)
806 Metabolic Effects of Ketohexokinase Inhibition on Individuals With Non-alcoholic Fatty Liver Disease Recruiting NCT05463575 Phase 2 Ketohexokinase inhibition
807 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered HEC96719 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis Recruiting NCT05397379 Phase 2 HEC96719;Placebo
808 An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects With Confirmed Non-Alcoholic Steatohepatitis Recruiting NCT04932512 Phase 2 ION224
809 A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL) Recruiting NCT04704063 Phase 2 Tocotrienols / Vitamin E;Placebo control
810 A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Recruiting NCT04697810 Phase 2 Namodenoson;Placebo
811 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as Well as in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NASH) Recruiting NCT05415722 Phase 2 TERN-501;TERN-101
812 A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fibrosis (EMMPACT) Recruiting NCT04880187 Phase 2 AXA1125;Placebo
813 A Pilot Study to Treat Adults With Non-Alcoholic Steatohepatitis With Oral Idebenone Recruiting NCT04669158 Phase 1, Phase 2 Idebenone;Placebo
814 U01 Pilot Trial of DUR-928 in Patients With Moderate and Severe Alcoholic Hepatitis Recruiting NCT03917407 Phase 2 DUR-928 (Moderate AH);DUR-928 (Severe AH)
815 VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis Recruiting NCT04173065 Phase 2 VK2809;Placebos
816 A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2) Recruiting NCT04378010 Phase 2 EDP-305 1.5 mg;EDP-305 2 mg;Placebo
817 Double-blind, Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of ZED1227 Capsules With Placebo in the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) With Significant Fibrosis Recruiting NCT05305599 Phase 2 ZED1227;Placebo
818 Comparative Study Evaluating the Outcome of Febuxostat Versus Vitamin E in Hyperuricemia Patients With Non-alcoholic Steatohepatitis Without Cirrhosis Recruiting NCT05574036 Phase 2 Febuxostat 80 MG Oral Tablet;vit E
819 A Randomized, Double-blind, Placebo-controlled, Phase 2b Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Alcoholic Hepatitis Recruiting NCT04563026 Phase 2 DUR-928 30 mg;DUR-928 90 mg;Placebo+ Standard of Care (SOC)
820 A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Recruiting NCT05232071 Phase 2 IVA337;Placebo;Empagliflozin
821 Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD Recruiting NCT04550481 Phase 2 Lisinopril
822 Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS) Recruiting NCT03617263 Phase 2 Saroglitazar Magnesium 4 mg Tablet;Placebo
823 Digoxin In Treatment of Alcohol Associated Hepatitis (DIGIT-AlcHep) Recruiting NCT05014087 Phase 2 Intravenous digoxin
824 A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE) Recruiting NCT04065841 Phase 2 Tropifexor;Licogliflozin
825 Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Recruiting NCT03375788 Phase 2 Tesamorelin;Identical Placebo
826 Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT04501406 Phase 2 Pioglitazone
827 A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Recruiting NCT04971785 Phase 2 Semaglutide (SEMA);Cilofexor (CILO)/Firsocostat (FIR);PTM SEMA;PTM CILO/FIR
828 The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study Recruiting NCT05364684 Phase 2 LUM-201
829 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects With Biopsy Confirmed NASH Recruiting NCT04505436 Phase 2 HM15211;Placebo of HM15211
830 A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis Recruiting NCT05011305 Phase 2 Saroglitazar Magnesium 2 mg;Saroglitazar Magnesium 4 mg;Placebo
831 A Phase 2A, Single Center, Open-label, Single-arm, 24-week Study to Evaluate the Safety, Tolerability and Efficacy of Saroglitazar Magnesium 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (EVIDENCES VIII) Recruiting NCT03639623 Phase 2 Saroglitazar
832 Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD Recruiting NCT04801849 Phase 2 Vitamin E;Placebo
833 Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT03576755 Phase 1, Phase 2 Spironolactone 100mg;Placebo oral capsule
834 Tocotrienol Against the Progression of End Stage Liver Disease Recruiting NCT02581085 Phase 2 Tocotrienol (TCT)
835 A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis Recruiting NCT04710524 Phase 2 Placebo;FM101 150 mg BID;FM101 300 mg BID
836 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Recruiting NCT05039450 Phase 2 EFX;Placebo
837 Vitamin E for NASH Treatment in HIV Infected Individuals Recruiting NCT03669133 Phase 2 Vitamin E;Placebos
838 Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial. Recruiting NCT04761848 Phase 1, Phase 2 Cilostazol 50 MG;Placebo
839 Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Recruiting NCT03459079 Phase 2 Lanifibranor
840 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Recruiting NCT04166773 Phase 2 Tirzepatide;Placebo
841 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH) Recruiting NCT04267393 Phase 2 BMS-986263
842 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 Recruiting NCT04321031 Phase 2 Placebo;PF-06865571;PF-05221304
843 Aspirin in Adults With Nonalcoholic Fatty Liver Disease Recruiting NCT04031729 Phase 1, Phase 2 Aspirin 81 mg;Placebo oral tablet
844 A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis. Recruiting NCT04583423 Phase 2 MK-3655;Placebo
845 Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder Active, not recruiting NCT04410913 Phase 2 Psilocybin plus Visual Healing Set and Setting;Psilocybin plus Standard Set and Setting
846 A Randomized Controlled Trial of N-Acetylcysteine for Alcohol Use Disorder and Comorbid Post Traumatic Stress Disorder Active, not recruiting NCT02966873 Phase 2 N-Acetylcysteine (NAC) Treatment;Placebo Oral Capsule
847 Brain Targets for Alcohol Craving in Veterans With mTBI. Active, not recruiting NCT03995173 Phase 2
848 A Phase I/II, Prospective, Randomized, Double-Blind, PlAcebo-ControLled Trial to EvAluate the Potential Efficacy of Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion. Active, not recruiting NCT03265808 Phase 1, Phase 2 allogeneic human mesenchymal stem cells (allo-hMSCs);Placebo
849 Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in Promoting Abstinence in Alcohol Use Disorder (AUD). Active, not recruiting NCT04581603 Phase 2 Topiramate (TOP)
850 Phase II Physician-initiated Clinical Trial Investigating the Efficacy and Safety of Guanabenz Acetate for Non-alcoholic Fatty Liver Disease Associated With Hypertension Active, not recruiting NCT05084404 Phase 2 Experimental: 4 mg/day of WY-8678 (guanabenz acetate);Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
851 A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis Active, not recruiting NCT04171765 Phase 2 Placebo;BFKB8488A
852 A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) Active, not recruiting NCT04216589 Phase 2 Semaglutide
853 IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) Active, not recruiting NCT03775109 Phase 2 Canakinumab 150mg/ml solution for injection;Placebo
854 Comparative Study Evaluating the Outcome of Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis Without Cirrhosis Active, not recruiting NCT05573204 Phase 2 Obeticholic Acid Oral Tablet;Vit E
855 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04052516 Phase 2 Icosabutate;Placebo
856 A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2) Active, not recruiting NCT04906421 Phase 2 TVB-2640
857 A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease Active, not recruiting NCT04944992 Phase 2 Efinopegdutide 20 mg/mL;Semaglutide 1.34 mg/mL
858 Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04773964 Phase 2 MET642;Placebo
859 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04767529 Phase 2 EFX;Placebo
860 A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04702490 Phase 2 MET409 Active;MET409 Placebo;Empagliflozin
861 A 12-week Phase 2a Randomized, Blinded, Placebo Controlled Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04880031 Phase 2 BOS-580;Placebo
862 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04929483 Phase 2 BIO89-100
863 An Open Label Extension Study of the Safety and Tolerability of LPCN 1144 for the Treatment of Subjects With Nonalcoholic Steatohepatitis (NASH) Who Have Completed the LPCN 1144-18-002 Trial Active, not recruiting NCT04685993 Phase 2 LPCN 1144
864 The University of Michigan Wellness Education for Liver Health Study Active, not recruiting NCT05010070 Phase 1, Phase 2
865 Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4) Active, not recruiting NCT04210245 Phase 2
866 A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Two-Arm Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04521114 Phase 2 Placebos;leronlimab
867 A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis Active, not recruiting NCT05338034 Phase 2 HPG1860;Placebo
868 Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: the First Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial Not yet recruiting NCT03380728 Phase 2 Ibogaine Hydrochloride
869 A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder Not yet recruiting NCT05414240 Phase 2 Ibudilast;Placebo
870 Cannabidiol for Reducing Drinking in Alcohol Use Disorder and Modifying the Effects of Alcohol on the Brain and the Liver: a Phase 2 Clinical Trial.-The CARAMEL Study Not yet recruiting NCT05159830 Phase 2 Cannabidiol Cap/Tab;Placebo Cap/Tab
871 A Pilot Study of N-acetylcysteine for Alcohol Use Disorder Not yet recruiting NCT04964843 Phase 2 N-acetylcysteine;Placebo
872 Woebot for Substance Use Disorders Phase 2 RCT: Digitally Delivered Intervention for Reducing Problematic Substance Use Not yet recruiting NCT04925570 Phase 2
873 The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial. Not yet recruiting NCT05416229 Phase 2 Psilocybin;Lactose
874 Cannabis' Impact on Alcohol Consumption: Integrating Laboratory and Ecological Momentary Assessment Methods Not yet recruiting NCT05389930 Phase 2 THC-dominant cannabis;CBD-dominant cannabis;Cannabis placebo;Alcohol;Alcohol placebo
875 Psilocybin-assisted Psychotherapy for Treatment of Alcohol Use Disorder Not yet recruiting NCT05421065 Phase 2 Psilocybin
876 Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study Not yet recruiting NCT04718792 Phase 2 Psilocybin
877 Lactobacillus Rhamnosus GG: A Novel Probiotic Therapy for Treating Alcohol Use Disorder Not yet recruiting NCT05178069 Phase 2 : Placebo for Probiotic
878 LSD Treatment for Persons With Alcohol Use Disorder: A Multicenter, Double-blind, Randomized, Active-placebo Controlled Phase II Study Not yet recruiting NCT05474989 Phase 2 LSD;Active placebo
879 Riboflavin for Glutamate Reduction in Alcohol Withdrawal Not yet recruiting NCT04232800 Phase 2 Riboflavin
880 Neurobehavioral Effects of Cannabidiol in Youth Alcohol Use Disorder Not yet recruiting NCT05317546 Phase 2 Cannabidiol
881 Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Not yet recruiting NCT05548452 Phase 1, Phase 2 Intestinal Microbiota Transplant (IMT) Capsules;Placebo Capsules
882 Dasatinib and Quercetin, a Combination of Senolytics to Treat Fibrotic Non-alcoholic Fatty Liver Disease - the TRUTH Study Not yet recruiting NCT05506488 Phase 1, Phase 2 Dasatinib 100 MG + Quercetin (1250 MG)
883 A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis Not yet recruiting NCT03468556 Phase 2 SNP-610;Placebo Oral Tablet
884 A Phase 2, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of JKB-122 in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Not yet recruiting NCT04255069 Phase 2 Placebo;Dose 1 JKB-122;Dose 2 JKB-122
885 17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Non-Alcoholic Steatohepatitis Not yet recruiting NCT05583344 Phase 2 GSK4532990;Placebo
886 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subjects With Acute Alcoholic Hepatitis Causing Decompensation of Alcohol-related Cirrhosis and Acute-on-Chronic Liver Failure Not yet recruiting NCT04620148 Phase 2 TAK-242;Placebo
887 The Effect of High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease Patients Not yet recruiting NCT05578404 Phase 2 Cholecalciferol;Placebo
888 A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors Not yet recruiting NCT05519475 Phase 2 ALN-HSD;Placebo
889 A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH) Not yet recruiting NCT05118360 Phase 2 ASC41 2 mg;ASC41 4 mg;Placebo
890 A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Not yet recruiting NCT05402371 Phase 2 Rencofilstat;Placebo
891 Effects of Febuxostat for Interventions of Lowering Uric Acid in Patients With Gout With Nonalcoholic Fatty Liver Disease: a Multicenter, Open-label, Randomized, Controlled Study Not yet recruiting NCT04772352 Phase 2 febuxostat treatment
892 A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD) Not yet recruiting NCT04371653 Phase 2 PRIM-DJ2727;Placebo
893 Effects of Cannabis/Alcohol on Driving Performance and Field Sobriety Tests Not yet recruiting NCT05273658 Phase 1, Phase 2 Cannabis;Alcohol
894 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis (NASH) in People Living With Human Immunodeficiency Virus (HIV) in the US Not yet recruiting NCT05211284 Phase 2 Saroglitazar Magnesium 4 mg;Placebo
895 Low Dose Thyroid Hormone, Mitochondrial Fatty Acid Oxidation, and Treatment of Nonalcoholic Steatohepatitis (NASH) Not yet recruiting NCT05526144 Phase 2 Synthroid;Placebo
896 Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver Suspended NCT00546455 Phase 2 Fenretinide;Placebo
897 Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics Suspended NCT01842282 Phase 2 Amlexanox
898 A Prospective, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Subjects With Alcohol Dependence. Terminated NCT00764660 Phase 2 SCH 900435;Placebo
899 A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence Terminated NCT00835718 Phase 2 Comparator: MK0594 5 mg/day;Comparator: MK0594 1 mg/day;Comparator: MK0594 1 mg/week;Comparator: Placebo to MK0594
900 A Phase II, Double-Blind, Placebo-Controlled, Pilot Trial of Vigabatrin for the Treatment of Cocaine and Alcohol Dependence Terminated NCT01335867 Phase 2 Vigabatrin;Placebo
901 A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of; Levetiracetam, Zonisamide, Topiramate, and Placebo Control for the Treatment of Alcohol Dependent Subjects. Terminated NCT00862563 Phase 2 Topiramate;Zonisamide;Levetiracetam;Sugar Pill
902 Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers Terminated NCT01764685 Phase 2 Topiramate;Placebo
903 Role of Proinflammatory Signaling in Alcohol Craving Terminated NCT01631630 Phase 2 Pioglitazone;Placebo
904 A Novel Compound for Alcoholism Treatment: A Translational Strategy - Part II Terminated NCT02707055 Phase 2 PF-05190457
905 A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study) Terminated NCT03060772 Phase 2 Pioglitazone
906 A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence Terminated NCT00249431 Phase 2 Sertraline
907 Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Terminated NCT00890149 Phase 2 Ondansetron;Placebo
908 Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial Terminated NCT01937364 Phase 2 Baclofen;Placebo
909 Zonisamide for Heavy Drinkers With Bipolar Disorder Terminated NCT01566370 Phase 2 Zonisamide;Placebo
910 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot) Terminated NCT03860753 Phase 1, Phase 2 Pioglitazone;Placebo
911 Human Laboratory Screening of Lorcaserin in Smokers With Alcohol Use Disorder Terminated NCT04396847 Phase 2 Lorcaserin Oral Tablet;Placebo oral tablet
912 Exploration of Gemfibrozil as a Treatment for Alcohol Use Disorder Terminated NCT03539432 Phase 2 Gemfibrozil 600 MG;Placebo oral capsule
913 Human Laboratory Study of ANS-6637 for Alcohol Use Disorder Terminated NCT03970109 Phase 2 ANS-6637;Placebo oral tablet
914 Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC) Terminated NCT01216020 Phase 2 cetuximab;cisplatin (associated to radiotherapy)
915 A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) Terminated NCT02605616 Phase 2 AZ compound
916 NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype Terminated NCT04147195 Phase 2 LYS006;LYS006 + Tropifexor (LJN452)
917 A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD) Terminated NCT01167088 Phase 2 Mitoquinone mesylate;Placebo
918 Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Terminated NCT00845845 Phase 2 Omega-3-acid ethyl esters (Lovaza);Placebo
919 A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH) Terminated NCT02913105 Phase 2 LMB763;Placebo
920 A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Terminated NCT02039219 Phase 2 Placebo;10 mg Obeticholic Acid (OCA)
921 A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis. Terminated NCT03452540 Phase 2 1000mg DS102 (BID)
922 Effects of 4-month Therapy of Levothyroxine on Non-Alcoholic Fatty Liver Disease (NAFLD) and Diabetes Control in Diabetic Patients Terminated NCT03281083 Phase 2 Levothyroxine Sodium
923 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Terminated NCT04048876 Phase 2 CC-90001;Placebo
924 Effect of Probiotics in Non-Alcoholic Fatty Liver Disease and Steatohepatitis Measured by Transient Elastography (PRONE Study). Terminated NCT04175392 Phase 1, Phase 2 Align Probiotic Supplement Capsule;Placebos
925 A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR Terminated NCT02855164 Phase 2 Tropifexor (LJN452);Placebo
926 Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease Terminated NCT00529204 Phase 2 exenatide
927 Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions Terminated NCT00152815 Phase 2 antioxidant vitamin E
928 A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD) Terminated NCT00677521 Phase 2 Acarbose
929 A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy Terminated NCT01912404 Phase 2 IDN-6556;Placebo
930 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) Terminated NCT01672879 Phase 2
931 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) Terminated NCT01672866 Phase 2
932 Evaluation of Alterations in Serum Inflammatory Markers and Fecal Microbiota Following Administration of the Probiotic Formulation VSL#3 in Patients With Nonalcoholic Fatty Liver Disease Terminated NCT03511365 Phase 1, Phase 2
933 Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) Terminated NCT03059446 Phase 2 Cenicriviroc
934 Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study Terminated NCT03436420 Phase 2 Gemcabene
935 Многоцентровое двойное слепое плацебо-контролируемое рандомизированное исследование препарата Рунихол® у пациентов с неалкогольной жировой болезнью печени на фоне метаболического синдрома Terminated NCT02930161 Phase 2 Runihol
936 An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Children and Adolescents, 8 to 17 Years of Age, With Nonalcoholic Steatohepatitis (NASH) Terminated NCT03883607 Phase 2 Elafibranor 80mg;Elafibranor 120mg
937 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure Terminated NCT01937130 Phase 2 IDN-6556
938 A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) Treatment Administered Once Daily on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL) Terminated NCT03953456 Phase 2 elafibranor 120mg;Placebo
939 A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH) Terminated NCT02787304 Phase 2 SHP626;Placebo
940 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis Terminated NCT02029586 Phase 2 MB12066 200mg;Placebo
941 Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT) Terminated NCT01244503 Phase 2 Sodium Octanoate Breath Test
942 Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial Terminated NCT03467217 Phase 2 Losartan potassium;Placebo losartan capsule
943 The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD Terminated NCT02244944 Phase 2 EZ-Urso combination therapy
944 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) Terminated NCT03551522 Phase 2 Seladelpar;Placebos
945 A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis Terminated NCT01703260 Phase 2 Roflumilast;Pioglitazone;Placebo
946 A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis Terminated NCT03329885 Phase 1, Phase 2 BMS-986251
947 The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Terminated NCT03294941 Phase 2
948 A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability and Efficacy of FT-4101 in Overweight/Obese Subjects With NASH Terminated NCT04004325 Phase 1, Phase 2 FT-4101;FT-4101 placebo
949 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Terminated NCT03823703 Phase 2 Miricorilant;Placebo
950 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH) Terminated NCT03676231 Phase 2 SGM-1019;Placebo
951 Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance (MR) Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT01930123 Phase 2 intravenous fructose challenge
952 Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons Withdrawn NCT01853293 Phase 2 Kudzu extract;Placebo
953 A Single Center, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy of JNJ 31001074 on Cue Induced Craving for Alcohol in Adult Subjects With Alcohol DependenceH3 Alcoholism Withdrawn NCT01362699 Phase 2 JNJ-31001074;Placebo
954 Preliminary Human Trial of NPI-028 Withdrawn NCT00010907 Phase 2 NPI-028
955 Intranasal Oxytocin Treatment for Alcohol Use Disorders: A Randomized, Placebo-Controlled Trial Withdrawn NCT03636555 Phase 2 Oxytocin;Placebo
956 A Pilot Human Laboratory Study of Cannabidiol in Alcohol Use Disorder Withdrawn NCT03904849 Phase 1, Phase 2 Cannabidiol;Placebo
957 The Effects of Intranasal Oxytocin on Approach Bias and Craving in Moderate to Heavy Alcohol Drinkers Withdrawn NCT03865615 Phase 2 Oxytocin;Placebo
958 cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use Withdrawn NCT01275391 Phase 1, Phase 2
959 Development of a Selective ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder Withdrawn NCT04311294 Phase 2 ANS-6637 Low Dose;ANS-6637 High Dose;Matched Placebo
960 A Double-Blind, Randomized, Controlled Trial of MAP4343 Treatment, a Ligand of the Neurospecific Microtubule Associated Protein-2, for Alcohol Use Disorder Withdrawn NCT04157114 Phase 2 MAP4343;Placebo
961 A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment Withdrawn NCT02800083 Phase 2 Pitolisant (BF2.649);Placebo
962 An Open Label Pilot Study Evaluating Safety and Efficacy of Divalproex Sodium (Depakote ER) in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence. Withdrawn NCT00204503 Phase 2 Depakote ER
963 Development of Minocycline as a Neuroimmune Therapy for Alcohol Use Disorder Withdrawn NCT03244592 Phase 1, Phase 2 Minocycline;Sugar pill
964 Zonisamide as a New Treatment for Post-Traumatic Stress Disorder and Co-Occurring Alcohol Use Disorder Withdrawn NCT03376139 Phase 2 Zonisamide;Placebo Comparator
965 A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH) Withdrawn NCT03437720 Phase 2 SAR425899;Placebo
966 Efficacy and Safety of Digoxin in the Treatment of Adults Patients With Non-alcoholic Steatohepatitis: a Multi-center, Randomized, Placebo-controlled Trial Withdrawn NCT04216693 Phase 2 Digoxin tablet
967 Arginine Treatment for Alcoholic Hepatitis Withdrawn NCT00200746 Phase 2 Arginine
968 GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis Withdrawn NCT04607655 Phase 1, Phase 2 GB1211;Placebo
969 A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis Withdrawn NCT01466894 Phase 2
970 A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Withdrawn NCT03291249 Phase 2 Foralumab;Omeprazole 20mg
971 Curcumin for Pediatric Nonalcoholic Fatty Liver Disease: A Pilot Randomized Controlled Trial Withdrawn NCT04109742 Phase 2 phosphatidylcholine-curcumin complex supplement;Placebo curcumin capsule
972 A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN Withdrawn NCT02769091 Phase 2 TEV-45478;Placebo
973 Brief Interventions for Heavy Alcohol Users Admitted to General Hospital Unknown status NCT00982306 Phase 1
974 Open-Label Proof of Concept Feasibility Study to Explore the Safety, Tolerability and Potential Role of MDMA-Assisted Psychotherapy for the Treatment of Detoxified Patients With Alcohol Use Disorder Unknown status NCT04158778 Phase 1 MDMA
975 CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change Unknown status NCT00269009 Phase 1
976 Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy Unknown status NCT00396617 Phase 1
977 A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis Unknown status NCT03838250 Phase 1
978 Neurosteroids and Acute Alcohol Intoxication in Humans Unknown status NCT00608686 Phase 1
979 Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Unknown status NCT02469272 Phase 1 Fecal Microbiota Transplantation
980 A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence. Completed NCT01551329 Phase 1 Ketalar (ketamine)
981 Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study Completed NCT00769158 Phase 1 Topiramate and Naltrexone
982 Development of Ibudilast as a Novel Treatment for Alcohol Dependence Completed NCT02025998 Phase 1 Ibudilast
983 PT150 (Formerly ORG34517) as a Potential Treatment for Alcohol Dependence-Alcohol Interaction Study Completed NCT03548714 Phase 1 PT150
984 Feasibility and Tolerability of a Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study. Completed NCT00614328 Phase 1 Naltrexone, Baclofen, Placebo and Behavior Therapy
985 Interventional, Randomized, Double-blind, Cross-over, Placebo-controlled Study to Investigate the Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge Completed NCT01969617 Phase 1 Nalmefene 18 mg, then placebo;Placebo, then Nalmefene 18 mg
986 Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence Completed NCT01904487 Phase 1 Tiagabine
987 A Novel Compound for Alcoholism Treatment: A Translational Strategy Completed NCT02039349 Phase 1 PF-05190457
988 A Phase 1, Single-Center, Open-Label Study of the Pharmacokinetics of Baclofen Formulations Administered to Healthy Adults Completed NCT00802035 Phase 1 Baclofen IR;Baclofen ER
989 ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults Completed NCT00800319 Phase 1 RDC-0313;Placebo
990 A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects Completed NCT02679469 Phase 1 nalmefene hydrochloride 10 mg
991 Alcohol & HIV in Kenya: Stage 1 Trial of a Peer-Led Alcohol Behavior Intervention Completed NCT00792519 Phase 1
992 Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects Completed NCT01232439 Phase 1 opioid receptor kappa antagonist
993 Effect of Fish Oil vs. Placebo on Subjective Effects of Alcohol in Healthy Humans Completed NCT03010917 Phase 1 Fish Oil with ethanol and placebo ethanol infusions;Placebo with ethanol and placebo ethanol infusions
994 Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders: A Translational Clinical Neuroscience Pilot Investigation of a Novel Pharmacological Agent Completed NCT03732248 Phase 1 Rapamycin;Placebo
995 Minocycline's Effects on Alcohol Responses in Humans Completed NCT02187211 Phase 1 Minocycline;Placebo (for Minocycline)
996 Individualized Treatment Program for Alcohol Problems Completed NCT00298792 Phase 1
997 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics Completed NCT01657760 Phase 1 citalopram
998 Matching Genotypes and Serotonergic Medications for Alcoholism Completed NCT01113164 Phase 1 Ondansetron and Sertraline
999 Cannabinoid Receptor Function & Alcoholism: Effects of Δ-9-THC Completed NCT00624715 Phase 1 THC;Placebo
1000 A Study to Investigate the Psychomotor and Cognitive Effects of Alcohol When Co-administered With GSK1144814 or Matching Placebo in Healthy Subjects. Completed NCT01181908 Phase 1 single dose
1001 A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers Completed NCT01738867 Phase 1 GSK1521498;Naltrexone (NTX);Placebo
1002 A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects Completed NCT01366573 Phase 1 GSK1521498
1003 A Phase I, Open-label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Completed NCT00698464 Phase 1 Pasireotide
1004 Health Behavior Feedback Study for Veterans With Hepatitis C Completed NCT00229580 Phase 1
1005 Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder Completed NCT02407340 Phase 1 oxytocin;placebo
1006 Cognitive Behavioral Treatment of HIV+ Drug Abusers Completed NCT00722644 Phase 1
1007 Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress Completed NCT02058251 Phase 1 Oxytocin;Placebo
1008 The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Completed NCT03872128 Phase 1 Pregnenolone300;Pregnenolone500;Placebo
1009 Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder Completed NCT02990455 Phase 1 Reduced nicotine cigarettes
1010 Exercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults Completed NCT01399554 Phase 1
1011 Woebot for Substance Use Disorders During COVID-19 Completed NCT04460027 Phase 1
1012 Exploration of the Potential Role of Anterior Cingulate (ACC) dTMS in Relapse to Alcohol Use Completed NCT02691390 Phase 1
1013 Family Motivational Interviews for ETOH+ Teens in the ER Completed NCT00247221 Phase 1
1014 Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers Completed NCT03271528 Phase 1 Lacosamide;Placebo oral capsule
1015 Couple-Based Treatment for Alcohol Use Disorders and PTSD Completed NCT00946322 Phase 1
1016 Effects of the Family Check-Up on Adolescents With Alcohol-Related Events and Their Siblings Completed NCT00925340 Phase 1
1017 Neuroendocrine Response to Oral Alcohol Administration Completed NCT03165942 Phase 1 Ethanol
1018 Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis Completed NCT03416751 Phase 1
1019 Computer-delivered SBIRT for Alcohol Use in Pregnancy: Planning a Stage II Trial Completed NCT01643044 Phase 1
1020 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin
1021 Resistance Training and Physical Functioning in Head and Neck Cancer Patients Completed NCT01332682 Phase 1
1022 A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF- 06865571 FOR 2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE Completed NCT03513588 Phase 1 Placebo;PF-06865571
1023 A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC96719 Tablets in Healthy Subjects Completed NCT04422496 Phase 1 HEC96719
1024 A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) Completed NCT04897594 Phase 1 TERN-201
1025 Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
1026 Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD). Completed NCT04845646 Phase 1 ASC41;Itraconazole;Phenytoin
1027 A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease Completed NCT03060538 Phase 1 BFKB8488A
1028 Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) Completed NCT00816465 Phase 1
1029 The Effect of Alcoholic-carrier Solutions Within-devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers Completed NCT02264145 Phase 1 Ethanolic Solution From HFA134a-MDI - low;Ethanolic Solution From HFA134a-MDI - medium;Ethanolic Solution From HFA134a-MDI - high;Ethanolic Solution From Respimat®
1030 The Clinical Safety of Alcoholic Extract Sahastara Remedy of Extract Capsule in Healthy Volunteers (Clinical Trial Phase I) Completed NCT02568059 Phase 1 Sahastara remedy alcoholic extract
1031 SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis Completed NCT02696941 Phase 1 Metformin;SGLT2 inhibitor
1032 A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Completed NCT03950882 Phase 1 PXL770;Placebo
1033 Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences. Completed NCT01277094 Phase 1 Placebo;RO5093151
1034 Clinical Study to Investigate the Effect of NASH (Non-alcoholic Steatohepatitis) on the Disposition of 99mTechnetium(Tc)-Mebrofenin in Healthy Subjects Compared to Patients With NASH. Completed NCT02235233 Phase 1 Technetium Tc 99M Mebrofenin
1035 Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH) Completed NCT04152473 Phase 1 Proglumide
1036 Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease Completed NCT00389376 Phase 1 Placebo;Silymarin
1037 A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease Completed NCT03357380 Phase 1 Semaglutide;Placebo
1038 Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease Completed NCT02826525 Phase 1 AZD4076;Placebo
1039 A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH)With Advanced Hepatic Fibrosis Completed NCT01899859 Phase 1 GR-MD-02;Placebo
1040 An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT03261739 Phase 1
1041 A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects Completed NCT02612662 Phase 1 AZD4076;Placebo
1042 A PHASE 1, 3-PART, SPONSOR OPEN STUDY OF PF-07202954 IN HEALTHY ADULTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE (IN PART 1), AND REPEATED (IN PART 2), ESCALATING, ORAL DOSES ALONG WITH CONDITIONAL PART 3 OF RANDOMIZED, OPEN-LABEL ASSESSMENT OF EFFECT OF FOOD ON PF-07202954 EXPOSURE Completed NCT04857437 Phase 1 PF-07202954 Repeat Dose;PF-07202954 Single Dose;Placebo
1043 A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects Completed NCT02571192 Phase 1 SHP626
1044 Investigation of Safety, Tolerability and Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Japanese and Non-Asian Male Subjects Completed NCT04722653 Phase 1 NNC0194-0499;Placebo (NNC0194-0499 )
1045 An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride Completed NCT01431521 Phase 1 MK-4074 200 mg;Placebo for MK-4074;Pioglitazone hydrochloride 30 mg;Placebo for pioglitazone hydrochloride
1046 A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects Completed NCT02974374 Phase 1 PF-06835919
1047 A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects Completed NCT03681457 Phase 1 LJN452
1048 A Multiple Dose, Randomized, Double-Blind (3rd Party Open), Placebo-Controlled Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of CP-945598 In Subjects With Nonalcoholic Steatohepatitis (NASH) Completed NCT00706537 Phase 1 Active treatment;Placebo
1049 A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects Completed NCT04142424 Phase 1 AZD2693;Placebo
1050 A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants Completed NCT05053165 Phase 1 LB-P6;LB-P8;Placebo
1051 A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH Completed NCT04202354 Phase 1 ARO-HSD Injection;sterile normal saline (0.9% NaCl)
1052 A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects Completed NCT02287779 Phase 1 SHP626;Placebo
1053 Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study) Completed NCT03143166 Phase 1 Dabigatran Etexilate;Rabeprazol sodium
1054 A Single Part, Three-Way Crossover, Randomised, Open-Label Study Designed to Evaluate the Relative and Absolute Bioavailability Following a Single Subcutaneous Injection of a Novel High Concentration Subcutaneous Formulation of Cotadutide Against a Low Concentration Subcutaneous Formulation and Intravenous (IV) Formulation for Reference, in Healthy Subjects Completed NCT05294458 Phase 1 cotadutide solution for injection
1055 The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine Completed NCT01677325 Phase 1 Chinese herb (YiQiSanJu)
1056 An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants Completed NCT03445208 Phase 1 BMS-986036
1057 A Single and Multiple Dose-escalation First-in-human With Food-effect Study Evaluating the Safety, Tolerability and Pharmacokinetics of SRT-015 Administered Orally. Completed NCT04887038 Phase 1 SRT-015
1058 An Open-Label, Single-Dose Pharmacokinetic Study of Liquid Subcutaneous Formulation of BIO89-100 in Subjects With Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis Completed NCT05022693 Phase 1 BIO89-100
1059 A Phase I, Two-part, Single and Optional Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 500 and 750 mg PXL770 in Healthy Subjects Completed NCT05441904 Phase 1 PXL770
1060 A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole and Quinidine on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers Completed NCT03610945 Phase 1 Fluconazole;Quinidine;EDP-305
1061 A Double-blind, Sponsor-Open, Placebo-controlled, Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of HU6 in High BMI Volunteers Completed NCT04709913 Phase 1 HU6
1062 A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 or Fenofibrate in Subjects With Normal and Impaired Hepatic Function Completed NCT02891408 Phase 1 Firsocostat;Fenofibrate
1063 A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics Completed NCT02654002 Phase 1 Cilofexor;Placebo
1064 A Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single Ascending Doses of HU6 in Healthy Volunteers Completed NCT04463017 Phase 1 HU6
1065 A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. Completed NCT04808154 Phase 1 SNP-630
1066 A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy Subjects, and of Multiple Ascending Doses (MAD) in Subjects With Presumptive NAFLD Completed NCT02918929 Phase 1 EDP 305;Placebo
1067 A Phase 1b, Open-label Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FXR Agonist/Modulator EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients Completed NCT03976687 Phase 1 EYP001a
1068 A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XW003 Injection in Healthy Adult Participants Completed NCT04389775 Phase 1 Cohort A;Placebo A;Cohort B;Placebo B
1069 A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects Completed NCT03783897 Phase 1 EDP-305;Oral Contraceptive
1070 A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-305 Following a Single Oral Dose in Healthy Male Subjects Completed NCT03748628 Phase 1 EDP-305
1071 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211 in Obese Subjects With NAFLD Completed NCT03744182 Phase 1 HM15211;Placebo of HM15211
1072 An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC) Completed NCT03332940 Phase 1 Tc 99M Sulfur Colloid;Tc99m-tilmanocept
1073 A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers Completed NCT04146805 Phase 1 BLD-0409;Control: Placebo
1074 A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP0678 and the Effect of Food on ZSP0678 Pharmacokinetics in Chinese Healthy Subjects. Completed NCT04137055 Phase 1 ZSP0678-10mg;ZSP0678-30mg;ZSP0678-60mg;ZSP0678-120mg;ZSP0678-180mg;ZSP0678-240mg;ZSP0678-320mg;ZSP0678;ZSP0678-Dose 1;ZSP0678-Dose 2;ZSP0678-Dose 3;ZSP0678 Placebo
1075 A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function Completed NCT02808312 Phase 1 Cilofexor
1076 A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Access the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC96719 Tablets in Chinese Healthy Volunteers Completed NCT04194242 Phase 1 HEC96719 tablets;Placebo tablet
1077 A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986036 in Participants With Varying Degrees of Renal Function Completed NCT03674476 Phase 1 BMS-986036
1078 A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease Completed NCT03998514 Phase 1 CB4211 Dose 1;CB4211 Dose 2;CB4211 Dose 3;CB4211 Dose 4;CB4211 Dose 5;CB4211 Dose 6;CB4211 Dose TBD;Placebo
1079 New Approaches to Smoking Cessation in Heavy Drinkers Completed NCT02151591 Phase 1 Varenicline
1080 A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2). Completed NCT04187339 Phase 1
1081 A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects Completed NCT04559126 Phase 1 EDP-297;Placebo
1082 A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects. Completed NCT03392779 Phase 1 ZSP1601 25 mg;Placebo 25mg;ZSP1601 50 mg;Placebo 50 mg;ZSP1601 100 mg;Placebo 100 mg;ZSP1601 175 mg;Placebo 175 mg;ZSP1601 275 mg;Placebo 275 mg;ZSP1601 350 mg;Placebo 350mg;Placebo 100mg
1083 A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics,and Randomized, Open-label,Crossover, Food Effect Study of HEC96719 in Healthy Chinese Subjects Completed NCT04546984 Phase 1 HEC96719
1084 A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers Completed NCT03213145 Phase 1 intraconazole;Rifampin;EDP 305
1085 A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers Completed NCT04561245 Phase 1 ALT-801
1086 PT150 (Formerly ORG34517) as a Potential Treatment for Alcohol Dependence-Alcohol Interaction Study Recruiting NCT04331288 Phase 1 PT150
1087 Characterization of Neuroimmune Dysfunction in Alcohol Use Disorder Recruiting NCT04210713 Phase 1 Minocycline;Sugar pill
1088 A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study Recruiting NCT03575403 Phase 1 Alcohol;Placebos;Duloxetine;Methylphenidate
1089 Emergency Department Initiated Oral Naltrexone for Patients With Moderate to Severe Alcohol Use Disorder: A Pilot Feasibility Study Recruiting NCT04817410 Phase 1 Emergency Department Initiated Oral Naltrexone
1090 Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Alcohol Interaction Study Recruiting NCT04827056 Phase 1 Placebo;Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg;Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
1091 The Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors Recruiting NCT04360018 Phase 1
1092 The Neural Mechanisms Associated With Alcohol and Cigarette Craving in Alcohol Use Disorder Smokers During Oxytocin Treatment Recruiting NCT04071119 Phase 1 Oxytocin nasal spray;Placebo
1093 Probenecid as Pharmacotherapy for Alcohol Use Disorder Recruiting NCT04218357 Phase 1 Probenecid;Matching placebo
1094 Effect of Allopregnanolone on Stress-induced Craving Recruiting NCT04015869 Phase 1 Allopregnanolone;Placebos
1095 Non-invasive Vagal Nerve Stimulation to Improve Functional Outcomes in Veterans With Alcohol Use Disorder Recruiting NCT05226130 Phase 1
1096 The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers Recruiting NCT04596267 Phase 1 Pitolisant;Placebo
1097 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
1098 A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Alleles Recruiting NCT04483947 Phase 1 AZD2693
1099 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease Recruiting NCT04857606 Phase 1 AMG 609;Placebo
1100 A Pilot Clinical Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cell in the Treatment of Decompensated Alcoholic Cirrhosis Recruiting NCT05155657 Phase 1
1101 Fecal Microbiome Changes Characterization and Safety Evaluation After Oral Administration of Lyophilized Capsules Containing Microbiota Suspension in Severe Alcoholic Hepatitis Patients: Double Blinded, Randomized, Placebo-Controlled Study. Recruiting NCT05006430 Phase 1
1102 An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease Recruiting NCT05560607 Phase 1 AZD7503 Intervention
1103 A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease Who Have the PNPLA3 I148M Genotype Recruiting NCT05395481 Phase 1 LY3849891;Placebo
1104 A Randomised, Double-blind, Placebo-controlled, SAD/MAD First-in-human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RXC007 Including Evaluation of Drug-Drug Interaction and Food Effect in Male Participants Recruiting NCT04931147 Phase 1 RXC007;RXC007 Matching Placebo
1105 A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects Recruiting NCT04829123 Phase 1 HEC88473 injection;Placebo
1106 Computer-Assisted Self-Administration of Ethanol (CASE) in Humans Recruiting NCT00713492 Phase 1 Alcohol
1107 A Phase I Clinical Trial to Determine the Safety and Tolerability of Anti-IL23 Monoclonal Antibody, for the Treatment of Patients With Alcohol Associated Liver Disease Recruiting NCT04736966 Phase 1 Guselkumab 30mg;Guselkumab 70mg;Guselkumab 100mg
1108 A Randomized, Double-Blind, Placebo Controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPN-01 Recruiting NCT04481594 Phase 1 HPN-01;Placebo
1109 A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function Recruiting NCT04643795 Phase 1 MGL-3196
1110 A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Recruiting NCT05117489 Phase 1 Miricorilant 150 mg;Miricorilant 100 mg;Miricorilant 50 mg;Miricorilant 10 mg
1111 Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation Recruiting NCT02639273 Phase 1 Nalmefene
1112 The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment Recruiting NCT04931095 Phase 1 Cannabis;Alcohol
1113 An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers Recruiting NCT04972396 Phase 1 ALT-801;Metformin;Atorvastatin;Warfarin;Digoxin;Ethinylestradiol and Levonorgestrel
1114 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers Recruiting NCT04781322 Phase 1 Alirocumab
1115 A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Ecc0509 In Healthy Volunteers Recruiting NCT05012423 Phase 1 Placebo;ECC0509
1116 A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of XZP-5610 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects. Recruiting NCT04913090 Phase 1 XZP-5610 Tablet (for Part A);Placebo to match XZP-5610 Tablet (for Part A);XZP-5610 Tablet (for Part B);Placebo to match XZP-5610 Tablet (for Part B);XZP-5610 Tablet (for "Part C1");XZP-5610 Tablet for "Part C2"
1117 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD Recruiting NCT04812262 Phase 1 DD01;Placebo
1118 A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers Recruiting NCT05090111 Phase 1 ALG-055009;Placebo
1119 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index Recruiting NCT05203237 Phase 1
1120 A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism Active, not recruiting NCT02262026 Phase 1 125 mg AZD0530;50 mg AZD0530;Placebo
1121 A Phase 1, Double-blind, Placebo-controlled, Single-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-AUD in Healthy Volunteers Active, not recruiting NCT05021640 Phase 1 DCR-AUD;Placebo for DCR-AUD
1122 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Active, not recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
1123 A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT05006885 Phase 1 ALT-801
1124 A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Active, not recruiting NCT05292911 Phase 1 ALT-801
1125 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Active, not recruiting NCT04565717 Phase 1 ALN-HSD;Placebo
1126 A Phase 1, First-in-Human, Double-blind, Placebo-controlled, Single-and Multiple-Ascending Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease Enrolling by invitation NCT05517564 Phase 1 GM-60106
1127 Acetyl-L-carnitine Supplementation for Co-occurring Depression and Alcohol Use Disorder in Adolescents: A Randomized Placebo-Controlled Pilot Study Not yet recruiting NCT05355311 Phase 1 Acetyl-l-carnitine;Placebo
1128 Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder Not yet recruiting NCT05223829 Phase 1 Brexanolone
1129 A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) Not yet recruiting NCT04892875 Phase 1 Zimberelimab;Etrumadenant;Cisplatin
1130 The Efficacy of Soluble Fibre Supplementation for the Treatment of Pediatric Non-alcoholic Fatty Liver Disease (NAFLD) Not yet recruiting NCT05480696 Phase 1
1131 Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis, a Pilot Study. Not yet recruiting NCT03803540 Phase 1
1132 Effect of Very Low-calorie Diet on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and Non-alcoholic Fatty Liver Disease Not yet recruiting NCT04861571 Phase 1
1133 A Phase I Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics (PK) of XZP-6019 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects Not yet recruiting NCT05063968 Phase 1 XZP-6019 tablet;Placebo
1134 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of BAR 502 in Healthy Subjects Not yet recruiting NCT05203367 Phase 1 BAR502;Placebo
1135 A Phase 1, Open-label, Single-dose, Adaptive Design Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Not yet recruiting NCT05553470 Phase 1 Miricorilant
1136 Genetics of the Acute Response to Alcohol in Humans Terminated NCT01375556 Phase 1 Ethanol
1137 Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System: a [18F]-Fallypride- and [18F]-Fluoro-DOPA-PET Study. Terminated NCT03854942 Phase 1 Placebo;Naltrexone
1138 The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers Terminated NCT03645408 Phase 1 Exenatide
1139 Probiotics and Non Alcoholic Steatohepatitis (NASH) Terminated NCT00808990 Phase 1
1140 A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis Terminated NCT00205049 Phase 1 pentoxifylline
1141 Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents Terminated NCT00694746 Phase 1 Omega-3-acid ethyl esters;Placebo
1142 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease Terminated NCT04766476 Phase 1 BMS-963272
1143 A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects Withdrawn NCT00908206 Phase 1 GSK598809
1144 Pilot Study of Deep Brain Stimulation (DBS) for Refractory Alcoholism Withdrawn NCT01798888 Phase 1
1145 Oxytocin in Alcohol Use Disorder: A Novel and Translational Approach Withdrawn NCT02711189 Phase 1 Oxytocin
1146 Feasibility Trial of Pregnenolone for Posttraumatic Stress Disorder and Alcohol Use Disorder Withdrawn NCT04464148 Phase 1 Pregnenolone 250 mg;Pregnenolone 400 mg
1147 Randomized Controlled Trial of Computerized SBI to Reduce Teen Alcohol Use Withdrawn NCT01784627 Phase 1
1148 Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL Withdrawn NCT03398252 Phase 1 Doxazosin XL;Placebo
1149 Randomized Controlled Trial of Computerized MET for Adolescent Substance Use Withdrawn NCT01784653 Phase 1
1150 A Pilot, Exploratory Dose Escalating Study on the Safety, Pharmacodynamics and Preliminary Efficacy of VLX103 in the Treatment of Moderate Alcoholic Steatohepatitis Withdrawn NCT03201159 Phase 1 VLX103
1151 Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study Withdrawn NCT02457286 Phase 1 Metformin
1152 A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor (ACCi) on Very Low Density Lipoprotein ApoB100 and TG Secretion Withdrawn NCT04395950 Phase 1 PF-05221304;Placebo
1153 Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence? Unknown status NCT02690987 Early Phase 1 Exenatide
1154 Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence Unknown status NCT00570388 Prometa Treatment Program
1155 Brain Imaging Study on the Effects of Treatment With Naltrexone on Cue-induced Craving and Brain's Metabolic Changes in Alcohol and Cannabis-dependent Patients Unknown status NCT01560013 Naltrexone
1156 Qi Gong as a Method of Craving Reduction in Severe Addict Patients Unknown status NCT03589118
1157 Executive Functioning in Alcoholics Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial Unknown status NCT01942954
1158 Development of an Interactive, Adaptable and Transportable Treatment for Veterans With Substance Use Disorders Unknown status NCT01812187
1159 A Randomised Controlled Trial of Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal Unknown status NCT04205682 Early Phase 1 Cannabidiol;Placebo
1160 Mechanisms Underlying the Approach and Avoidance Task (AAT) in Alcoholic Inpatients Unknown status NCT04054336
1161 The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients Unknown status NCT02385643
1162 Sequence of Symptom Change During AUD (Alcohol Use or Dependence) or PTSD (Posttraumatic Stress Disorder) Treatment for Comorbid PTSD/AUD Unknown status NCT01663337
1163 Binge Drinking And Addiction : Case-Control Study in Hospital Unknown status NCT03204214
1164 From Uncomplicated Alcoholism to Korsakoff's Syndrome: Clinical, Genetic, Neuropsychological and Brain Examinations Unknown status NCT01455207
1165 Bipolar Disorder With Alcoholism in Han Chinese Unknown status NCT01188395
1166 Evaluation of the Diagnostic Utility of Serum Dexamethasone Measurements in the Overnight 1mg Dexamethasone Suppression Test in Patients Investigated for Cushing's Syndrome and Incidentalomas Unknown status NCT01504555
1167 Impact for Care for Patients With Alcohol Addiction and Treated for ORL Cancer Unknown status NCT00825448
1168 Satisfaction With Care and Quality of Life in Subjects With Substance Dependence Unknown status NCT02894476
1169 New Therapeutic Strategies for Inhibitory Control Improvement of Alcohol-dependent Patients Unknown status NCT03058276
1170 New Therapeutic Strategies for the Treatment of Alcohol Use Disorders Unknown status NCT03028662
1171 Optimizing Treatment for Alcohol Use Disorder (AUD) Using Targeted Transcranial Magnetic Stimulation Unknown status NCT03969251
1172 A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury Unknown status NCT01326663 Medication Trial
1173 Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology Unknown status NCT02759874
1174 Etude Des déterminants Endocrinologiques Des Apports énergétiques et Fluides Des Patients Alcooliques en Cours de Sevrage Unknown status NCT00447785
1175 Dietary Fiber Intake in Alcohol-dependent Patients Unknown status NCT03803709
1176 Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder Unknown status NCT03120468 Early Phase 1 Topiramate and N-Acetyl Cysteine;Topiramate and Placebo
1177 Impact of Attention Deficit/Hyperactivity Disorder on the Post-detoxification Alcohol Relapse Rate Unknown status NCT02364817
1178 Biological and Cognitive Markers of Violent Behavior in Forensic Patients With Polysubstance Use: Retrospective Evaluation Unknown status NCT00797329
1179 Outcomes Related to Use of Soberlink Within In-Home Addiction Treatment Program for Individuals With Alcohol Use Disorder Unknown status NCT03902171
1180 Effectiveness of a Remote Behavioral Intervention and Coaching Support for Risky Substance Users in a Randomized Control Trial Unknown status NCT03069118
1181 Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction Unknown status NCT02643264
1182 Virtual Reality Cognitive Training in Individuals With Alcohol Use Disorder Undergoing Residential Treatment: A Randomized Controlled Trial Unknown status NCT04505345
1183 Ambulatory Alcohol Detoxification With Remote Monitoring Unknown status NCT03582150
1184 Alcohol Early Intervention for Freshmen Unknown status NCT00852033
1185 Biomarkers for the Detection of Heavy Alcohol Use in Patients With and Without Liver Disease Unknown status NCT02873663
1186 The Ketone Mono Ester Study - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans Unknown status NCT03878225
1187 Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial Unknown status NCT03660124
1188 The Effect of an Interdisciplinary "Booster" Session in Primary Care Following Brief Intervention in Hospitals - a Randomized Clinical Trial Unknown status NCT01208571
1189 Scale-up of Prevention and Management of Alcohol Use Disorders and Comorbid Depression in Latin America Unknown status NCT03524599
1190 Brief Intervention for ICU Patients With Alcohol Use Disorders- a Randomized Controlled Trial Unknown status NCT03047577
1191 Comparing Effectiveness and Costs of Internet-based Treatment for Problematic Alcohol Use and Face-to-face Treatment in Addiction Care: A Randomized Controlled Trial Unknown status NCT02671019
1192 Contingency Management Treatment of Alcohol Abuse American Indian People Unknown status NCT02174315
1193 Transcranial Direct Current Stimulation of the Bilateral Dorsolateral Prefrontal Cortex for Alcohol Use Disorders: A Randomised, Sham-controlled Clinical Trial Unknown status NCT04135599
1194 Open-label Trial on Therapeutic Effect and Tolerability of Nalmefene in Subjects With Alcohol Use Disorder and Comorbid Borderline Personality Disorder Unknown status NCT02752503 Nalmefene
1195 Neurophysiological Mechanisms of Accelerated Resolution Therapy (ART) Unknown status NCT04121884
1196 Massive Mental Health Screening Using Smartphone in Milpa Alta Community, Mexico. Unknown status NCT04067063
1197 Effectiveness of Repeated MOTivational InterVention to Reduce Ethanol Intake During prEgnancy Unknown status NCT04275570
1198 Self-estimates and Objective Measurement of Blood Alcohol Concentration in Patients With Alcohol Intoxication Presenting to an Emergency Department Unknown status NCT03998397
1199 REMOTE: Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder: Smartphone and Wearable Sensors Unknown status NCT03991650
1200 A Randomized Controlled Trial of a Virtual Reality Based, Approach-avoidance Training Program for Alcohol Use Disorder Unknown status NCT04283305
1201 Alcohol Cue-Reactivity in Patients With Alcohol Dependency and Effects of Transcranial Direct Current Stimulation (tDCS) on Cue-exposure Therapy Unknown status NCT02228486
1202 Cutaneous Denervation in Alcoholic Neuropathy Unknown status NCT00190073
1203 The Effect of Intermittent Theta Burst Stimulation (iTBS) in Patients With Alcohol Use Disorder Unknown status NCT03932149
1204 Repetitive Transcranial Magnetic Stimulation (rTMS) in Alcohol Dependent Patients: a Mechanistic Study. Unknown status NCT01973127
1205 Randomized Controlled Trial on the Effectiveness of Immediate Versus Delayed Access to Hospital-based Addiction Services Unknown status NCT01934751
1206 Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking Unknown status NCT01881841
1207 Efficacy Evaluation of Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders Unknown status NCT03230006
1208 Pilot Evaluation of the VetChange Mobile App for Veterans With PTSD Who Engage in Problem Drinking Unknown status NCT03208738
1209 The Effectiveness of a Smartphone Application in the Treatment of Alcohol Use Disorder Unknown status NCT03396887
1210 Systematic Screening for Comorbid Psychological Conditions in Cardiac Ambulatory Care Sensitive Conditions (ACSC) Patients With Multimorbidity in the Emergency Departments (ED) Unknown status NCT03188861
1211 Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule as a Novel Treatment in Severe Alcohol Addiction Unknown status NCT01658592
1212 Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population Unknown status NCT01595568
1213 Piloting ProHealth: A Program for Male Soldiers on Sex, Dating and Alcohol-Use at Fort Bragg Unknown status NCT03184298
1214 Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare Unknown status NCT02544581
1215 Single Blind Randomised Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression Unknown status NCT02404662
1216 Study of Mindfulness Practice Efficacy in Alcoholic Relapse Prevention Unknown status NCT03150550
1217 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
1218 Sammenligning Mellem Standard Tube og Den Ultra-tynde Tritube® Til Intubation, og Til Opretholdelse af Adgang Til Trachea Efter anæstesi, Hos Patienter Med Forventet Vanskelig Direkte Laryngoskopi Unknown status NCT03653039
1219 Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Patients With Non-alcoholic Fatty Liver Disease Using Markers and Imaging Techniques Unknown status NCT02717000
1220 A Clinical Study on the Effect of Adjustable Intragastric Balloon in Obese Patients With Non Alcoholic Fatty Liver Disease(NAFLD) or Non-Alcoholic Steatohepatitis (NASH) With or Without Diabetes Mellitus Unknown status NCT04182646
1221 Diagnostic Accuracy in a New Ultrasound Software Compared to Histology for Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH) in Morbidly Obese Individuals Undergoing Bariatic Surgery and/or Cholecystectomy Unknown status NCT04101162
1222 Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease Unknown status NCT03307408
1223 Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial Unknown status NCT02075164
1224 Prognostic Value of Liver Volume on Acute Decompensation of Alcoholic Cirrhosis, a Prospective Multicenter Observational Study Unknown status NCT03508388
1225 Metabolic Surgery for the Treatment and Understanding of Non-Alcoholic Steato-Hepatitis (NASH): Weight-Dependent and Weight-Independent Effects Unknown status NCT04282005
1226 Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis Unknown status NCT03801577
1227 The Role of Immune Semaphorins in NAFLD Unknown status NCT04573543
1228 A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China Unknown status NCT02391168
1229 Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease) Unknown status NCT03186859
1230 Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals Unknown status NCT04482153
1231 An Open-Label Study to Assess the Hepatic Protection Effect of a Food Supplement Product, SNP-612, in Patients With Non-alcoholic Fatty Liver Disease Unknown status NCT03868566 SNP-612 dose1;SNP-612 dose2;SNP-612 dose3;SNP-612 placebo
1232 Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT03487068
1233 AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease Unknown status NCT03474328
1234 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD). Unknown status NCT01511523
1235 Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches Unknown status NCT00844779
1236 Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Unknown status NCT03848390
1237 Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease Unknown status NCT02947568
1238 Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano Unknown status NCT02038387
1239 Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity Unknown status NCT04442620
1240 Evaluation of the Effect of a Food Supplementation With a Combined Food Supplement on Lipid Pattern, Indexes of Non-alcoholic Fatty Liver Disease and Systemic Inflammation in Moderately Hypercholesterolemic Subjects: a Three-arm Double-blind, Placebo-controlled, Randomized, Clinical Trial Unknown status NCT04485793
1241 The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01139632
1242 CIRRAL: Hepatocellular Carcinoma in Patients With Uncomplicated Alcoholic Cirrhosis: Incidence and Predictive Factors. A Multicentric Prospective Cohort Unknown status NCT01213927
1243 C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease Unknown status NCT02083159
1244 Non-invasive Diagnostic Model of Liver Fibrosis Associated With Non-alcoholic Fatty Liver Disease and Prediction of Prognosis Unknown status NCT03842748
1245 A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis A Randomized Controlled Trial. Unknown status NCT03091010 Steroids
1246 A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) and Elevated Alanine Aminotransferase (ALT) Unknown status NCT03073343
1247 Effect of 2% Alcoholic Chlorhexidine Compared to Povidone Iodine Solution to Limit Colonisation After Perineural Catheterization in Orthopaedic Surgery Unknown status NCT02950246 2% alcoholic chlorhexidine;povidon iodine
1248 Controlled Trial on the Effect of Tomato Products in Obese Children With Non Alcoholic Fatty Liver Disease Unknown status NCT03463967
1249 The Relationship of Adiponectin With Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease Unknown status NCT01472120
1250 Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture Unknown status NCT02006329
1251 Prospective Study: Early Detection of Advanced Fatty Liver Disease in the General Adult Population by Using Non-Alcoholic Fatty Liver Disease Score and Elastography Unknown status NCT03608748
1252 Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test Unknown status NCT01281059
1253 Lifestyle Interventions for the Treatment of Non-alcoholic Fatty Liver Disease in Overweight and Obese Adults Unknown status NCT03972631
1254 The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, β-cell Function and Triglyceride Kinetics in Patients With Non-alcoholic Fatty Liver Disease (NAFLD). Unknown status NCT01834300
1255 Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study Unknown status NCT01791452
1256 G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study Unknown status NCT01341951 Granulocyte colony stimulating factor
1257 Investigation on the Preventive Effect of Reduced Fructose Consumption on the Development of Non-alcoholic Fatty Liver Disease in Children in a Long Term Study Unknown status NCT01306396
1258 Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis Unknown status NCT01282892
1259 Proof-of-concept Study of the Use of Endoscopic Gastroplasty in Patients With Obesity and Non-alcoholic Steatohepatitis Compensated Liver Cirrhosis (NASH) Unknown status NCT04281303
1260 Immunomediated Non-alcoholic SteaTohepatitis; Prevalence and Characterization. INSTInCT Study Unknown status NCT03760172
1261 Effects of Non-alcoholic Beer in Patients With Type 2 Diabetes: A Randomized Controlled Trial Unknown status NCT03746093
1262 Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence. Unknown status NCT04099147
1263 Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) Unknown status NCT01083992 Galvus (vitagliptin);Galvus + vitamin D
1264 The Effect of Oral β- Glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver Echogenicity and Enzymes in Non Alcoholic Fatty Liver Disease Treating With Hypocaloric Diet and Vitamin E Unknown status NCT02178839
1265 Evaluation of the Effects of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease Unknown status NCT03734510
1266 Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis Unknown status NCT00394238
1267 Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease Unknown status NCT03354247
1268 Stratification of Chronic Alcoholic Liver Diseases (SCALE Study) Based on Organs Injury: a Multi-center Prospective Observational Study Unknown status NCT03295812
1269 T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease Unknown status NCT04220450
1270 Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN). Unknown status NCT04142723
1271 Study of the Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Non-alcoholic Fatty Liver Disease: a Randomised Controlled Trial Unknown status NCT04074889
1272 Randomised Controlled Trial Assessing the Effect of S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease Unknown status NCT03938662
1273 Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals Unknown status NCT04328259
1274 Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome Unknown status NCT03827772
1275 Study of the Effect of Metformin in Patients With Non-Alcoholic Fatty Liver Disease Unknown status NCT00247117 Metformin
1276 Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications Unknown status NCT00577044
1277 A Study Of Metabolic Factors And Efficacy Of Pentoxifylline Versus Pioglitazone In Lean And Obese Nash (Non-Alcoholic Steatohepatitis) Patients. Unknown status NCT00681733 Pioglitazone;Pentoxifylline
1278 Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers Unknown status NCT04191044
1279 Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat Unknown status NCT04240145
1280 Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients -A Randomized Controlled Trial. Unknown status NCT04066179 Gcsf;Prednisolone
1281 Evaluation of the Effects of Hesperidin and Flaxseed Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease Unknown status NCT03377153
1282 Evaluation of the Effects of Hesperidin Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease Unknown status NCT03377140
1283 Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis) Unknown status NCT04544020
1284 The Effect of Bariatric Surgery on Hepatic Urea Nitrogen Handling and Cognitive Functions in Patients With Severe Non-alcoholic Fatty Liver Disease Unknown status NCT03260036
1285 Investigation on the Frequency and Obstetric Significance of Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy Unknown status NCT02276144
1286 The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease Unknown status NCT01619215
1287 Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population Unknown status NCT03388320
1288 Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions: Observational Case Control Study in Upper Egypt Unknown status NCT03172650
1289 Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease Unknown status NCT02488941
1290 Association Between Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease Investigated by Liver Biopsy Unknown status NCT03373643
1291 Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease Unknown status NCT01638832
1292 Non-alcoholic Fatty Liver Disease (NAFLD) in Overweight and Obese People Under Nutritional and Lifestyle Follow-up: a Randomized Controlled Trial Unknown status NCT03183193
1293 Global Osteopathic Treatment for Patients With Non-Alcoholic Fatty Liver Disease Unknown status NCT03156881
1294 Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis Unknown status NCT02404636
1295 Protein-rich Diet and Non-Alcoholic Fatty Liver Disease in Bariatric Surgery Unknown status NCT02400099
1296 Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO). Unknown status NCT03426111
1297 Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients: a Prospective, Longitudinal Study Employing Serum Cytokeratin 18 and Transient Elastography (Fibroscan) Unknown status NCT03128918
1298 Mediterranean Diet Versus Paleolithic Diet for the Treatment of Non Alcohlic Fatty Unknown status NCT04400864
1299 Effect of Probiotic Supplementation in Nonalcoholic Steatohepatitis Patients: Randomized Clinical Trial - PROBILIVER TRIAL Unknown status NCT03467282
1300 Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy Unknown status NCT02644239
1301 Urinary Metabonomics of Two Major Patterns of NAFLD Unknown status NCT02077283
1302 Effect of Substituting Vegetable Protein for Animal-Protein on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Feeding Trials to Provide Evidence-Based Guidance for Nutrition Guidelines Development Unknown status NCT02037321
1303 Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease Unknown status NCT03635541
1304 Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials Unknown status NCT02702479
1305 "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population: a Multidisciplinary Clinical and Experimental Approach" (PRECISED) Unknown status NCT02248311
1306 The Effects of Plant Sterol and Plant Stanol Ester Enriched Foods on Biopsy Proven Liver Inflammation in NAFLD Patients - a Proof-of-concept Pilot Study Unknown status NCT03627819
1307 Oral Dietary Fucoxanthin Rich Supplement for Liver Health Unknown status NCT03625284
1308 Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity Unknown status NCT03492879
1309 Efficacy, Safety of Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease Unknown status NCT03648086
1310 Effect of Fructose on Metabolic Control in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development Unknown status NCT01363791
1311 (BAFLA- Barzilai Fatty Liver and Iron Metabolism Study) Unknown status NCT01307254
1312 the Role of plin5 in the Development of a Sequence Polymorphism in Patatin-like Phospholipid Domain Containing Protein 3 Polymorphism-associated Nonalcoholic Fatty Liver Disease Unknown status NCT04104282
1313 An Observational Cohort Study to Evaluate Factors Affecting Prevalence of Fatty Liver Disease and Fibrosis and Factors Affecting Response to Treatment in Patients With Psoriasis Unknown status NCT02174367
1314 Measuring Fatty Liver With Ultrasound and MRS in Children With Overweight or Obesity (Dutch Title: Het Meten Van Leververvetting Met Echo en MRS in Kinderen Met Overgewicht of Obesitas) Unknown status NCT03787108
1315 Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design Unknown status NCT02716870
1316 Effects of Intermittent and Continuous Calorie Restriction on Body Weight and Metabolism in Adults With Nonalcoholic Fatty Liver Disease Unknown status NCT04355910
1317 Effect of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02764047
1318 Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis: A Randomized Control Trial Unknown status NCT02721264
1319 Phenotypical and Pathophysiological Characterization of Patients With Alcohol-related Liver Disease Unknown status NCT04363424
1320 Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD Unknown status NCT02285218
1321 Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in Patients With Nonalcoholic Hepatitis Unknown status NCT04555434
1322 Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver: Identification of Biomarkers and Development of Personalized Therapy: The MicroKid Project Unknown status NCT04575506
1323 Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study Unknown status NCT03534908
1324 Lipid Metabolism, Lipotoxicity and Nonalcoholic Fatty Liver Disease: Implication of Postprandial Cytotoxic Lipids Unknown status NCT03836443
1325 Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP): Exploring Attendance at Incidents Involving Substance and/or Alcohol Use During COVID-19 Pandemic Unknown status NCT04474444
1326 Nonalcoholic Fatty Liver Disease and Associated Liver Fibrosis in Peri-menopausal Women Unknown status NCT03602573
1327 Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection Unknown status NCT00842205 pegylated interferon;Ribavarin
1328 THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS Unknown status NCT01735799
1329 Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver Unknown status NCT01694342
1330 Hydrolyzed Oyster Extract for Liver Health: a Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02992470
1331 Metformin Versus Atorvastatin in Nonalcoholic Hepatic Steatosis: a Randomized Study Unknown status NCT01544751 Low dose metformin;Metformin;Atorvastatin
1332 Multimodal Approach in IBD Patients Unknown status NCT01705522
1333 NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL) Unknown status NCT03968354
1334 A Double Blind, Randomised, Placebo-controlled, Within-subject Crossover Study to Examine the Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication Unknown status NCT01350089 Placebo (without alcohol, caffeine, energy drink);Comparator 1 (with alcohol; without caffeine and energy drink);Comparator 2 (with alcohol and caffeine; without energy drink);Comparator 3 (with alcohol and energy drink)
1335 Non-invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients Unknown status NCT03725631
1336 The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease Unknown status NCT04127370
1337 Evaluation of the Effects of a Low Free Sugar Diet on Lipid Profile, Glycemic Indices, Liver Enzymes, Inflammatory Factors and Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Unknown status NCT04369521
1338 Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis: A Prospective Cross Over Trial Unknown status NCT00152711
1339 Trials of Ventilation Assisted Substance Elimination Via the Lung - Ethanol (VASEL - Ethanol) Unknown status NCT04229732
1340 Predictors of Improvement of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery Unknown status NCT04059029
1341 The Epidemiological Investigation and Pathogenesis of NAFLD in HIV-infected Patients: a Cross-sectional Study Unknown status NCT04215926
1342 Bariatric Surgery vs. Lifestyle Modification: Effects Against Nonalcoholic Steatohepatitis Randomized Trial Unknown status NCT04298736
1343 Screening of NASH in Oupatients Followed in Various Hospital Specialty Clinics at the University Hospital of Strasbourg Unknown status NCT04282447
1344 Identification of Microbial Properties Predicting a Worsening Course of Fatty Liver Disease Unknown status NCT03748511
1345 French Cohort for the Study of Non-invasive Tests of Liver Lesions in NAFLD/NASH (FreSH Cohort) Unknown status NCT03695796
1346 Comparative Trial of Omega-3 Polyunsaturated Fatty Acids vs a Very Low Calorie Liquid Diet for Liver Volume Reduction Prior to Bariatric Surgery Unknown status NCT03132662
1347 Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis Unknown status NCT03386890
1348 Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in Nonalcoholic Fatty Liver disease-a Randomized Controlled Study Unknown status NCT03375580 metformin;Compound Zhenzhu Tiaozhi capsule;Simvastatin
1349 Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis Unknown status NCT02307344
1350 Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD) Unknown status NCT02458586
1351 Development of LabPatch-alcohol: A Wearable Biosensor for Detecting Alcohol in Interstitial Fluid Unknown status NCT03242161 Early Phase 1
1352 Effect of Two Programs of Physical Activity of Different Intensity, Mediterranean Diet and the Combination of Both on NAFLD and Erytrocyte Membrane Lipid Profile. Unknown status NCT02347696
1353 Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence Completed NCT01528748
1354 Imaging Cannabinoid CB1 Receptors in Alcohol Dependence Completed NCT00816439
1355 CM Treatment for Alcohol Dependence Using New Technology Completed NCT02143037
1356 Evaluation Study of the Effectiveness of a High- Versus Low-frequency Telephone-based and Sort Message-based (Sms) Continuing Care Provided to Patients Who Have Achieved a 12 Week In-patient Treatment for Alcohol Dependence Completed NCT02030093
1357 Longitudinal Changes in the Oral and Gut Microbiome of Individuals With Alcohol Dependence Completed NCT02911077
1358 Treating Alcohol Dependence : Testing a Combined Treatment Model Using Transcranial Direct Current Stimulation (tDCS) and Inhibitory Control Training (ICT) Completed NCT03447054
1359 Internet-based vs Face-to-face Treatment for Alcohol Dependence: A Randomised, Controlled Non-inferiority Trial Completed NCT02888002
1360 Physiological Effects of FGF21 in Humans and Its Pathophysiological Role in Alcohol Dependence Completed NCT03892369
1361 Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome Completed NCT03470168
1362 Psychosocial Intervention for Relatives of Individuals Suffering From Chronic Alcohol Dependence Completed NCT02112396
1363 Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study Completed NCT02107352
1364 The Neural Mechanisms of the Incubation of Cue-induced Craving in Alcohol Dependence Completed NCT01991704
1365 A Tailored Physical Activity Smartphone App for Patients With Alcohol Dependence Completed NCT02958280
1366 Impact of Enhancements to Smartphone Based Continuing Care for Alcohol Dependence Completed NCT02681406
1367 Novel Treatments for Alcohol Dependence: A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity Completed NCT01941693
1368 Comparison of Anti-craving Efficacy of Right and Left Prefrontal High Frequency rTMS in Alcohol Dependence: a Randomized Double-blind Study Completed NCT01093716
1369 This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns. Completed NCT01014533 Placebo dispensed to subject.;Gabapentin dispensed to subject.
1370 Gamma-Aminobutyric Acid (GABA) Mechanisms Underlying the Vulnerability to Alcohol Dependence Completed NCT00611767 Thiopental;Placebo
1371 A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling Completed NCT00326807 Naltrexone
1372 Comparison Between the Use of Music and Relaxation Training on Craving Alcohol in Patients With Alcohol Dependence Syndrome: A Pilot Study Completed NCT04351217
1373 Randomized Controlled Trial of a Expert System for Patients With At-risk Drinking, Alcohol Abuse and Alcohol Dependence in General Hospital Completed NCT00400010
1374 Evaluation of the Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal Among Adult Inpatients With Alcohol Dependence in an Ear, Nose, Throat and Jaw Surgery Department Completed NCT02782156
1375 Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study Completed NCT02181569
1376 Sub-Project No 8 of the Research Group RISKDYNAMICS: Addiction Risk - the Dynamic of Risk Perception and Risk Behavior in Alcohol Dependence, Work Package 1, Study 1. Completed NCT03339674
1377 Auricular Percutaneous Electrical Neural Field Stimulation in Short-Term Treatment of Alcohol Dependence- Neurohaemodynamic Correlates and Feasibility Study Completed NCT04106739
1378 Stress Reactivity in Veterans Receiving Pharmacological Treatment for Post-traumatic Stress Disorder (PTSD) and Alcohol Dependence Completed NCT00923923
1379 Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking Completed NCT01077310 Vivitrol- Intramuscular naltrexone (depot-formulation);Placebo
1380 The Measurement of Mood Variability and Sustained Attention in Women With Alcohol Dependence. Completed NCT00230425
1381 Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in French Gastro and Hepatology Departments Completed NCT02835365
1382 Cognitive Bias Modification: A Novel Intervention for Alcohol Dependence and Social Anxiety Completed NCT01886716
1383 Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence Completed NCT02486900
1384 Cerebral Hemodynamics With rTMS in Alcohol Dependence: A Randomized, Sham Controlled Study Completed NCT02446067
1385 Internet Based Treatment for Alcohol Dependence Among Anonymous Help Seekers on the Internet : A Randomized Controlled Trial Completed NCT02377726
1386 Biomarkers to Measure Treatment Response for Alcohol Dependence Completed NCT02315885
1387 HealthCall: Enhancing Brief Intervention for HIV Primary Care Alcohol Dependence Completed NCT02501057
1388 Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence - Protocol Optimisation Phase Completed NCT02406456
1389 Stress, HPA Dysfunction, and Relapse in Alcoholism Completed NCT00744588
1390 Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits Completed NCT01171677
1391 Mechanisms of Change, Motivation, and Treatment Outcome in AD-PTSD Completed NCT01409707
1392 Endophenotyping With fMRI: Genetic Modulation and Treatment Response Completed NCT01503931
1393 Development and Testing of Adolescent Twelve-Step Facilitation Completed NCT01449981
1394 Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal Completed NCT02146963
1395 Effects of Acute Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Individuals With Alcohol Use Disorders Completed NCT02664727
1396 Cross-Sectional and Longitudinal Study of Structural Imaging Completed NCT02564991
1397 Outpatient Psychotherapeutic Treatment for Alcohol Dependent Individuals With Comorbid Psychiatric Disorders Completed NCT02141789
1398 Technology-Supported Physical Activity Intervention for Depressed Alcoholic Women Completed NCT02705898
1399 Pilot Study of Text Message Brief Interventions for Problem Drinkers Completed NCT01180829
1400 Automated Bilingual Computerized Alcohol Screen and Intervention in Latinos Completed NCT02247388
1401 Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET Completed NCT01719497 [C-11]OMAR
1402 Learning to Resist the Urge: Inhibition Training in Abstinent Patients With Alcohol Use Disorders. A Randomized Controlled Trial Completed NCT02968537
1403 Usability Study for SOBERLINK System Completed NCT02650180
1404 Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months Following After Alcohol Withdrawal in Alcohol-dependent Subjects in Relation to Abstinence Completed NCT01491347
1405 Network and Contingency Management for Alcohol Treatment Completed NCT00845208
1406 Alcohol Consumption and Stress at Patients Alcohol-dependants Completed NCT02087358
1407 Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge? Completed NCT02634476
1408 Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use Completed NCT02603471
1409 Alcohol SBIRT Implementation in an HMO: Non-Physician Providers Vs Physicians Completed NCT01135654
1410 Treatment Settings for Alcoholics: A Field Extension Completed NCT02986776
1411 Integrated Treatment of Operation Enduring Freedom/Operation Iraqi Freedom Veterans With Post-traumatic Stress Disorder and Substance Use Disorders Completed NCT01338506
1412 Effects of Sulfasalazine on BOLD Response to Alcohol Cues Completed NCT01312129 Sulfasalazine;Placebo
1413 Helping Problem Drinkers on the Internet Completed NCT01114919
1414 Intensive Intervention for Smokers in Alcohol Treatment Completed NCT00217984
1415 Impact of Group Motivational Interviewing for Dually Diagnosed Veterans Completed NCT00706901
1416 Motivating Chronic Hepatitis C Patients to Reduce Alcohol Use Completed NCT00596960
1417 Validation of a Short Questionnaire (SSI) for Sleep Disorders in Patients With Alcohol Completed NCT04007042
1418 A Randomized Controlled Trial of Extended Brief Interventions for Alcohol-dependent Patients in an Acute Care Setting Completed NCT01060397
1419 Maternal Child Health Bureau Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial Completed NCT00619255
1420 Stages an Processes of Change in Help-Seeking and Drinking Behavior Completed NCT00424112
1421 Treatment of Alcohol Use Disorders in Schizophrenia Completed NCT00280813
1422 Efficacy of Approach Avoidance and Attentional Bias Retraining in Alcohol-dependent Patients: a Randomized Controlled Trial in a Clinical Setting Completed NCT03338361
1423 The Effect of Dorsolateral Prefrontal Cortex Theta Burst Stimulation on Alcohol Cue Reactivity and Cognitive Control: a Double-blind, Sham Controlled Study of Heavy Alcohol Drinkers With a History of Alcohol Related Injury. Completed NCT04223154
1424 Developing and Testing a Computer-Based Alcohol Use Disorder Recovery System Completed NCT01003119
1425 Effect of Varenicline on Reactivity to Smoking and Drinking Cues in Individuals With Concurrent Tobacco Dependence and Alcohol Use Completed NCT00873535 Varenicline;Placebo
1426 Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User: Results of the Randomized Controlled Trial Completed NCT02173041
1427 Effect of Naltrexone on Craving and Ethanol-Induced Brain Activity Completed NCT00667771 Early Phase 1 Naltrexone
1428 Component Analysis of Motivational Interviewing Completed NCT00665249
1429 Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects Completed NCT00635102 D-Cycloserine PO and Glycine IV;Placebo D-Cycloserine PO and placebo Glycine IV;Placebo D-Cycloserine PO and Glycine IV;D-Cycloserine PO and placebo Glycine IV
1430 Contingency Management for Chronic Recidivist Alcohol-Dependent Patients Completed NCT00408161
1431 Comparison of Efficacy of an Outpatient vs Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence. A Prospective Randomized Clinical Trial. Completed NCT00226720
1432 Assessment and Treatment of People With Alcohol Drinking Problems Completed NCT00106093
1433 Episodic Thinking (ET) as a Candidate Technique to Reduce Alcohol Consumption Completed NCT03340051
1434 A Randomized Controlled Study of Patients Matching Themselves to Treatment Options: The Self-Match Study Completed NCT03278821
1435 Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) Completed NCT00579267
1436 Chronic Alcohol, Stress Inflammatory Response and Relapse Risk Completed NCT02193204
1437 Reducing Risky Alcohol Consumption Using Skills-training in the App-form: A Randomized Controlled Study in the General Population. Completed NCT03696888
1438 Disseminating Organizational SBI Services (DO-SBIS) at Trauma Centers Completed NCT00607620
1439 Helping Alcoholics Link to Substance Abuse Treatment Programs After Being in the Hospital for Detoxification Completed NCT00513708
1440 Alcohol and Gender Effects on Stress Circuit Function Completed NCT00226694 Citalopram
1441 Improving Longterm SUD Outcomes With Telephone Case Monitoring Completed NCT00265512
1442 Ambivalence Model of Craving: Re-examining the Drinking-craving Relationship Completed NCT01883089
1443 From Feasibility to Efficacy: the Use of EMDR to Reduce Craving and Drinking Behaviour in Alcohol Dependent Outpatients - A Multiple Baseline Study and Randomized Controlled Trial (RCT) Completed NCT01828866
1444 Electrophysiological Correlates of Emotional and Crossmodal Stimuli Processing Among Alcohol-dependent Participants : Exploration of the Peripheral Presentation Effect Completed NCT01633905
1445 Use of Selincro and Impact on Usual Practice Completed NCT02492581 Nalmefene
1446 Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Alcoholism Completed NCT03448016 Early Phase 1 NOP-1A
1447 Therapeutic Alliances in Alcoholism Treatment Completed NCT01689103
1448 Neurobiological Correlates of Disturbed Cognitive Function in Patients With Alcoholism - Simultaneous Measurement With EEG and fMRI Completed NCT00216905
1449 NMDA Dysregulation in Individuals With a Family Vulnerability to Alcoholism Completed NCT00588952 Ketamine and Placebo
1450 Brain Inflammation and Function in Alcoholism Completed NCT02233868 Early Phase 1 neuroinflammation
1451 Trauma, Stress and Persistence of HPA Dysregulation in Alcoholism Completed NCT00536146
1452 Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism Completed NCT00612352 Ethanol High Dose, Ethanol Low Dose, and Placebo
1453 GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA) Completed NCT00681655
1454 PET Evaluation of Serotonin Transporters Using [C-11] DASB in Alcoholism Completed NCT00085865
1455 Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens Completed NCT00001294
1456 Study of the Links Between Suicidal Intentionality and Acute Alcoholism Completed NCT03230448
1457 The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients Completed NCT00865774
1458 Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects Completed NCT00802321 Dutasteride
1459 Consequences of At-risk Alcohol Consumption in ICU Patients : the Impact OH Study. Completed NCT03565016
1460 Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery Completed NCT01389297
1461 Alcohol and Women : Screening in General Medicine. Completed NCT04647565
1462 Functional Magnetic Resonance Imaging of Stress and Addictive Disorders Completed NCT01558973
1463 Reducing Alcohol Use & PTSD w/ Cognitive Restructuring & Experiential Acceptance Completed NCT00760994
1464 Evaluation of Physical Activity of Patients Admitted to Addiction Service Completed NCT04953403
1465 Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse Completed NCT02242955 Diazepam
1466 The Effect of the Psychiatric Nursing Approach Based on the Tidal Model on Coping and Self-esteem in People With Alcohol Dependency: A Randomized Trial Completed NCT02604758
1467 Randomised Controlled Trial Testing the Incremental Effect of Strategies That Raise Awareness, Acceptance and Performance of Identification and Brief Intervention Programmes for Harmful Alcohol Consumption in Primary Health Care Completed NCT01501552
1468 The Effects of a Single Session of Real Versus Sham Theta Burst Stimulation on the Brain Response to Drug-cues Completed NCT02939352 Early Phase 1
1469 Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound. Completed NCT01208311
1470 Study on Non-communicable and Selected Communicable Chronic Comorbidities Among HIV-positive Patients on Anti-retroviral Therapy in Rural Lesotho and Their Association to Virologic Outcome Completed NCT02126696
1471 Integrated Stepped Care for Unhealthy Alcohol Use in HIV Completed NCT01410123
1472 Subjective and Physiological Effects of Alcohol: Role of Genetic Variation and Adrenal Hormones Completed NCT00734656 dutasteride + ethanol;placebo medication + ethanol;dutasteride + placebo alcohol;placebo medication + placebo alcohol
1473 Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications: a Multicenter Retrospective Comparative Study. Completed NCT04964687
1474 Neural Substrate of Approach-Avoidance Conflict Completed NCT02119624
1475 The OPTI-AGED Study : Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality in Elderly Patients. A Randomized, Multicentre, Prospective Controlled Study Completed NCT02668250
1476 VIP (Very Important Patient) Project on Alcohol and Drug Abusers - RCT of Efficacy of the Adding the Health Promotion and Rehabilitation for Treatment of Alcohol and Drug Abusers Completed NCT01414907
1477 Functional Outcomes in OEF/OIF Veterans With PTSD and Alcohol Misuse Completed NCT01123642
1478 Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention) Completed NCT02610517
1479 Alcohol Addiction: A Systems-oriented Approach; Functional Validation II: Neuroimaging x Genetics Completed NCT02910193
1480 Effects of Ghrelin on Alcohol Cue Reactivity and Craving Completed NCT01190085 Ghrelin;Saline solution
1481 Treatment Engagement With Technology-assisted Treatment Completed NCT02674477
1482 Project 4: Acute Effects of Alcohol on Learning and Habitization in Healthy Young Adults Completed NCT01858818
1483 Impact of Marketing of Alcohol Products on Young People Completed NCT03818750
1484 "Brief Alcohol Intervention: The Healthy Moms Project." Completed NCT00244062
1485 Clinical-Genetic Variation in GABA/Alcohol Sensitivity Completed NCT00223444
1486 Brief Alcohol Intervention in HIV+ Women Completed NCT00127231
1487 Alcohol Self Administration Laboratory Completed NCT00398918 zonisamide;Placebo
1488 Randomized Controlled Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia Completed NCT02790827
1489 Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 1: Assess the Initial Slope of Adolescent Drinking Trajectories, Beginning at the Age of Eighteen Completed NCT01063166
1490 Ultra-brief Intervention for Problem Drinkers Completed NCT00688584
1491 Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis Completed NCT00615862
1492 The Effects of Five Dosages of Ethanol on Simulated Driving Performance and Event-Related Potentials Completed NCT00477984 alcohol
1493 Health Focused Motivational Treatment for Alcohol Dependent Veterans Completed NCT00252590
1494 AMICA: Assessing the Fit of Motivational Interviewing by Cultures With Adolescents Completed NCT01948700
1495 Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services Completed NCT02233738
1496 Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking: Efficacy and Mechanisms of Change Completed NCT02861807
1497 Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 2: To Examine the Effect of Acute Alcohol Administration on Forebrain Disinhibition Using Functional Magnetic Resonance Imaging (fMRI) Completed NCT01097213 Ethanol;Placebo - half-normal saline
1498 Chronic Alcohol and Brain Stress Circuit Response Completed NCT01031264
1499 OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine Completed NCT00401999
1500 Effects of Acute Plasma Tryptophan Depletion on Serotonin Receptor Occupancy and Binding Affinity Using PET in Healthy and Alcoholic Human Subjects Completed NCT00011752 FCWAY
1501 Screening Evaluation for NIAAA Protocols Completed NCT00001673
1502 Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN Completed NCT03341715 Early Phase 1 Mavoglurant (AFQ056)
1503 A Probe Study of Acamprosate: Genes Associated With Response Completed NCT00662571 acamprosate
1504 An Internet-based Intervention for Problem Drinking Completed NCT00367575
1505 Group Interventions to Prevent HIV in High Risk Women Completed NCT00220597
1506 Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits Completed NCT00001500
1507 Functional Neuroanatomy of Positive and Negative Affect in Alcoholics and Non-Alcoholics Completed NCT00001675
1508 Alcohol Abuse, Oxidative Stress, and Zinc Deficiency in Lung Disease Completed NCT01899521
1509 Tailored Mobile Text Messaging to Reduce Problem Drinking Completed NCT01885312
1510 Interest of Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Didease in Alcoholic Patients in Weaning. Completed NCT01789008
1511 A Double Blind Trial of Divalproex Sodium for Affective Lability and Alcohol Use Following Traumatic Brain Injury Completed NCT01760785 divalproex sodium;Placebo
1512 Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study Completed NCT03152760
1513 Evaluating Interventions for Alcohol Use Disorder Completed NCT02409888
1514 Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients Completed NCT01671501
1515 The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving Completed NCT02316574
1516 Adaptive Interventions for Problem Drinkers Completed NCT02511808
1517 The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder Completed NCT02469259 Early Phase 1 Oxytocin
1518 Component Analysis for Motivational Interviewing Completed NCT01642381
1519 Clinical Study of TripleA Connected to Diagnosis, Care and Aftercare of Alcohol Addiction in Outpatient Care Completed NCT03195894
1520 Micro-targeted Computerized Alcohol Misuse Intervention System for Health Care Completed NCT02368899
1521 Supportive Text Messages to Reduce Mood Symptoms and Problem Drinking in Patients With Primary Depression or Alcohol Use Disorder - Randomised Controlled Pilot Trials Completed NCT02327858
1522 Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology Completed NCT04440098
1523 Evaluation de l'efficacité thérapeutique de la Stimulation magnétique transcrânienne répétée Sur le Traitement du Craving à l'Alcool et la prévention de la Rechute Alcoolique à 6 Mois Chez Les Sujets dépendants et Des Facteurs génétiques déterminant la réponse thérapeutique Completed NCT01569399
1524 Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth: A CBPR RCT Completed NCT01442753
1525 Contingency Management Treatment Duration Completed NCT00732342
1526 Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Alcoholic Inpatients Completed NCT02091284
1527 Web Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse Completed NCT02073825
1528 Effect of CBT Microinterventions on Mechanisms of Behavior Change Among Adults With AUD: Using Eye Tracking to Measure Pre-Post Cognitive Control, Stimulus Salience, and Craving Completed NCT03661853
1529 Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C Completed NCT01707030
1530 Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study Completed NCT03037060
1531 The Effects of Electronic Cigarette Use on Alcohol Consumption: A Neurocognitive and Behavioral Investigation Completed NCT03449017
1532 Alcohol Misuse Intervention in Active Duty US Navy Personnel Completed NCT04893044
1533 Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill Completed NCT01567943
1534 Impact Evaluation at 3 Months Follow-up of a Brief Motivational Intervention in Reducing Alcohol Consumption Versus Simple Written Advice Only Among Adolescents Aged 16-24 in Pontchaillou Hospital Emergency Department in Rennes, France Completed NCT01435668
1535 Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting Completed NCT00862212
1536 Placebo-controlled Randomized Clinical Trial: tDCS to Prevent Relapse in Alcohol Use Disorder Completed NCT04990375
1537 Personalized Drinking Feedback Interventions for OEF/OIF Veterans Completed NCT01211353
1538 Pilot Study of a Computer-driven Platform That Uses Text Messages to Collect Drinking Information and Deliver Personalized Motivational Messages to At-risk Young Adults Completed NCT01197352
1539 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA) Completed NCT02060162
1540 Relational Agent to Improve Alcohol Screening and Treatment in Primary Care: RCT Completed NCT02030288
1541 Learning in Young Adults as Predictor for the Development of Alcohol Use Disorders Completed NCT01744834
1542 PNF 2.0: A Novel, Gamified, Facebook-Integrated Personalized Normative Feedback Intervention to Reduce Alcohol Use and Negative Consequences Among Sexual Minority Women Completed NCT03884478
1543 Piloting "Signs of Safety": A Deaf-Accessible Therapy Toolkit for Alcohol Use Disorder and Trauma Completed NCT03845985
1544 Development and Pilot Trial of an Intervention to Reduce Disclosure Recipients Negative Social Reactions and Victims Psychological Distress and Problem Drinking Completed NCT03488927
1545 Prevention and Mental Health Education for Mental Health Problems in Community: A Model of Common Mental Health Problems in Seven Metropolis of China Completed NCT01422447
1546 Use of Personalized Virtual Reality and Paper-and-pencil Interventions as Complementary Tools in the Treatment of Alcohol Use Disorder: From Cognitive Rehabilitation to the Prevention of Relapses. Completed NCT04639895
1547 Understanding Genetic Risk for Alcohol Use Disorder Completed NCT05143073
1548 Charleston ARC Clinical Project 4 Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues Completed NCT02939313 Early Phase 1
1549 Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder Completed NCT02929979
1550 Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study Completed NCT02147483
1551 Contingency Management for Alcohol Use Disorders Completed NCT02135237
1552 The Effects of Cognitive Training on Alcohol Consumption, Cognition and Craving in Alcohol Use Disorder Completed NCT02113618
1553 Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV: Clinical Trial Completed NCT03652675
1554 Adapting Alcohol Behavioral Couple Therapy for Service Members in Post-Deployment Completed NCT03589521
1555 Effects of Long-term Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Heavy Drinkers Completed NCT02664766
1556 Alcohol Approach Bias Modification to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study Completed NCT02600832
1557 Collaborative Care for Primary Care Patients With Alcohol Use Disorders Completed NCT01400581
1558 Automated Reinforcement Management System (ARMS): Phase I Study Completed NCT04656925
1559 Adolescent Family-Based Alcohol Prevention Completed NCT00858065
1560 Study of Mechanisms of Emotion Regulation in Short- and Long-term Alcohol-abstinent Patients Completed NCT02881983
1561 Digitally Assisted Virtual Recovery Coach to Improve Inpatient Alcohol Withdrawal Management: A Proof-of-concept Pilot Study Completed NCT05393544
1562 Family Intervention for Teen Drinking and Alcohol-Related Crises in the ER Completed NCT01229748
1563 Effect of Hypnotherapy in Alcohol Use Disorder Compared to Motivational Interviewing. A Randomised Controlled Trial Completed NCT03583788
1564 Mentored Research on Improving Alcohol Brief Interventions in Medical Settings Completed NCT02978027
1565 Sustained Implementation of Patient-Centered Care for Alcohol Misuse Completed NCT02675777
1566 Alcohol and Employment - a Randomized Controlled Trial Completed NCT01416103
1567 Prevention of Alcohol Related Incidents in the US Air Force Completed NCT01398319
1568 Evaluating the Efficacy of a Mobile App (Drinks:Ration) and Personalized Text and Push Messaging to Reduce Alcohol Consumption in a Veteran Population: Protocol for a Randomized Controlled Trial Completed NCT04494594
1569 Screening to Augment Referral to Treatment- Project START Completed NCT01539525
1570 Brain Functional Connectivity During Early Recovery in Alcohol Use Disorder as a Marker for Relapse Completed NCT02877849
1571 Estimating the Acute Impact of Competing Mental Imagery on Craving in Alcohol Use Disorder Completed NCT04958655
1572 Examining Common Substrates of Eating and Alcohol Use Disorders Completed NCT01172210
1573 The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders (LeAD P5) Completed NCT02094196
1574 Testing CBT Models and Change Mechanisms for Alcohol Dependent Women Completed NCT03589274
1575 A Non-randomized Comparative Cohort Study Evaluating a Home-based Community Health Worker Program in the Rural Eastern Cape Province of South Africa Completed NCT03517878
1576 Binge Drinking Among Young Students is a Risk Factor for the Development of Alcohol Use Disorders: Results From an Epidemiologic-observational Study Completed NCT03062189
1577 Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action. Completed NCT02994043
1578 Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy: A STROBE Compliant Study Completed NCT03467022 Vitamin C
1579 Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing Completed NCT03435783
1580 Integrating Combined Therapies for Persons With Co-occurring Disorders Completed NCT02598518
1581 Can a Chatbot-delivered Alcohol Intervention Engage Users and Enhance Outcomes Over a Smartphone App? Development and Feasibility Testing of a StepAway 'Bot' Completed NCT04447794
1582 Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation Completed NCT04412824 Early Phase 1 Intravenous blood draw
1583 "ALCO-VR": Virtual Reality Cue Exposure Therapy for the Treatment of Alcohol Use Disorder. Completed NCT04858061
1584 Z 31601 - Understanding Longitudinal Clinical Outcomes and Post-release Retention in Care Among HIV-infected Prisoners in Lusaka, Zambia Completed NCT02905162
1585 Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention Completed NCT02895984
1586 Portrayal of Hospital Alcohol Detoxifications and Factors Associated With Longer or Ulterior Hospitalizations in France From 2011 to 2020 Completed NCT04973202
1587 Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake Completed NCT01168687 Levetiracetam (Keppra);Placebo
1588 Motivational Enhancement Therapy and Community Reinforcement Approach For Treating Alcohol Problems in the Elderly Completed NCT02084173
1589 Mobile Phone-Based Motivational Interviewing to Reduce Alcohol Use Problems in Kenya Completed NCT03573167
1590 Prediction and Detection of Intermediate and Long-term Developmental Hazards in Adolescents After Alcohol Intoxication Completed NCT01692054
1591 Alcohol Approach Bias Modification Effects on Alcohol Consumption: A Pilot Human Laboratory Study Completed NCT03898323
1592 Brief Online Interventions for Alcohol Use: A Crowdsourced Study Completed NCT03438539
1593 Cognitive Training in the Treatment of Alcohol Use Disorders in Older Veterans Completed NCT02664038
1594 Internet Based Cognitive Behavior Treatment for Alcohol Use Disorders - a Randomized Controlled Trial Completed NCT02645721
1595 Learning and Decision Making as Predictors of Treatment Outcome in Alcohol Use Disorder (Funding Period 2) Completed NCT02615977
1596 Navigation Services to Avoid Rehospitalization (NavSTAR) Among Substance Users Completed NCT02599818
1597 Optimizing Alcohol Brief Interventions in the ED: Computer vs. Clinician Delivery Completed NCT01370226
1598 Effectiveness of Inpatient Alcohol Detoxification and Psychotherapeutic Support Program Completed NCT03988478
1599 The Effect of a Self-Forgiveness Model on Self-Stigma in Individuals Diagnosed With Substance Use Disorder. Completed NCT03971097
1600 Pilot Study of an Integrated Exposure-Based Model for Posttraumatic Stress Disorder and Substance Use Disorder Completed NCT01274741
1601 A Web App for Patients With Alcohol and Drug Use Problems in Primary Care Completed NCT01830114
1602 Pilot Evaluation of the Empower Neuromodulation System in Alcohol Use Disorder (AUD) Patients Completed NCT03983317
1603 Evaluation of a Therapeutic Education Programme for Harm Reduction in People With Alcohol Use Disorder Completed NCT03954054
1604 Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics Completed NCT01323738
1605 fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults Completed NCT01320748
1606 Risk Factors for Alcohol Abuse and Deviant Behaviour - Biochemical and Molecular Studies in Adolescents From Swedish County Completed NCT01306812
1607 D-Cycloserine to Enhance Extinction to Alcohol Cues Completed NCT01362309 d-cycloserine.
1608 Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD Completed NCT02226367 prazosin hydrochloride;placebo
1609 Treatment of Depression Concurrent With Alcohol Abuse, an Extension of Alcohol Use Disorder in Patients Treated for Depression Completed NCT00369746 citalopram
1610 Services Interventions for Injured ED Problem Drinkers Completed NCT00234221
1611 Adapting an Effective CBT for Comorbidity to a Computer-Delivered Format Completed NCT03300232
1612 Mental Health and Well-being of People Who Seek Help From Their Member of Parliament Completed NCT04203966
1613 Using Counter Attitudinal Advocacy to Change Drinking Behavior & Related Problems Completed NCT04026633
1614 Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality Completed NCT04380116
1615 A Pilot Study on the Feasibility of Alcohol Brief Intervention Plus Personalized Mobile Chat-based Intervention to Reduce Alcohol Misuse in an Emergency Department in Hong Kong Completed NCT03823599
1616 Imaging Beta-amyloid in Middle Age Alcoholics as a Mechanism That Increases Their Risk for Alzheimer's Disease Completed NCT03746366 Early Phase 1 Pittsburgh Compound B
1617 Family Based Contingency Management for Adolescent Alcohol Abuse Completed NCT00595478
1618 Computer-based Alcohol Reduction Intervention for Alcohol-using HIV/HCV+ Russian Women in Clinical Care Completed NCT03362476
1619 Quantification of Liver Iron Overload and Steatosis Using a New Magnetic Resonance Imaging Multiecho Gradient-echo Sequence Completed NCT00401336
1620 Tailored Teen Alcohol and Violence Prevention in the ER Completed NCT00251212
1621 Intermittent Theta Burst TMS for the Treatment of Alcohol Use Disorders in Veterans Completed NCT03291431
1622 Filling the Gap Between Lab and Clinical Impact: an Open Randomized Diagnostic Trial Comparing Urinary Ethylglucuronide and Ethanol in Alcohol Dependent Outpatients. Completed NCT03276520
1623 Observational Study of EEG Monitoring of Patients in the Emergency Department Completed NCT04070521
1624 Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers Completed NCT04018560
1625 Improving Brief Alcohol Interventions With a Behavioral Economic Supplement Completed NCT02834949
1626 Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders Completed NCT02742246
1627 Preventing FAS/ARND in Russian Children Completed NCT01961050
1628 A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome Completed NCT01037868
1629 Study of Retinal Function Using Electroretinogram in Regular Alcohol Users Completed NCT03818971
1630 Effects of Active Virtual Reality Working Memory Retraining on Heavy Drinking Veterans With Mild Traumatic Brain Injury Completed NCT03786276
1631 Early Recovery Adherence Therapy for Bipolar Alcoholics Completed NCT00167323
1632 Comparison of 2 Tests for Screening for Cognitive Disorders (MoCA / BEARNI) Completed NCT04009707
1633 Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly. A French Multicentered Prospective Interventional Study. Completed NCT02822911
1634 Developing a Brief Early Cognitive Intervention for PTSD and Alcohol Misuse Completed NCT02808468
1635 Feasibility and Pilot Testing of SBI to Reduce Alcohol Misuse Among Active Duty Members in a Military ER Setting Completed NCT02228967
1636 Treatment for Teens With Alcohol Abuse and Depression Completed NCT02227589
1637 The Impact of CBT for Insomnia on Alcohol Treatment Outcomes Among Veterans Completed NCT03806491
1638 Integrating Contingency Management Into Routine Care for Alcohol Use Disorder Completed NCT03701204
1639 Applying Mental Contrasting With Implementation Intentions to Prevent Relapse and Drop-out in Patients With Alcohol Use Disorders Completed NCT03684798
1640 Bone Mineral Density in the Korean Patients With Chronic Schizophrenia With Alcohol Abuse Completed NCT00540267
1641 Student Athlete Drug Surveillance Trail Completed NCT00451854
1642 Reducing Unsafe Drinking in HIV Primary Care Completed NCT00371969
1643 Project ACTIVE: A Randomized Controlled Trial of Personalized and Patient-Centered Preventive Care Completed NCT04211883
1644 Financially Sustainable Remote Treatment for Alcohol Abuse: Feasibility Completed NCT04182022
1645 Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder Completed NCT04059549
1646 Treatment Engagement in Families With Substance Use and Psychosis: A Pilot Study Completed NCT04284813
1647 Affective Modulation of Positivity for Alcohol Use Disorder (AMP-A): Feasibility and Pilot Study Completed NCT04278365
1648 Pilot Trial of Emergency Department Intervention and Referral for Alcohol Misuse in Older Adults Completed NCT02236494
1649 Alcohol, Suicide, and HIV Prevention for Teens in Mental Health Treatment Completed NCT02228044
1650 Pilot Trial of Varenicline and Prazosin to Treat Heavy Drinking Smokers Completed NCT02193256 Early Phase 1 Varenicline;Prazosin;Placebo
1651 Relay Model for Recruiting Alcohol Dependent Patients in General Hospitals - A Single-blind Pragmatic Randomised Trial Completed NCT02188043
1652 Mobilizing to Reduce Overuse of Alcohol in Emergency Department Patients Completed NCT02158949
1653 Study to Optimize and Validate the Treatment Parameters for the Empower Neuromodulation System Completed NCT03807544
1654 Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients? Completed NCT00372749
1655 Developing, Implementing and Evaluating Preschool Based Interventions to Address Family Violence and Alcohol and Drug Misuse in Sri Lanka Completed NCT03341455
1656 Addiction Treatment Outcome Monitoring Study Completed NCT04155385
1657 Resolving Psychological Stress (RePS): a Mobile Health Application for Modifying Attention Bias to Threat in Post-traumatic Stress Disorder Completed NCT03996876
1658 C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under- Served College Population Completed NCT03927482
1659 EARN-Health: A Randomized Controlled Trial of the Effects of an Incentivized Savings Program on Depression, Anxiety, Substance Abuse, and Locus of Control Completed NCT02185612
1660 Effectiveness of Alcohol Interventions Among TB Patients in Tomsk Oblast, Russia Completed NCT00675961 Naltrexone
1661 Study That Examines Integration of the Telephone Linked Care Behavioral Change (Automated Counseling) System Into Primary Care Completed NCT00314197
1662 Telephone Disease Management At-Risk Drinking (TDM 11) Completed NCT00123409
1663 Integrated CBT for Substance Use and Depressive Disorders Completed NCT00108407
1664 Mindfulness for at Risk Youth: Understanding Substance Use and Important Mechanisms of Change Completed NCT04160754
1665 Alcohol Use Disorders- Mobile Based Brief Intervention Treatment (AMBIT) Technology Innovation to Bridge the Treatment Gap for Hazardous Drinking: A Pilot RCT Completed NCT04078360
1666 Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin Completed NCT01916941 Prazosin;Placebo
1667 Testing the Efficacy of an Online Self-Help Treatment for Comorbid Alcohol Misuse and Emotional Problems in Young Adult Canadians: A Randomized Controlled Trial (RCT) Completed NCT03406039
1668 mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease Completed NCT02480062
1669 Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD Completed NCT01751035
1670 Therapist-guided Internet Treatment for Hazardous and Harmful Alcohol Use. a Feasibility Study Completed NCT04544930
1671 A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder Completed NCT03216954 Early Phase 1 Alcohol;Placebos;N-acetyl cysteine
1672 Sex Differences, Cognitive Training & Emotion Processing Completed NCT03137654
1673 Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women Completed NCT02272023
1674 Assisted vs Unassisted Domiciliary Alcohol Detoxification: A Randomised Control Trial Completed NCT05563740
1675 Contingency Management to Reduce Alcohol Use in a Soup Kitchen Sample Completed NCT02499913
1676 Multimedia Toolkits to Implement 12-Step Recovery Concepts in Group Counseling Completed NCT02333357
1677 Learning Mechanisms as Predictors of Treatment Outcome in Alcohol- Dependent Patients Completed NCT01679145
1678 Treatment for Excessive Alcohol Use and Depression in Students (TREADS) Completed NCT01632319
1679 CCTAP: Cognitive Control Training for Treatment of AUD-PTSD Completed NCT03200028
1680 Evaluation of ED Triage of Adult Patients With Alcohol Abuse Completed NCT02449772
1681 Guided and Unguided Internet Treatment for Problematic Alcohol Use: A Randomized Pilot Study Completed NCT02384304
1682 Improving Outcomes Among Medical/Surgical Inpatients With Alcohol Use Disorders Completed NCT03258632
1683 Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer Completed NCT02489032
1684 A Community-Based Strategy for Preventing Underage Drinking Completed NCT02448134
1685 Internet Based Cognitive Behavior Treatment for Alcohol Problems: A Pilot Study Completed NCT02384278
1686 Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT Completed NCT01678196
1687 Computer Based Training in Cognitive Behavioral Therapy Web-based Delivery of CBT4CBT for Alcohol Completed NCT01615497
1688 Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram Completed NCT03212599 Disulfiram
1689 Alcohol Cue Exposure: An Investigator-blinded, Randomized, Controlled Study of Exposure-based Aftercare in Alcohol Use Disorder Individuals Completed NCT02298751
1690 : Developing a Brief Family-Involved Treatment for Alcohol Use Disorders Completed NCT05545644
1691 Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking Completed NCT02527720
1692 Single-dose Interventions to Reduce Re-admissions for Hospitalized Patients With Refractory Alcohol Use Disorder: A Randomized Pilot Feasibility Study. Completed NCT04562779 Early Phase 1 Naltrexone 380 MG;Ketamine Hydrochloride
1693 Behavioral Counseling Intervention Trial to Reduce Alcohol-related Sexual Risk Behavior Among HIV-negative Men in Namibia Completed NCT02359487
1694 Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer Completed NCT01084733
1695 Sentinel Node Localization in Larynx and Pharynx Cancers After Flexible Endoscopy-guided Tracer Injection: a Feasibility Study. Completed NCT04068636
1696 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Completed NCT03934294 Metoclopramide 10mg
1697 Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx Completed NCT00001167
1698 Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer Completed NCT00140556 Early Phase 1 Cisplatin;Bevacizumab;Erlotinib
1699 Clinical Study of the Effect of Different Alcoholic and Non-Alcoholic Beverages on Markers of Inflammation Completed NCT00764426 red wine, beer, ethanol;de-alcoholised red wine, de-alcoholised beer, water
1700 A Prospective Study of Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis Completed NCT02048267
1701 Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis Completed NCT01324414
1702 Influence of ABO Blood Group on the Risk of Complications in Alcoholic or Viral C Cirrhosis? Analysis From Two French Prospectives National Cohorts CIRRAL and CIRVIR of Patients With Alcoholic or Viral Cirrhosis Child Pugh A Completed NCT03342170
1703 A Randomized Controlled Pilot Trial of a Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease Completed NCT03839082
1704 Role of Mitochondrial Dysfunction in Non-Alcoholic Fatty Liver Disease Completed NCT02690792
1705 Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study. Completed NCT01696487
1706 Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis Completed NCT05357352
1707 Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Ten Clinical Trials Comparing Drug Therapy in Patients With Severe Alcoholic Hepatitis Completed NCT02796469 Pentoxifylline;Corticosteroid;Placebo
1708 A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area Completed NCT00913757
1709 Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human : Study of Pro- and Anti-inflammatory Cytokines and ADIPOKINES.. Completed NCT00388323
1710 Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Non-alcoholic Fatty Liver Disease. Completed NCT01894438
1711 A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis Completed NCT02528305
1712 Validation of an Accelerated Procedure of Selection in Early Liver Transplantation for Severe Alcoholic Hepatitis Not Responding to Medical Treatment QuickTransHAA. Completed NCT01756794
1713 Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis in Addition to Prednisolon Therapy Completed NCT02326103 Early Phase 1 Ciprofloxacin;Placebo
1714 Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls Completed NCT01674972
1715 Clinical Performance Evaluation of LIVERFASt Tests to Determine Fibrosis Staging, Inflammatory Activity and Steatosis Grading Compared w/ Liver Biopsy in Patients w/ Metabolic Factors & Presumed Non-Alcoholic Fatty Liver Disease (NAFLD). Completed NCT04579874
1716 The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults Completed NCT03142867
1717 Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease - A Randomized Control Trial Completed NCT02140294
1718 A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis Completed NCT02072746
1719 Investigation of the Effects of a Synbiotic on Liver Fat, Disease Biomarkers and Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Completed NCT01680640
1720 Validation of the Assignment of Alcoholic Drinks to Predefined Drink Groups in the Composite International Diagnostic Interview (CIDI) Completed NCT03097354
1721 Does Mixing Alcoholic Drinks Make Hangover Worse? A Randomized Controlled Trial in a Naturalistic Setting Completed NCT03506516
1722 Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease (BEN) Study Completed NCT02950610
1723 The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial Completed NCT02679417
1724 The Effect of an Enhanced Rice Bran Nutritional Supplement on Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT02568787
1725 Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients Completed NCT04779905
1726 Role of CCL2 in Alcoholic Liver Diseases Completed NCT01128010
1727 Effect of DPP-4I and Related Treatment on Non-alcoholic Fatty Liver Disease Completed NCT05480007 sitagliptin and metformin;Sitagliptin;Metformin
1728 The Influence of Superimposed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution: a Matter of Body Composition Completed NCT05416970
1729 The Role of Resistance Training in Non Alcoholic Fatty Liver Disease Completed NCT01264198
1730 Selenoprotein P and Non-alcoholic Fatty Liver Disease Completed NCT01257685
1731 Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis Completed NCT01245257
1732 Evaluation Of The Therapeutic And Dietary Properties Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis Completed NCT03664596 Ursodeoxycholic Acid
1733 The Diagnostic Performance Assessment of Quantitative Ultrasound Imaging Indices for Differentiating Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease Completed NCT04462562
1734 Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy Completed NCT04452409
1735 Evaluation of Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients Completed NCT04834063
1736 The Role of the PNPLA3, TM6SF2 and MBOAT7 Genetic Variants in the Response to Silybin-phospholipid Complex, Vitamin D and Vitamin E Based Therapy for Non-alcoholic Fatty Liver Disease Patients Completed NCT04640324 Nutraceutical therapy
1737 Diets Based on PNPLA3 Genotype for Reducing Liver Fat in Hispanics With Pediatric Non-alcoholic Fatty Liver Disease Completed NCT02948647
1738 Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents Completed NCT02116192
1739 Effectiveness of a Mediterranean Diet to Treat Non-Alcoholic Fatty Liver Disease in Children Completed NCT04415112
1740 Effect of Dietary Intervention on Intestinal Microbiota in Patients With Non-alcoholic Fatty Liver Disease Completed NCT01477307
1741 Prospective Histopathologic Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease Completed NCT00815009
1742 De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease Completed NCT00714129
1743 Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation? Completed NCT02148471
1744 The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance Completed NCT02132780
1745 Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus Completed NCT01997424
1746 A Prospective Study of Hepatitis B Virus (HBV) Immunity and Hepatitis B Vaccination in Patients With Non Alcoholic Fatty Liver Disease (NAFLD) in Canada Completed NCT02985450
1747 Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients Completed NCT04462081
1748 Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of Non-alcoholic Fatty Liver: a Randomized Clinical Trial Completed NCT04450875
1749 Effect of Oral L-Citrulline Supplementation on Liver Function and Non-Alcoholic Fatty Liver Disease in Adolescents With Obesity Completed NCT04871360
1750 Investigation of Hepatic and Cardiac Fatty Acid Metabolism in Patients With Type 2 Diabetes Mellitus With and Without Non-alcoholic Fatty Liver Disease Completed NCT04698486
1751 The Effect of Cigarette Smoking Reduction on Liver Function Tests and Metabolic Profile in Subjects With Non-alcoholic Steatohepatitis Completed NCT04688307
1752 Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Completed NCT02875392
1753 Study of Metabolism Influence in Human Alcoholic Liver Disease Completed NCT01122797
1754 Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study Completed NCT03536650
1755 A Randomized Controlled Study on the Effects of Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy or Intensive Lifestyle Modifications on Non Alcoholic Steato-Hepatitis Completed NCT03524365
1756 The Feasibility of Liver Biomarkers as Prognostic Markers in Decompensated Alcoholic Liver Disease Completed NCT01701687
1757 Impact of Text Messaging in the Management of Non-alcoholic Fatty Liver Disease Completed NCT03082703
1758 The Genetic Effect on Omega 3 Fatty Acid Supplementation for the Treatment of Non Alcoholic Fatty Liver Disease in Obese Children and Adolescents Completed NCT01556113
1759 Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease Completed NCT01237574
1760 Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis Completed NCT02075918
1761 The Efficacy of Antibiotic Rifaximin on the Lipopolysaccharides (LPS) and Related Cytokine Levels in Non Alcoholic Fatty Liver Disease Patients Completed NCT02009592 Rifaximin
1762 Alcohol Biosensor Monitoring for Alcoholic Liver Disease Completed NCT03533660
1763 Low Glycemic Index Mediterranean Diet Effect on Moderate or Severe Non-alcoholic Fatty Liver Disease Completed NCT01798719
1764 A Randomized Controlled Trial of Home Monitoring Versus Hospitalization in Mild Non-Alcoholic Acute Interstitial Pancreatitis Completed NCT01796652
1765 Intensive Enteral Nutrition in Association With Corticosteroids in Severe Acute Alcoholic Hepatitis: a Multicenter, Randomized, Controlled Trial Completed NCT01801332
1766 Effect of Korea Red Ginseng on Non-alcoholic Fatty Liver Disease Completed NCT03945123
1767 Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial. Completed NCT01820208 G-CSF;Placebo
1768 Is Access to Liver Transplantation Similar in Alcoholic or Not Patients? A Prospective Cohort Study Completed NCT01820819
1769 Validation Study of the NASHMIR Test for Non-alcoholic Steatohepatitis (NASH) Diagnosis in Patients With Severe or Morbid Obesity Completed NCT03978247
1770 Effect of a Chia Supplemented Diet (Salvia Hispanica) on the Cardiometabolic Risk Profile in Patients With NAFLD (Non Alcoholic Fatty Liver Disease) Completed NCT03942822
1771 Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis Completed NCT01065233
1772 Leptin, Soluble Leptin Receptor and Adiponectin in Non Alcoholic Steatohepatitis Completed NCT00583999
1773 Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI) Completed NCT03294850
1774 Non-invasive Rapid Assessment of Non-alcoholic Fatty Liver Disease (NAFLD) Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1) Completed NCT03289897
1775 Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis Completed NCT04084522
1776 Prevelance of Non Alcoholic Fatty Liver Disease,Its Complications Among Employees at Banha University Hospital,Egypt Completed NCT04367012
1777 Effect of Intermittent Calorie Restriction on Non-alcoholic Fatty Liver Disease Patients With Disorders of Glucose Metabolism Completed NCT04283942
1778 Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium Completed NCT02172898
1779 A Randomized Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Improving Activity of Non-Alcoholic Fatty Liver Disease Completed NCT03791203
1780 Study of the Role of Insulin Resistance in the Pathogenesis of the Metabolic Syndrome and of Non-alcoholic Steatohepatitis Completed NCT00523562
1781 Open-label, Non-Pharmacological, Intervention Cohort Study Without Control Arm, in Patients With Non Alcoholic Fatty Liver Disease and in Healthy Subjects. Completed NCT03300661
1782 Diagnostic Value of Quantitative Ultrasound Imaging Parameters for Hepatic Steatosis in Patients With Non-alcoholic Fatty Liver Disease Completed NCT04180631
1783 A Pilot Study, Non-comparative Efficiency of Techniques of 'Snail ' and 'Go-back' Application of an Alcoholic Antiseptic on Healthy Skin Before the Placement of a Intra-vascular Device, Completed NCT04002245
1784 Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease Completed NCT02728765
1785 MRS Validation Study of Hepatic Triglyceride Content in Non-alcoholic Fatty Liver Disease (NAFLD)Subjects Pre- and Post-Prandial Completed NCT00940537
1786 A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis Completed NCT00930384
1787 Interval Training Versus Electro Acupuncture on Liver Functions in Patients With Non-alcoholic Fatty Liver Disease Completed NCT03936803
1788 the Effect of Omega 3 Fatty Acids Supplements on Antioxidant Capacity in Egyptian Children With Non Alcoholic Fatty Liver Disease Completed NCT04281121
1789 A Randomized Controlled Trial to Study the Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis. Completed NCT02231333 S-adenosylmethionine (SAMe);pentoxiphylline (PTX)
1790 Prevalence and Metabolic Impact of Non-alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes With Normal Renal Function or Chronic Kidney Disease Completed NCT03826381
1791 Ke-To Liver Health Study: A Randomized Controlled Trial to Study the Effects of a 28-day Ketogenic Dietary Intervention on Non-alcoholic Fatty Liver Disease Progression Completed NCT03784716
1792 Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics-An Observational Study Completed NCT03753438
1793 Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease Completed NCT00610597
1794 Randomized Clinical Trial of the Effect of Standard Versus Intensive Intervention Protocol in Attempting to Reduce Recurrent Episodes of Acute Alcoholic Pancreatitis Completed NCT00534534
1795 Recurrence of Acute Alcoholic Pancreatitis Completed NCT00523874
1796 Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus: A Comparative Egyptian Study Completed NCT03276039
1797 Effect of Focused Ultrasound on Abdominal and Intrahepatic Fat in Patients With Non-alcoholic Fatty Liver Disease Completed NCT04161703
1798 Is HOMA-IR(Homeostatic Model Assessment for Insulin Resistance) a Potential Screening Test for Non-alcoholic Fatty Liver Disease in Adults With Type 2 DM? Completed NCT04084925
1799 A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT04073368
1800 A Randomised Controlled Exercise Intervention in Subjects With Non-alcoholic Fatty Liver Disease Completed NCT03995056
1801 Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH Completed NCT02820285
1802 Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study Completed NCT02806011
1803 The Effect of the Dietary Supplement Protandim on Non-Alcoholic Steatohepatitis: A Randomized, Double Blind, Placebo-Controlled Study Completed NCT00977730
1804 Non Invasive Diagnostic Methods for Fibrosis in Alcoholic Liver Disease : FIBROSCAN Validation and Comparison of Fibrotest - FIBROSCAN Association With FIBROSCAN Alone Completed NCT00708617
1805 Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease Completed NCT00641524
1806 Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study) Completed NCT04146636
1807 Effect of a Multifactorial Intervention (Non-alcoholic Beer, Diet and Exercise) on Endothelial Function, Nutritional Status and Quality of Life in Patients With Cirrhosis Completed NCT04041115
1808 Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis. A Pato-etiological Study With Focus on the Endotoxin Pathway. Completed NCT00992888
1809 The Cross Sectional Study to Investigate the Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease and Healthy Controls Completed NCT02176811
1810 Role and Pathogenetic Mechanisms of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Severity in Obese and Non-obese Subjects Completed NCT02158351
1811 Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis Completed NCT02808663
1812 Effect of a Whey Protein Supplementation on Intrahepatic Lipids in Obese Patients With Non-alcoholic Fatty Liver Disease Completed NCT00870077
1813 Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference. Completed NCT01985009
1814 Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis Completed NCT00701792
1815 The Effect of Berberine on Lipid Profile, Liver Enzymes and Fasting Blood Glucose in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial Completed NCT04049396
1816 The Impact of Bariatric Surgery on Non-alcoholic Fatty Liver Disease Completed NCT02828579
1817 Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure Completed NCT02737345
1818 Assessment of Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Predictors of Cardiovascular Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass: Development of a New Paradigm in Defining "Morbid Obesity" and in the Application of Bariatric Surgery Completed NCT01007955
1819 An Interdisciplinary Approach to the Study of Non-alcoholic Fatty Liver Disease Completed NCT00949403 Early Phase 1 Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
1820 Protective Immune Mechanisms in Alcoholic Hepatitis Completed NCT01918462
1821 Randomized Clinical Trial to Detect Advanced Fibrosis by Non-invasive Methods in Subjects With Non-alcoholic Fatty Liver Disease Completed NCT01874249
1822 Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) Completed NCT01761370
1823 The Production of a Functional Roll Supporting the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Completed NCT04520724
1824 Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among Non-alcoholic Fatty Liver Disease Patients Completed NCT03250572
1825 Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease Completed NCT05325398
1826 Study of Hybrid Training on Lipid Profile and Non-alcoholic Fatty Liver Disease in Middle-aged Obese Women Completed NCT05231564
1827 Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease Completed NCT02520609
1828 Clinical Trial for Investigating the Effects of "Hepafast" on Non-alcoholic Fatty Liver Disease (NAFLD) Completed NCT02491229
1829 Clinical Trial on the Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD) Completed NCT02369536
1830 Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT03245606
1831 The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis. Completed NCT03157388 Combined Vancomycin and Gentamycin and Meropenem
1832 Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease Completed NCT02363309
1833 Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients Completed NCT03380416
1834 Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis Completed NCT02458079 Pentoxiphylline;Stool microbiota transplantation
1835 Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome Completed NCT02358928
1836 Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis Completed NCT02526732
1837 Relation of Serum Irisin Levels, Non-Alcoholic Fatty Liver Disease, Glucose and Lipid Metabolism Parameters in Obese Children Completed NCT04524936
1838 Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases Completed NCT02319252
1839 The Impact of Non-Alcoholic Fatty Pancreas Disease on Outcome of Acute Pancreatitis Completed NCT03394378
1840 Metabolic Imprints of Alcoholic Beverages Completed NCT03384147
1841 Impact of Chlordecone Exposure on Evolution of Fibrosis to Cirrhosis in Chronic Hepatitis C, B or Alcoholic, in Guadeloupe. Completed NCT03373396
1842 Cognitive Function of Alcoholic Liver Disease Patients Completed NCT04557774
1843 Histological Improvement of Non-alcoholic Steatohepatitis With a Prebiotic: a Pilot Clinical Trial Completed NCT03184376
1844 Prognostic Indicators as Provided by the EPIC ClearView Completed NCT01476995
1845 Indicators for the Metabolic Syndrome as Well as the Influence of Different Gen-polymorphs on Weightloss and the Maintenance of Lower Weight Among Children in Treatment for Overweight Completed NCT00823277
1846 Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT- A Randomized Clinical Control Trial Study Completed NCT03836937 Obeticholic acid
1847 Screening Inpatients With Type 2 Diabetes for Nonalcoholic Fatty Liver Disease Using Controlled Attenuation Parameter and Liver Stiffness Measurements Completed NCT03060694
1848 Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress Completed NCT02650830
1849 Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes Completed NCT01492283
1850 Makuuchi Versus Barcelona Clinic of Liver Cancer Criteria in Cirrhotic Patients With Hepatocellular Carcinoma. Does Etiology of Cirrhosis Influence the Relationship Between the Portal Pressure and Quantitative Tests of Liver Function? Completed NCT00827723
1851 Fatty Liver and Obstructive Sleep Apnea Completed NCT00730873
1852 A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care Completed NCT02923804
1853 Combined Endoscopic Ultrasound Guided Core Liver Biopsy and Intragastric Balloon Placement for the Diagnosis and Management of Nonalcoholic Steatohepatitis and Obesity Completed NCT02880189
1854 Could Rifaximin Modify the Pathogenesis of NAFLD? AMulticenter, Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT02884037 Rifaximin group 1
1855 Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production Completed NCT01262326
1856 Effect of Alive Probiotics Supplementation With Absorbent Smectite Gel in NAFLD Completed NCT03614039
1857 Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade Completed NCT01747772
1858 The Effect of Curcumin on Liver Fat Content in Obese Subjects Completed NCT03864783 Placebo Oral Tablet
1859 Body Composition, Adiposity Phenotype, Metabolic Flexibility, and Gut Microbiota in PNPLA3 and TM6SF2 Gene Variant Carriers and Non-carriers With Nonalcoholic Fatty Liver Disease. Effects of a Nutritional Intervention Combined to Exercise Completed NCT02951546
1860 Study of IL-6 Transsignaling in Chronic Human Liver Disease Completed NCT00770198
1861 Alcohol, Gut Leakiness, & Liver Disease Completed NCT05428072 Early Phase 1 Aspirin Challenge
1862 Hepatic Metabolic Changes in Response to Glucagon Infusion Completed NCT03526445 Glucagon;Saline
1863 A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes: a Six-month Study of Changes in Metabolism, Liver- and Cardiovascular Function (ReDuCtion) Completed NCT03068078
1864 Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study Completed NCT03439917
1865 Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism Completed NCT01371396
1866 Efficacy and Safety of a Probiotic Composition as Adjunct Treatment in the Comprehensive Management of Metabolism-Associated Hepatic Steatosis in Adults Completed NCT04823676
1867 Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation Completed NCT01579162
1868 Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients Completed NCT01695083
1869 VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China Completed NCT02962297 Vitamin E softgel;Placebo
1870 Mobile Health Delivered Lifestyle Intervention Program in Patients With Nonalcoholic Steatohepatitis: A Proof of Concept Study Completed NCT04872777
1871 Exercise Dose and Nonalcoholic Fatty Liver Disease Completed NCT00771108
1872 The Effect of Exercise on Hepatic Fat in Overweight Children; the EFIGRO Study Completed NCT02258126
1873 Coffee Consumption and NASH in the French Population. Completed NCT03432377
1874 MRI Fat Quantification of the Liver, Subcutaneous and Visceral Fatty Tissue in Patients Before and After Bariatric Surgery Completed NCT02682173
1875 Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples Completed NCT02650115
1876 Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients. Completed NCT01548079 Ursodeoxycholic Acid (UDCA)
1877 Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis Completed NCT01188083
1878 Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression Completed NCT02267148
1879 ObeSity Related Colorectal Adenoma Risk Completed NCT03663062
1880 Effects of Hydrogen-rich Water on Liver Fat Accumulation, Blood Lipids and Body Fatness in Patients With Non-alchoholic Fatty Liver Disease Completed NCT03625362
1881 Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Completed NCT03590626 Dulaglutide
1882 WayToServe Español: A Culturally-Appropriate Online Responsible Beverage Service Training for Spanish-Speaking Servers Completed NCT03001024
1883 Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study Completed NCT02686476 Empagliflozin
1884 How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype? Completed NCT01790984
1885 Behavior and Driving Safety Study II Completed NCT01270217
1886 Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease Completed NCT01327443
1887 Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver! Completed NCT01317576
1888 Fish Oil for the Treatment of Nonalcoholic Fatty Liver Disease in Children Completed NCT01285362 Fish Oil Supplementation;Placebo Supplementation
1889 Inter-Center Reproducibility Study of Magnetic Resonance Imaging (MRI) for Quantification of Hepatic Fat Fraction in Diabetic and Pre-Diabetic Patients Completed NCT01110577
1890 EUS Guided Liver Biopsy Proposal Titled : EUS Guided Liver Biopsy - Will it Give Better Yield , More Tissue With Less Complication ? Completed NCT04235855
1891 Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study Completed NCT03339245
1892 Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons Completed NCT00889577
1893 Genetics of Fatty Liver Disease in Childhood Obesity. Completed NCT01966627
1894 Somatic Disease Among Alcohol Abusers in an Out-day Patients' Clinic. A Neglected Area Completed NCT01081197
1895 Transient Versus Bidimensional Shear Wave Elastography in Serial Combination Strategy to Diagnose Advanced Fibrosis in NAFLD Patients Completed NCT04384159
1896 Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) Completed NCT01958411
1897 Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry) Completed NCT04336800
1898 Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease: a Randomized Controlled Trial Completed NCT04320199
1899 Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.) Completed NCT00586313
1900 Influence of High-fat Overfeeding on Circulating Hepatokine Concentrations: a Randomised Crossover Study Completed NCT03369145
1901 The Impact of Type 2 Diabetes and Exercise on Liver Fat Quality Completed NCT04004273
1902 Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease Completed NCT02779946
1903 Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates Completed NCT00887393
1904 A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Trehalose in Patients With Fatty Liver Disease Completed NCT03738358
1905 Obesity and Nonalcoholic Fatty Liver Disease Completed NCT00262964 Niacin;fenofibrate;placebo
1906 A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity Completed NCT02787668
1907 Behavior and Driving Safety Study Completed NCT00575679
1908 Motivational Interviews for Incarcerated Teens Completed NCT00227916
1909 Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans Completed NCT04130321
1910 Impact of Free Sugar Replacement by Maple Syrup on Prevention of Metabolic Disorders Associated With Overweight in Humans : Role of Gut Microbiota Completed NCT04117802
1911 Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease Completed NCT02860884
1912 Clinical Study of Phytosterols for Insulin-like Growth Factor-1 and Endothelial Progenitor Cell Levels in Patients With Nonalcoholic Fatty Liver Disease Completed NCT01875978
1913 Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients Completed NCT03402256
1914 The Effect of Protein-enriched Diet on Body Composition and Appetite Completed NCT01634048
1915 THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS. Completed NCT02381769
1916 Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization Completed NCT04571957
1917 Exercise and Overweight Children's Cognition (Supplement) Completed NCT02383485
1918 Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH Completed NCT02390232
1919 Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia Completed NCT02337660
1920 Mastiha Treatment for Obese With NAFLD Diagnosis Completed NCT03135873
1921 Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth Completed NCT02461212
1922 Ultrasound Quantification of Liver Fat Completed NCT04523584
1923 Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome Completed NCT01787591
1924 Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults Completed NCT03149627
1925 Effects of Anke Malz on Women During Lactation Completed NCT02523729
1926 Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI Completed NCT03198104
1927 Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial Completed NCT00868933
1928 Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome Completed NCT02083367
1929 Using Imaging to Assess Effects of THC on Brain Activity Completed NCT03655717 Dronabinol;Ethanol;Placebo dronabinol;Placebo ethanol
1930 Feasibility of Vigorous-Intensity Interval Training in Adults With Nonalcoholic Steatohepatitis Completed NCT03861819
1931 Assessment of Dietary Intakes of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT02649049
1932 Nutrition-based Therapy of Liver Disease of Different Origin: Effect of n-3 Polyunsaturated Fatty Acid in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome. Completed NCT02647294
1933 Effects of Sleeve Gastrectomy on Hepatic and Metabolic Abnormalities in Adolescents With Complicated Morbid Obesity and NAFLD Completed NCT02564679
1934 The Effect of Mediterranean Diet and Low Fat Diet on Hepatic Fat, Inflammation and Oxidative Stress in Obese Adolescents With Nonalcoholic Fatty Liver Disease Completed NCT04845373
1935 Noninvasive Biomarkers of Metabolic Liver Disease 1.1 Completed NCT04828551
1936 The Development of Preventive Methods for Chronic Noncommunicable Diseases Based on Modulation of Gut Microbiota Composition and Function Completed NCT04820556
1937 Stop-Service to Obviously-Impaired Patrons Completed NCT03608787
1938 The Effect of Physical Activity on the Liver and the Heart's Metabolism of Fatty Acids in Obese With and Without NAFLD Completed NCT03583437
1939 Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD: Randomized Clinical Studies Completed NCT03528707
1940 Web-based Family Prevention of Alcohol and Risky Sex for Older Teens Completed NCT03521115
1941 The Liver in the World Trade Center Health Program General Responder Cohort and Controls Completed NCT03858920
1942 Vitamin D Replacement in Nonalcoholic Fatty Liver Disease Completed NCT03084328
1943 The Effects of a Novel Real Food Based Digital Education-assisted Lifestyle Intervention Program on Metabolism in Type 2 Diabetes Completed NCT04509245
1944 The Effect of High Fructose Corn Syrup Feeding in Nonalcoholic Fatty Liver Disease Completed NCT02018237
1945 The Effect of Modulating Hepatic Glycogen Content on Hepatic Fat Oxidation Completed NCT03593343
1946 Effects of Fructose Restriction on Liver Steatosis Completed NCT03067428
1947 Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism Completed NCT01446276
1948 Pilot Randomized Control Trial of Smartphone-enabled Breath Alcohol Monitoring on Perceived Fitness to Drive a Vehicle Among Intoxicated Adults Completed NCT05028413
1949 The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Biochemical Markers and Imaging Studies of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT02983669
1950 Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings? Completed NCT02580318
1951 Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, Study 3 Completed NCT01464801
1952 A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis Completed NCT01210989 Phyllanthus urinaria;Placebo
1953 Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis Completed NCT02044523
1954 Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912 Completed NCT03611101 BMS-986036
1955 Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis Completed NCT03566173
1956 Effects of Chinese Bayberry Juice on Liver Enzymes and Plasma Antioxidant Activity in Adult Subjects With Features of Fatty Liver Disease: a Randomised Placebo-controlled Trial Completed NCT01707914
1957 Association of Light-to-moderate Alcohol Consumption With Risk of Type 2 Diabetes Mellitus in Individuals With Nonalcoholic Fatty Liver Disease Completed NCT03847116
1958 Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH (The Elvis Study) Completed NCT03490370
1959 Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With Nonalcholic Fatty Liver Disease Completed NCT03461562
1960 Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-14 (NCT02960204) Completed NCT03439189 Emricasan;Placebo oral capsule
1961 Alcohol-Containing Products' Effect on Breathalyzer Results in Healthy Adults Without Acute Intoxication Completed NCT04878653
1962 Liquid Biopsy as a Non-invasive Tool for the Diagnosis of NASH and Liver Fibrosis Completed NCT04677101
1963 Effects of Time-Restricted Feeding on Nonalcoholic Fatty Liver Disease in Obese Adults: a 12-month Randomized Clinical Trial Completed NCT04988230
1964 Pilot Study: Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease Completed NCT04988204
1965 A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults Completed NCT01688245
1966 Effects of Purified Anthocyanin on Oxidative and Inflammatory Markers in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial Completed NCT01940263 Early Phase 1
1967 Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease Completed NCT03986684
1968 Nonalcoholic Steatohepatitis in HIV Mono-infection: Exploring Non-invasive Methods for Diagnosis and the Therapeutic Role of Vitamin E Completed NCT03988725
1969 The Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease and Cardiovascular Risk Utilizing Non-invasive Measures Completed NCT01828528
1970 Influence of Increasing Dietary Protein on Hepatic Fat Accumulation and Postprandial Metabolism Completed NCT01354626
1971 Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Utilizing Ultrasound and Percutaneous Liver Biopsy: A Prospective Cohort Study Completed NCT01100398
1972 Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Completed NCT01030484
1973 Cannabis Impairment Detection Application (CIDA) Completed NCT04230460 Cannabis (THC) (Inhaled) Placebo;Cannabis (High% THC) (Inhaled);Cannabis (Very High% THC) (Inhaled);Alcohol (oral)
1974 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02217345 Growth hormone;Placebo
1975 Effects of High-Intensity Interval and Moderate Intensity Continuous Exercise on Diabetic Obese Patients With Nonalcoholic Fatty Liver Disease- A Comparative Randomized Controlled Trial Completed NCT03774511
1976 Contribution of de Novo Lipogenesis in Severity of Nonalcoholic Fatty Liver Disease Completed NCT03683589
1977 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver Completed NCT03319199
1978 Reducing Risky Drinking Using Smartphone Paired Breathalyzer Completed NCT04086576
1979 Splanchnic and Systemic VLDL-TG and FFA Balance in Individuals With NAFL and NASH Completed NCT04292977
1980 Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant Completed NCT02196831 tesamorelin;Placebo
1981 The Prevalence of Liver Steatosis, Steatohepatitis, Fibrosis, and Hemosiderosis in Overweight and Obese US Military Dependent Pediatric Patients Using MR Elastography and Quantitative MRI Completed NCT04284371
1982 Nonalcoholic Fatty Liver Disease is Associated With Increased Atrial Fibrillation Risk in an Elderly Chinese Population: a Cross-sectional Study Completed NCT03366987
1983 A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis Completed NCT00586885 L-alanine
1984 Screening for Undiagnosed NAFLD and NASH Completed NCT03726827
1985 Effects of Exercise on VLDL-TG Metabolism in Individuals With NAFL and NASH Completed NCT03678727
1986 Pilot Trial Leveraging Smartphone-paired Breathalyzers and Loss- and Gain-framed Text Notifications for Reducing Drinking Driving Completed NCT03335735
1987 Comparison of Dietary Sugar Reduction Methods Completed NCT04186793
1988 Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values Completed NCT02722564
1989 Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics Completed NCT00870012 Lepicol probiotic & prebiotic formula
1990 Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents Completed NCT01045499
1991 Effects of Time-Restricted Feeding on Nonalcoholic Fatty Liver Disease in Obese Adults: a Randomized Clinical Trial Completed NCT03786523
1992 The Effect of a Low Compared to a High Glycemic Index/Saturated Fatty Acid Diet on Hepatic Fat Completed NCT04054297
1993 Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents Completed NCT02726542 Early Phase 1 somatropin
1994 Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services Completed NCT01783223
1995 Determinants of Liver Fat Composition in Overweight and Obese Humans Completed NCT03211299
1996 Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD Completed NCT02513121
1997 Effect of Two Different Programs of Physical Activity on the Grade of Severity of NAFLD Completed NCT02367742
1998 Study of the Prevalence of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease. Completed NCT01657773
1999 A Randomized Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection Completed NCT01645852
2000 The Effects of Ginger on Biochemical Markers and Imaging Studies of Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT02289235 Early Phase 1 Ginger;Placebo
2001 A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Fermented Ginseng Powder on Liver Function Completed NCT03260543
2002 The Effect of Weight Gain After Smoking Cessation Increased the Risk of Type 2 Diabetes in Individuals With Nonalcoholic Fatty Liver Disease Completed NCT05550688
2003 Determination of the Effect of Lyophilized Dried Cornus Mas L. Fruit Powder on Nutritional Status in Individuals With Metabolic Associated Fatty Liver Disease Combined With Medical Nutrition Therapy Completed NCT05546450
2004 Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD Completed NCT05523648 Early Phase 1 Chronic Hepatitis B
2005 Anthropometric Evaluation and Body Composition in Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity Completed NCT02427087
2006 A Machine Learning Approach for Inferring Alcohol Intoxication Levels From Gait Data Completed NCT03246490
2007 Genetic Variations in Adipokine to Improve Risk Prediction for NAFLD and Its Progression to NASH in Egyptian Patients Completed NCT04561895
2008 The Effectiveness of a Mediterranean Diet Intervention in NAFLD Clinical Course Completed NCT03203486
2009 Effects of Pitavastatin on Insulin Sensitivity and Liver Fat Completed NCT02290106 pitavastatin
2010 A Parallel Cohort Controlled Trial of Outcome of Nonalcoholic Steatohepatitis in Adolescents After Bariatric Surgery vs. Comprehensive Lifestyle Intervention (NASH ABC) Completed NCT02412540
2011 Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH) Completed NCT03375008
2012 Efficacy of Repetitive Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy on Alcohol Dependence Recruiting NCT03910686
2013 SPIRA: Development of a Smartphone Based Intervention for the Prevention of Relapse in Alcohol Dependence Recruiting NCT03952429
2014 (Epi)Genetic Modulators of Fear Extinction in Alcohol Dependence Recruiting NCT02438969
2015 Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Recruiting NCT03842670
2016 Characterization Imaging Instruments for Addiction Neuroimaging Assessments Recruiting NCT02108080
2017 Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease Recruiting NCT04876443
2018 Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients Recruiting NCT04490330
2019 Behavioral and Functional Task Development, Implementation, and Testing Recruiting NCT02108054
2020 TREAT Child Alcohol Use Disorder (C-AUD) in Eastern Uganda: Screening, Diagnostics, Risk Factors and Handling of Children Drinking Alcohol Recruiting NCT04743024
2021 Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill Recruiting NCT03481049
2022 Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users Recruiting NCT04154111
2023 A Multi-centre Registry Study on Patient Trajectories After Interventions for Alcohol-related Health Problems in Somatic Hospital Wards, for People in Late Adulthood (60+) Recruiting NCT04164940
2024 Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study Recruiting NCT04014413
2025 General Evaluation of Eligibility for Substance Abuse/Dependence Research Recruiting NCT00439049 modafinil;d-amphetamine;L-Dopa;Naltrexone
2026 Applying Technology-Enabled Contingency Management for Alcohol Use Disorder at Scale in a Medicaid Population Recruiting NCT04581499
2027 Characterizing the Effects of Family History of Alcoholism on Alcohol Analgesia Recruiting NCT04925076 Ethanol
2028 Neurobiological Responses in Alcoholism and Early Trauma Recruiting NCT04128228
2029 Ketogenic Diet (KD) in Alcoholism Recruiting NCT03255031 Early Phase 1
2030 Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant Recruiting NCT05203965 Early Phase 1 Mavoglurant (AFQ056);Placebo
2031 Examining the Impact of Stress on the Emotionally Reinforcing Properties of Alcohol in Heavy Social Drinkers: A Multimodal Investigation Integrating Laboratory and Ambulatory Methods Recruiting NCT03449095 Alcohol
2032 Characterization of CB1 Receptors Using [11-C]OMAR Recruiting NCT01730781
2033 Predicting Alcohol Use and Alcohol Use Disorder Symptoms From Subjective Responses to Alcohol in a Laboratory Social Setting Recruiting NCT03467191 Early Phase 1 Alcohol
2034 Effectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder: A Multicentre Randomised Controlled Study Recruiting NCT04773691
2035 Suicidal Behavior in Patients Diagnosed With Bipolar Disorder: The Roles of Biological and Childhood and Adult Environmental Risk Factors Recruiting NCT02604277
2036 Impact of Combined Recovery Program and Home Telehealth Among Veterans With Substance Use Disorders in the VA Inpatient Setting Recruiting NCT05054738
2037 Individual Differences After Consumption of Alcohol and Other Common Substances and Long-Term Follow-Up of Social Drinking, Young Adults Recruiting NCT00961792 Ethanol;Placebo;Diphenhydramine;Caffeine
2038 PTSD, AUD, and Interpersonal Conflict: Within-person Associations Recruiting NCT04552782
2039 Retinoic Acid Homeostasis in Neuropsychiatric Diseases Recruiting NCT02439099
2040 Patterns of Alcohol Use and Suicide-related Thoughts Among Recently Discharged Veterans: Risk Factors Associated With the Military-to-Veteran Transition Recruiting NCT04463225
2041 Online Cognitive Behavior Therapy in Routine Addiction Care for Comorbid Sleep Problems in Alcohol Use Disorder Recruiting NCT04402619
2042 Understanding and Targeting Stress Reactivity in Women Veterans With Alcohol Misuse Recruiting NCT04393623
2043 Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment Recruiting NCT04841655
2044 Development of a Mobile Mindfulness Intervention for Alcohol Use Disorder and PTSD Among OEF/OIF Veterans Recruiting NCT04769986
2045 Factors Associated With Quality of Life in Patients With Alcohol Use Disorder Recruiting NCT04748822
2046 Dissecting Responses to Alcohol in Individuals With Familial Risk for Bipolar Disorder Recruiting NCT04716036
2047 Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment Recruiting NCT04667520
2048 Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Facilities "Outside the Walls" Using the Dual Screening Method TROD (Rapid Diagnostic Tests) and FibroScan Recruiting NCT05361603
2049 The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers Recruiting NCT02037867
2050 A Visuomotor Rotation Task as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use Recruiting NCT03662737
2051 Brief Individual and Parent Interventions for Substance Use in Truant Adolescents Recruiting NCT03655574
2052 HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function Recruiting NCT03902366
2053 A Randomized Trial of Pioglitazone for the Treatment of Alcohol Use Disorder Recruiting NCT03864146
2054 Computer Based Training in CBT for Spanish-Speaking Alcohol Users Recruiting NCT03474588
2055 Baclocur® Post-Authorisation Safety Study in Real-life Settings in France Recruiting NCT04679142 Baclofen Tablets
2056 Investigation of Social Cognition and Executive Functions as Cognitive Vulnerability Markers for the Development and Maintenance of Alcohol Use Disorders - a Transverse Study Design Recruiting NCT04647422
2057 Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity Recruiting NCT05117255
2058 AAT-App Trial: A Clinical Trial of a "Brain-training" Smartphone App to Help Reduce Alcohol Use in People Accessing Outpatient Alcohol Treatment Recruiting NCT05120856
2059 Pathological Risk: Dynamics of Risk Perception and Risk Behavior in Alcohol Use Disorder and Schizophrenia Recruiting NCT04985786
2060 Loneliness and Health Outcomes in the High Need Population Recruiting NCT05484258
2061 Training Inhibition in Alcohol Use Disorder: an add-on Randomized Controlled Trial Recruiting NCT03530384
2062 Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers Recruiting NCT03457077
2063 Feasibility, Acceptability, and Efficacy of a Dialectical Behavioral Therapy Digital Health Solution in the CAMH Rainbow/COMPASS Service Recruiting NCT05094440
2064 Vulnerability for Alcohol Use Disorder After ACE: the Role of Stress Sensitivity, Emotion Processing, Cue Reactivity and Cognitive Functions in Relapse Risk Recruiting NCT05048758
2065 Neuromodulation and Cognitive Training for Substance Use Disorders Recruiting NCT04426214
2066 Impact of a Brief Motivational Intervention Including Counter-marketing Arguments With a Population of Patients With Moderate to Severe Alcohol Use Disorders Who Are Followed up on an Outpatient Basis (Primary Care or Addictology) Recruiting NCT04881500
2067 Behavioral Economic and Wellness-based Approaches for Reducing Alcohol Use and Consequences Among Diverse Non-student Emerging Adults Recruiting NCT04776278
2068 Development of a Personalized Feedback Intervention Targeting Pain-Related Anxiety for Hazardous Drinkers With Chronic Pain Recruiting NCT05036499
2069 The Impact of COVID-19-related Medication Assisted Treatment Policy Changes on Care and Outcomes for Patients With Opioid Use Disorder Recruiting NCT05028998
2070 MPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience Recruiting NCT04998916
2071 Early Intervention Programs for at Risk Use of Psychoactive Substances and Gambling: ''My Choices'' Family Recruiting NCT05358613
2072 Mindfulness for Alcohol Abusing Offenders Recruiting NCT03883646
2073 Motivational Strategies in Batterer Intervention Programs for Intimate Partner Violence Offenders With Alcohol/Drug Abuse Problems: An Experimental Study Recruiting NCT03885349
2074 Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for Severe Alcoholic Hepatitis (SAH) Recruiting NCT03845205
2075 Glucocorticoid Antagonists in Heavy Drinkers: Effects on fMRI Connectivity, Withdrawal and Drinking Recruiting NCT02989662 Mifepristone;Placebo - Cap
2076 Targeting Sleep Homeostasis to Improve Alcohol Use Disorder Treatment Outcomes Recruiting NCT04457674
2077 AAT-APP+: A Pilot RCT of a Novel Smart-phone App to Reduce Alcohol Consumption Among Middle to Older Adults in the Eastern Health Community Recruiting NCT04923256
2078 The Michigan Sustained Patient-centered Alcohol-Related Care (MI-SPARC) Trial Recruiting NCT04861792
2079 Measuring Beliefs and Norms About Persons With Alcohol Use Disorder Recruiting NCT04832321
2080 Novel Methods for Investigating Stress-related Processes in Social Drinkers and Individuals With Alcohol Use Disorder Recruiting NCT05155176
2081 Facilitating Use of the National Suicide Prevention Lifeline in Alcohol Patients Recruiting NCT04488055
2082 Alterations of the Brain-Gut-Microbiome Axis Modulates Sex Differences in Outcomes of Alcohol-Related Liver Disease Recruiting NCT05007470 VSL #3 112.5 Capsule
2083 Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration Recruiting NCT04971681
2084 The Efficacy of a Mobile Application in Reducing Craving and Lapse Risk in Alcohol and Stimulants Problematic Use Recruiting NCT05434416
2085 Remote Alcohol Monitoring to Facilitate Abstinence Reinforcement With an Underserved Population Recruiting NCT03883126
2086 Randomised Controlled Feasibility Study to Examine the Efficacy of a Combined Group-based Exercise and Educational Programme on Alcohol Consumption, Mental Health and Physical Health Among Alcohol-Dependent Adults Recruiting NCT03848000
2087 Ultrabrief Behavioral Activation for Reducing Alcohol Use Recruiting NCT05086172
2088 Sex Differences in Risk for Alcohol Use Disorder: Neural and Hormonal Influences Recruiting NCT04929288 Alcohol
2089 Factors Predicting Outcome in Group Treatment of Alcohol Use Disorders (AUDs) Recruiting NCT04822987
2090 Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse Recruiting NCT04788004
2091 Biobehavioral Pathways Underlying Alcohol Use and Health Recruiting NCT05135767
2092 Multifactorial Analysis of the Influence of Alcohol Marketing Stimuli in Adults With Regular Alcohol Consumption on the Perception of Alcohol Risks and According to Types of Use and Individual Vulnerabilities Recruiting NCT05125783
2093 Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform Recruiting NCT05476588
2094 Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders Recruiting NCT05471154
2095 Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 Recruiting NCT05419128
2096 Qungasvik (Toolbox): Prevention of Alcohol/Suicide Risk in Alaska Native Youth Recruiting NCT05400135
2097 A Targeted, Real-Time, Technology-Supported Intervention for Patients With Alcohol Use Disorder on Disulfiram Recruiting NCT03543735
2098 Building Mobile HIV Prevention and Mental Health Support in Low-resource Settings Recruiting NCT03912753
2099 Effectiveness of a Brief Motivational Intervention in Addressing Excessive Alcohol Consumption in Primary Care Recruiting NCT04811729
2100 Addressing Alcohol-Use Related Health Disparities: A Hybrid Effectiveness Implementation Study of a Culturally Adapted MI for Latino/a Alcohol and Drug Users Recruiting NCT04771650
2101 BioWare to Enhance Treatment for Alcohol Use Disorder and Posttraumatic Stress Disorder Recruiting NCT05187364
2102 Sleep and Emotional Reactivity in Alcohol Use Disorder Recruiting NCT04979507
2103 Serving Those Who Protect the Public: The Pitt Center for Emergency Responder Wellness Recruiting NCT05357586
2104 Human Alcohol Seeking Despite Aversion Recruiting NCT03648840
2105 Investigating a Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder Recruiting NCT03535129
2106 Physiological Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes Recruiting NCT03056872
2107 Development and Evaluation of Harm Reduction Talking Circles for Urban American Indians and Alaska Natives With Alcohol Use Disorders - Phase III Randomized Clinical Trial Recruiting NCT04267692
2108 Physiological, Neural and Behavioral Correlates of Psychosocial Stress and Alcohol Craving Recruiting NCT03810950
2109 Impact of Art Therapy on Alexithymia in People With Alcohol Use Disorder Recruiting NCT04206930
2110 sTMS for Substance Use-disordered Veterans Recruiting NCT04336293
2111 Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) for Reduction of Negative Affect and Treatment of Alcohol Use Disorder Recruiting NCT03829761
2112 Dual Reinforcement Contingency Management for Alcohol Use Disorders Recruiting NCT04064463
2113 Using Counter Attitudinal Advocacy to Change Drinking Behavior Recruiting NCT04042909
2114 Integrating mHealth for Alcohol Use Disorders Into Clinical Practice Recruiting NCT04011644
2115 The Weaving Healthy Families Program to Promote Wellness and Resilience and Prevent Alcohol and Other Drug Abuse and Violence Recruiting NCT03924167
2116 Brief Motivational Therapy Versus Enhanced Usual Care for Alcohol Use Disorder in Primary Care in Chile, an Exploratory Randomised Trial Recruiting NCT04345302
2117 Sex Differences in the Response to Abstinence From Alcohol. Recruiting NCT03827460
2118 Selective Attention to Emotional and Alcohol-associated Cues in Patients With Alcohol Use Disorder and Healthy Participants Recruiting NCT03816527
2119 Subjective Response to Alcohol and Associated Neural Systems in Bipolar Disorder Recruiting NCT04063384
2120 Modification of Pavlovian and Instrumental Learning in Human Addiction Recruiting NCT04032587
2121 Internet-based Adolescent Community Reinforcement Approach (I-A-CRA) With Therapist Support for Young Adults With Problematic Alcohol Use: A Randomized Controlled Trial Recruiting NCT04381533
2122 Prevalence of Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints Recruiting NCT04368416
2123 Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Alcohol Use Disorder Recruiting NCT02168400
2124 The Effect of rTMS to the Prefrontal Cortex in Alcohol Use Disorder Recruiting NCT03809286
2125 The Impact of CBT for Insomnia on Substance Use Treatment Outcomes Recruiting NCT04198311
2126 Facilitating Alcohol Screening and Treatment (FAST), Colorado Recruiting NCT04303676
2127 Reducing Stigma Among Healthcare Providers to Improve Mental Health Services: Cluster Randomized Controlled Trial (RESHAPE-cRCT) Recruiting NCT04282915
2128 Randomized Controlled Trial of Mindfulness-Based Relapse Prevention for Opioid and Alcohol Use Disorders Recruiting NCT04278352
2129 Stress-related Predictor Profiles for Craving and Relapse in Human Addiction Recruiting NCT03810924
2130 Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women Recruiting NCT03718104
2131 Neurobiology of Alcohol and Nicotine Co-Addiction Recruiting NCT03338933
2132 Using Neuroeconomics to Characterize State-Based Increases and Decreases in Alcohol Value Recruiting NCT04067765
2133 Tdcs And cogNitive traininG cOmbined for AUD (TANGO) Recruiting NCT05062369
2134 NIAAA Natural History Protocol Recruiting NCT02231840
2135 Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions Recruiting NCT03299205
2136 Reinforcer Pathology 1A: Increasing the Temporal Window Recruiting NCT04125238
2137 Efficiency of Prevention Program Dedicated to Addictive Behaviors (PREVENTURE) of Vulnerable Teenagers Recruiting NCT04599270
2138 Developing and Implementing an Online Relapse Prevention Psychotherapy Program for Patients With Alcohol Use Disorder Recruiting NCT05579210
2139 Extension and Online Adaptation of the FITSTART Parent-based Intervention to Reduce Drinking Among First-year Students Recruiting NCT04549454
2140 PRACT: A Pragmatic Randomized Adaptive Clinical Trial to Investigate Controlling Alcohol Related Harms in a Low-Income Setting; Emergency Department Brief Interventions in Tanzania Recruiting NCT04535011
2141 Collaborative and Stepped Care in Mental Health by Overcoming Treatment Sector Barriers: A Cluster-randomized Controlled Trial (COMET) Recruiting NCT03226743
2142 Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders Recruiting NCT03191266
2143 Pilot Study on Mindfulness Meditation and Behavioral Flexibility Among Emerging Adults Recruiting NCT05560425
2144 Integrated Early Intervention for Alcohol Use Disorder and Posttraumatic Stress Disorder Following Sexual Assault Recruiting NCT04582695
2145 Promoting Alcohol Treatment Engagement Post-hospitalization With Brief Intervention, Medications and CBT4CBT: A Randomized Clinical Trial in a Diverse Patient Population. Recruiting NCT05338151
2146 Dexamethasone to Target Stress and Immune System Changes During Early Abstinence in Individuals With Alcohol Use Disorder (AUD) Recruiting NCT05305404 Early Phase 1 Dexamethasone Oral;Placebo
2147 Impact of the Coronavirus 2019 (COVID-19) Pandemic on Patient Outcomes, Telehealth Care Delivery, and Treatment for Unhealthy Alcohol Use in Vulnerable Patients With Advanced Liver Disease Across Two Healthcare Systems Recruiting NCT05191446
2148 Testing an Online Insomnia Intervention Recruiting NCT04564807
2149 Prevention of Alcohol Abuse in Educational Settings (PRVENALC) Recruiting NCT05281172
2150 A Randomized Double-blind Clinical Trial on the Efficacy of Transcranial Direct Current Stimulation (tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder Recruiting NCT02505126
2151 Cultural Innovations for Recovery in Community-Based Learning Environments (CIRCLE) Phase 3: Testing an Online Learning Community Application Recruiting NCT05326438
2152 Evaluation of an Addiction Intervention in Candidates for Liver Transplantation Recruiting NCT05322226
2153 Brief Personalized Feedback Intervention for Latinx Hazardous Drinkers: A Community-Based Intervention Recruiting NCT05288699
2154 Latinx Hazardous Drinkers With Clinical Anxiety: Effectiveness Trial of a Personalized Normative Feedback Intervention Recruiting NCT05246202
2155 Development of a Comprehensive and Dynamic AA Process Model: One Day at a Time Recruiting NCT04618653
2156 Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder Recruiting NCT04598399
2157 Addressing Health Disparities by Providing Evidence-Based Treatment in the Black Church Recruiting NCT04580810
2158 Neurobiological Factors Underlying Sex Differences in Risk for Alcohol Abuse Recruiting NCT04543942 Alcohol
2159 Addiction Telemedicine Consultation in Primary Care: Increasing Access to Pharmacotherapy and Specialty Treatment for Alcohol Problems Via Telehealth Recruiting NCT05252221
2160 Evaluation of Liver Disease in Individuals Attending Alcohol Abuse Treatment - a Randomized Controlled Pilot Trial Recruiting NCT05244720
2161 Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical Intensive Care Unit Survivors Recruiting NCT02465177
2162 Quality of Life After Primary Transoral Robotic Surgery vs Intensity-modulated Radiotherapy for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma: A Randomized National Trial Recruiting NCT04124198 Cisplatin;Nimorazole.
2163 Evaluation of the French Translation of Swallowing (SOAL-VF) Patient Reported Outcomes (PRO) After Total PharyngoLaryngectomy Recruiting NCT05497947
2164 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Recruiting NCT04028479 Systemic Treatment (T)
2165 Biospecimen Procurement for NIDCD Clinical Protocols Recruiting NCT03429036
2166 EUS Based Prevalence of Chronic Pancreatitis in Alcoholic Cirrhosis: Any Difference Between Alcoholic and Non-alcoholic Patients Recruiting NCT04245189
2167 Integrated Diagnostics for Early Diagnosis of Liver Disease Recruiting NCT04666402
2168 Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease: Cross-sectional Comparative Study Between Patients and Healthy Controls Recruiting NCT04141592
2169 Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease Recruiting NCT04106518
2170 The European Paediatric Non-alcoholic Fatty Liver Disease Registry (EU-PNAFLD): a Prospective, Longitudinal Follow-up of Children With Non-alcoholic Fatty Liver Disease Recruiting NCT04190849
2171 Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects Recruiting NCT03151473
2172 Disease Mechanisms and Markers for Non-alcoholic Steatohepatitis in a Population With Non-alcoholic Fatty Liver Disease: a Prospective Cohort Study With Biobank Recruiting NCT02422238
2173 Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results in a Pediatric Population Recruiting NCT04800094
2174 Integrated Approaches for Identifying Molecular Targets in Liver Disease Recruiting NCT03915002
2175 Investigation on Novel Route of Gut Microbiota Products for Bariatric Surgery to Improve Non-alcoholic Steatohepatitis and Development on Therapeutic Implications Recruiting NCT04501042
2176 Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results Recruiting NCT04657523
2177 The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF Recruiting NCT04682600
2178 A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG): Effects of ESG on Non-Alcoholic Steatohepatitis (NASH) and Portal Pressure Gradient in Patients With Obesity and NASH With Advanced Fibrosis Recruiting NCT04820036
2179 Prognostic Significance of Fatty Liver Disease in Bariatric Patients Recruiting NCT03535142
2180 The Olmsted NAFLD Epidemiology Study (TONES) Recruiting NCT04365855
2181 Technical Validation of Magnetic Resonance Biomarkers of Obesity-Associated Non-Alcoholic Fatty Liver Disease Recruiting NCT03674528
2182 Repeatability and Reproducibility of Multiparametric MRI (LiverMultiScan) Recruiting NCT03743272
2183 Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study Recruiting NCT02754037
2184 Mild Hypothermia and Acute Kidney Injury in Liver Transplantation (MHALT) Trial Recruiting NCT03534141
2185 Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis Recruiting NCT04088370
2186 Effectiveness of Lifestyle Modification Program in Reversal of Non-alcoholic Fatty Liver Disease (NAFLD) and Reduction of Cardiovascular Risks in Moderate Obesity: A Ultrasound Attenuation Imaging-Based Study Recruiting NCT04440540
2187 Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults Recruiting NCT04899102
2188 German NAFLD-Registry Characterization of Patients With Non-alcoholic Fatty Liver Disease (NAFLD) in Germany - Phase 1 (Observation of the Natural Course) Recruiting NCT04721665
2189 The Efficacy and Safety of Alcoholic Dehydrogenase (ALDH) Enzyme Supplement in Chemotherapy-Related Fatigue With Advanced Gastrointestinal Cancer Patients: A 2-Period, Crossover, Single-Center Study Recruiting NCT05030363 ALDH enzyme supplementation
2190 Lifestyle Modification Programme for HIV-infected Individuals With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial Recruiting NCT03913351
2191 Alcoholic Hepatitis Network Observational Study Recruiting NCT03850899
2192 Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19 Recruiting NCT04858412
2193 A Randomized Controlled Trial of Effects of DAIry PROtein Products on Liver Disease Severity and Metabolism in Patients With Non-Alcoholic Fatty Liver Disease. Recruiting NCT04841915
2194 Screening for Non-Alcoholic Fatty Liver Disease (NAFLD) in a General Practitioner Population, in Flanders, Belgium. Recruiting NCT04647409
2195 Assessment of Safety and Efficacy of Non-alcoholic Pasteurized Beverage Based on Kombucha, Enriched With Inulin and Vitamins in Patients With Constipations Recruiting NCT05164861
2196 Study of the Characteristics of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus Patients Followed in a Hospital Environment in Flanders, Belgium Recruiting NCT04999124
2197 Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style Intervention Recruiting NCT03875625
2198 Effects of an Iso-energetic Low Glycemic Index (GI) Diet on Liver Fat Accumulation and Gut Microbiota Composition in Patients With Non- Alcoholic Fatty Liver Disease (NAFLD) Recruiting NCT04415632
2199 Identification and Characterization of Non-alcoholic Fatty Liver Disease in Primary Care Recruiting NCT04918732
2200 A Multicenter, Controlled Study to Evaluate the Efficacy and Safety of an Endoscopic Sutured Gastroplasty (With Endomina Device) in Patients With Non Alcoholic Steatohepatitis (NASH) and Fibrosis. Recruiting NCT04653311
2201 Mechanism of HA35 in Patients With Alcoholic Liver Disease Recruiting NCT05018481 Early Phase 1 Sodium Hyaluronate;Placebo
2202 Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound Recruiting NCT05486429
2203 Evaluation of the Natural History of Alcoholic Liver Disease According to Baseline Severity Recruiting NCT04400604
2204 Accuracy of Imaging Techniques Including Ultrasound and Magnetic Resonance Imaging in the Diagnosis of Steatohepatitis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease: Comparison With the Histological Reference Standard Recruiting NCT04785937
2205 Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis Recruiting NCT03587831
2206 The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial Recruiting NCT02965898
2207 Impact of Exercise Intervention for Patients With Non-alcoholic Fatty Liver Disease Recruiting NCT04463667
2208 Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease: Beyond the Paradigm of Weight Loss. Recruiting NCT05130346
2209 A Prospective, Multi-Centre, Propensity Score Based Matched Pair Controlled, Study of Standard Medical Care Plus CytoSorb® 300 mL Device Compared to Standard Medical Care Alone in Patients With Acute on Chronic Liver Failure Due to Severe Alcoholic Hepatitis in Combination With Systemic Hyperinflammation and Acute on Chronic Liver Failure Score ≥2 Recruiting NCT05131230
2210 The Economic Burden of Non-Alcoholic Fatty Liver Disease Patients in Flanders, Belgium Recruiting NCT05035043
2211 Effects of Compound Silymarin on Biomarkers of Lipid Metabolism and Inflammation in Patients With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Double-blind Trial Recruiting NCT05497765
2212 Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans Recruiting NCT05480943
2213 Sidekick Health Digital Solution (SK-241) for Individuals With Non Alcoholic Fatty Liver Disease (NAFLD): A Feasibility Study Recruiting NCT05426382
2214 Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) Recruiting NCT05423327
2215 Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography Recruiting NCT05351515
2216 Use of Shear Wave Elastography in Adolescents and Children With Obesity to Assess Non-alcoholic Fatty Liver Disease (NAFLD) Recruiting NCT03587298
2217 Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study Recruiting NCT05093881
2218 AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) Recruiting NCT04807868
2219 Non-alcoholic Fatty Liver Response of Cardio-metabolic Risk Factors to Laser Acupuncture Versus Cupping-with-scarification Recruiting NCT04971434
2220 The Prevalence of Non-Alcoholic Fatty Liver Disease in Patients With an Acute Cardiac Event Followed at Ziekenhuis Oost-Limburg, Genk, Belgium Recruiting NCT05378321
2221 Liver and Metabolic Effects of Insulin Pump Therapy in a Population of Type 2 Diabetics With Non-alcoholic Hepatic Steatosis Recruiting NCT04270656
2222 A Multi-center, Randomized, Placebo-controlled Trial of S-Adenosylmethionine (SAMe) in Patients With Alcoholic Cirrhosis Recruiting NCT04250259
2223 Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease Recruiting NCT03773887
2224 Prevalence of Metabolic Liver Diseases in Patients With Type 1 Diabetes Mellitus: Non-alcoholic Fatty Liver Disease and Glycogenic Hepatopathy Recruiting NCT05054712
2225 Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis Recruiting NCT02206841
2226 MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH) Recruiting NCT04227782
2227 The Effect of Aerobic and Resistant Exercise Training on Hepatic Functions, Inflammatory Markers and Functional Capacity in Patients With Non-Alcoholic Steatohepatitis Recruiting NCT05065593
2228 Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery / Untersuchung Der Pathogenese Der Nicht-alkoholischen Steatohepatitis Und Der Leberregeneration Nach Bariatrischer Chirurgie Recruiting NCT02792634
2229 Efficacy of Silymarin in Patients With Non-alcoholic Fatty Liver Disease - The SILIVER Trial: Randomized Clinical Trial Recruiting NCT03749070
2230 Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Recruiting NCT00575133
2231 Effect of Omega-5 Fatty Acid Supplement on Markers of Inflammation and Oxidative Stress in Patients With Severe Alcoholic Hepatitis Treated With Prednisone Recruiting NCT03732586
2232 Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease (NAFLD) Recruiting NCT04132440
2233 STudy to Evaluate the Efficacy and Safety of Endoscopic Sleeve Gastroplasty (ESG) Versus LAparoscopic Sleeve Gastrectomy (LSG) in Obese Subjects With Non-Alcoholic SteatoHepatitis (NASH) Recruiting NCT04060368
2234 Progression of LIver Damage and Cardiometabolic Disorders in Non-alcoholic Fatty Liver dIsease: an Observational Cohort STUDY. The Plinio Study Recruiting NCT04036357
2235 Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease: A Pilot Randomized Controlled Trial Recruiting NCT04594954
2236 Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease Recruiting NCT04576923
2237 Diet and Meal Timing in Patients With Non-Alcoholic Fatty Liver Disease: A Pilot Study Recruiting NCT05332613
2238 Immune Cell Dysfunction in Severe Alcoholic Hepatitis Recruiting NCT02275195
2239 In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions Recruiting NCT03371641
2240 Non-Alcoholic Fatty Liver Disease Patient Registry Recruiting NCT02298439
2241 Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome" Recruiting NCT04616664
2242 Prevention of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanic Children Recruiting NCT05292352
2243 The Impact Of Choline Administration On Oxidative Stress And Clinical Outcome Of Patients With Non-Alcoholic Fatty Liver Disease NAFLD Recruiting NCT05200156
2244 A Prospective/Retrospective, Observational Follow-up Study of Chronic Hepatitis B With Non-alcoholic Fatty Liver Disease. Recruiting NCT05255978
2245 Machine Learning to Identify Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease Recruiting NCT05560997
2246 Randomised Clinical Trial on the Role of the Dentist in the Control of the Alcoholic Habit, in Elderly Patients With Potentially Malignant Oral Lesions Recruiting NCT04584333
2247 Evaluating Alcohol Use in Alcoholic Liver Disease Recruiting NCT03267069
2248 Fecal Microbiota Therapy in Steroid Ineligible Alcoholic Hepatitis: A Randomized Controlled Trial. Recruiting NCT05285592 Standard Medical Treatment
2249 Diet Intervention to Promote Liver and Brain Health in Adults With Non-alcoholic Fatty Liver Disease Recruiting NCT05216796
2250 Identification and Characterization of Non-alcoholic Fatty Liver Disease Among Risk Groups in Turkey Recruiting NCT05194553
2251 24-h-ambulatory Blood Pressure Monitoring (24-h-ABPM) and Pulse Wave Analysis (PWA) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) to Evaluate the Individual Cardiovascular Risk Profile. Recruiting NCT04543721
2252 Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement Recruiting NCT03160651 Methylprednisolone or placebo
2253 A Case-Control, Observational, Proof of Mechanism Study to Define Microbiome-Mediated Gut Dysfunction Across the Spectrum of Non-Alcoholic Fatty Liver Disease Recruiting NCT05209100
2254 Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver Disease Recruiting NCT05200585
2255 Dietary Fructose as a Mediator to Altered Liver Energy Metabolism and Oxidative Stress in Youth With Non-alcoholic Fatty Liver Disease: HELP THEM FLY. Recruiting NCT05528471
2256 Screening for NAFLD-related Advanced Fibrosis in High Risk popuLation: Optimization of the Diabetology Pathway Referral Using Combinations of Non-invAsive Biological and elastogRaphy paramEters Recruiting NCT04435054
2257 To Evaluate the Clinical Efficacy of Probiotic in Patients With NAFLD Recruiting NCT05402449
2258 Influence of Vitamins Status on Severe Obesity Related Complications Recruiting NCT02663388
2259 Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic Steatosis Recruiting NCT04907721
2260 Predicting Obesity Consequences Using Body Measure and Urine Metabolomics Recruiting NCT04989062
2261 Development of Kinetic Biomarkers of Liver Fibrosis Based on Stable Isotope Mass Spectrometry Techniques for Measuring Nonalcoholic Fatty Liver Disease NAFLD) Recruiting NCT02124577
2262 The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover Recruiting NCT04859322 Glucagon
2263 Diagnostic échographique Non-invasif Des Maladies Chroniques du Foie en Consultation d'hépatologie Recruiting NCT04782050
2264 "CAP" Fetge Gras. Lifestyle Modification Program of Nurse Management Through a Mobile Application for Patients With MFLD. Recruiting NCT04988633
2265 Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases Recruiting NCT03025074
2266 Role of Probiotics in Treatment of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Patients by Assessing With Fibroscan Recruiting NCT04671186
2267 Nonalcoholic Fatty Liver Disease: Crosstalk Between Genetic Predisposition and Epigenetic Lysosomal Acid Lipase Activity Reduction in Blood, Plasma and Platelets Recruiting NCT05419765
2268 Effectiveness of Long-term Low-frequency High-Intensity Interval Training (HIIT) to Improve Body Adiposity and Liver Fat in Adults With Central Obesity: A Randomized Controlled Trial Recruiting NCT03912272
2269 Controlled Attenuation Parameter for the Evaluation of Donor Steatosis in Living Donor Liver Transplantation Recruiting NCT02579408
2270 Copenhagen Liver Cohort Study: Disease Characteristics, Outcomes and Rehabilitation in Liver Cirrhosis - A Prospective Cohort Study Recruiting NCT04422223
2271 Treating Pediatric NAFLD With Nutrition Recruiting NCT05499585
2272 Effect of F. Prausnitzii on Glycemic Control - a Randomized, Double Blind, Placebo-controlled Study Recruiting NCT04938843
2273 Investigation of the Electrical Impedance Tomography (EIT) Effectiveness in Detecting Fatty Liver Disease Recruiting NCT05189990
2274 Study of Neutrophils and Circulating Platelets in Correlation With the Activity of T Lymphocytes in Patients With NAFLD (Nonalcoholic Fatty Liver Disease) Recruiting NCT05358496
2275 Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in Overweight Children and Adolescent With Biopsy Proven NAFLD: A Randomised Control Trial Recruiting NCT05073588
2276 Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis Recruiting NCT03985020
2277 Integrating Alcohol Myopia and Objectification to Understand Sexual Assault Recruiting NCT03956238
2278 The Effects of a Low Energy Diet Versus Low Energy Diet and Intragastric Balloon in Adults With Obesity, All in Combination With Group Treatment: a Randomized, Controlled Trial Recruiting NCT04230655
2279 Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers Recruiting NCT03308916
2280 Interest of tDCS in Help for Supporting Alcohol Abstinence Recruiting NCT03287154
2281 The Influence of Autophagy on Nonalcoholic Fatty Liver Disease Recruiting NCT01988441
2282 Fatty Acid MetabOlism in Individuals Undergoing Sulforaphane Supplementation (FAMOUS) Recruiting NCT04364360
2283 Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population Recruiting NCT04336618
2284 Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER Recruiting NCT04165343
2285 Biological Adaptations of Strength Training to Obese and Normal Weight Middle-aged Men Recruiting NCT04098484
2286 Fatty Liver Disease in Nordic Countries (FLINC): a Prospective Cohort Study Recruiting NCT04340817
2287 Assessment of Invasive Fungal Infections as a Result of Fungal Dysbiosis in Patients With Severe Alcohol-associated Hepatitis Recruiting NCT04103840
2288 Bariatric Surgery Effect Nonalcoholic Fatty Liver Disease: a Prospective Cohort Study Recruiting NCT04366999
2289 Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH): A Case-control Study Recruiting NCT04341246
2290 Liver Health and Metabolic Function in People With Obesity Recruiting NCT03701828
2291 Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk Recruiting NCT01104220
2292 Prevalence and Impact of NAFLD in Patients With Symptomatic Coronary Artery Disease Recruiting NCT03819283
2293 The Danish Childhood Obesity Biobank Recruiting NCT00928473
2294 Effects of Very Low Calorie Ketogenic Diet on Microbiota, Adipose Tissue and Immunitary Regulation: Pilot Study on Patients With Metabolic Syndrome Recruiting NCT05275608
2295 Early Vascular Ageing in the YOUth - An Observational Study Into the Predictors of Atherosclerotic Changes in Adolescents Recruiting NCT04598685
2296 Combi-elastography Assessment of Chronic Liver Disease Multi-center Study Recruiting NCT04625166
2297 Comparison of ALD, NASH, and Healthy Control Patients Recruiting NCT03224949
2298 Nonalcoholic Steatohepatitis in Chinese Children: a Long Term Follow-up Recruiting NCT03190538
2299 Effect of Probiotics or Berberine Supplementation on Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL - A Randomized Double- Blind Clinical Study. Recruiting NCT05523024
2300 Clinical Observation of the Effect of Ursodeoxycholic Acid on Parameters Affecting Liver, Metabolic and Cardiovascular Morbidity and Mortality - Pilot Project Recruiting NCT05256979
2301 Risk Prediction System for Metabolic Associated Fatty Liver Disease, a Community-based Cohort Study Recruiting NCT05546086
2302 Mechanisms of Skeletal Muscle Proteolysis With Ethanol Consumption: an Integrated Molecular Metabolic Approach Recruiting NCT03209791
2303 Moderately Carbohydrate-restricted Diet as Treatment Targeting Improvement in Hepatic Lipid and Insulin Sensitivity in Adolescents With NAFLD Recruiting NCT05268042
2304 Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 Diabetes Recruiting NCT05259475
2305 A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, FTIH Study to Investigate the Safety, Tolerability, PK and PD of ECC4703 in Healthy Volunteers and Participants With Treatment-Unnecessary LDL-C Under 160 mg/dL Recruiting NCT05552274 Early Phase 1 ECC4703;Placebo
2306 Effect of a Physical Training Program on Cerebral Hemodynamics in Patients With Metabolic-associated Fatty Liver Disease Recruiting NCT05520697
2307 The Effects of Plant Sterol and Plant Stanol Ester Enriched Foods on Liver Inflammation in Subjects at Risk to Develop NASH Recruiting NCT05037890
2308 A Cluster Randomized Trial to Determine Diagnostic and Clinical Outcomes From Enhanced SCREENing Strategies for Advanced NASH in Type 2 Diabetes (SCREEN NASH T2D) Recruiting NCT05029583
2309 Brief Training for Heavy Drinking Young Adults: Regulation of Alcohol Craving Recruiting NCT05491551
2310 Influence of Bariatric Endoscopy on Clinical Course of NAFLD Recruiting NCT04895943
2311 Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance Recruiting NCT05165706
2312 Novel MRE Technique to Assess Tissue Viscoelasticity as a Risk Factor for Liver Cancer Recruiting NCT05165446
2313 Characterization of the Platelet Inflammatory Response in NAFL and NASH Recruiting NCT05128253
2314 Nonalcoholic Fatty Liver Disease In Persons Living With HIV Database Study Recruiting NCT05023044
2315 Th17 Immune Response in Patients With COVID-19 and Nonalcoholic Fatty Liver Disease Recruiting NCT04982328
2316 Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes:A Registry and Diagnostic Cohort Study Recruiting NCT03525769
2317 Evaluating Prevalence and Severity of NAFLD In Primary Care Recruiting NCT03864510
2318 Postprandial Hepatic Fatty Acid Metabolism During Oral High-fat Mixed-meal Challenge Test in Patients With Type 2 Diabetes With and Without NAFLD Recruiting NCT05044130
2319 Nonalcoholic Fatty Liver Disease (NAFLD) Database 3 Recruiting NCT04454463
2320 The European NAFLD Registry Recruiting NCT04442334
2321 Impacts of Subsidized Ridesharing on Drunk Driving, Alcohol Consumption, and Mobility Recruiting NCT04949711
2322 Promoting Prosocial Bystander Behavior in Intoxicated Men: Evaluation of RealConsent2.0 Recruiting NCT04912492
2323 Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV Recruiting NCT04795219
2324 Formula Diet Treatment for Weight Reduction in NASH Patients. Recruiting NCT04707651
2325 Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet on Diagnostic and Prognostic Markers in Liver Disease Recruiting NCT05477212
2326 Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD Recruiting NCT05430178
2327 Prospective Multicentric, Open Label, Randomized Clinical Trial of Superiority, With Two Arms, Comparing Bariatric Surgery to the Recommended Medical Treatment for NASH Recruiting NCT03472157
2328 Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE); An FNIH Biomarkers Consortium Study: Study 1.2 Recruiting NCT05081427
2329 Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth Recruiting NCT04634643
2330 Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & Validation of Imaging Modality Performance Across the NAFLD Spectrum in a Prospectively Recruited Cohort Recruiting NCT05479721
2331 Dietary Modulation of Intestinal Microbiota as Trigger of Liver Health: Role of Bile Acids - "A Diet for Liver Health (ADLH)" Recruiting NCT03897218
2332 Influence of Bariatric Endoscopy on Clinical Course of NAFLD Recruiting NCT04669470
2333 Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus Obtained Via a Non-invasive Screening Protocol Recruiting NCT04664036
2334 Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Recruiting NCT05421572
2335 The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology Recruiting NCT05370053
2336 Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis Recruiting NCT03572465
2337 Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference Recruiting NCT04389593
2338 Iron Reduction by Phlebotomy for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease Recruiting NCT03696797
2339 Hepatic Energy Fluxes, NASH, and Vertical Sleeve Gastrectomy Recruiting NCT03997422
2340 Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis Recruiting NCT04383951
2341 PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies Recruiting NCT04371042
2342 Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1 Recruiting NCT04232566
2343 Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD) Recruiting NCT02863757
2344 Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study Recruiting NCT04306939
2345 Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study Recruiting NCT04081571
2346 Characterization and Comparison of the Human Microbiome in Peritoneum, Jejunum, Rectum and Stool Recruiting NCT04067440
2347 A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) Recruiting NCT02815891
2348 Brief ROC Training Effects on Alcohol Drinking Recruiting NCT03928626
2349 Mechanism of DCs Dysfunction in Chronic HBV Infection Recruiting NCT03753308
2350 Non-Invasive Quantification of Liver Health in NASH (N-QUAN): A Prospective Diagnostic Accuracy Study Recruiting NCT04054310
2351 Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study for Patients With Nonalcoholic Steatohepatitis Recruiting NCT04012242
2352 Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE Recruiting NCT04591106
2353 A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China Recruiting NCT04573283
2354 Intestinal Permeability in Patients With Liver Fibrosis and NASH Progression Undergoing Bariatric-metabolic Surgery Recruiting NCT05257200
2355 Copeptin and Nonalcoholic Fatty Liver Disease Recruiting NCT03254563
2356 Impact of Time-restricted Feeding on Hepatic Steatosis in NAFLD Recruiting NCT05220956
2357 The Effectiveness of Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children: A Study Protocol for a Randomized Controlled Trial Recruiting NCT05527938
2358 Nutrient Overload, Insulin Resistance, and Hepatic Mitochondrial Dysfunction Recruiting NCT03151798
2359 Effect of 12-week Intermittent Calorie Restriction on Liver Fat Content in Comparison With Standard-of-care in Patients With Nonalcoholic Fatty Liver Disease: a Randomized Controlled Trial Recruiting NCT05309642
2360 A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH) Recruiting NCT05320146
2361 Weight, Energy, Lipids, and the Liver (WELL) Study: Dietary Fat Quality and Ectopic Lipids in the Liver Recruiting NCT05199948
2362 Mechanism of Serum PRL in the Development of MAFLD Recruiting NCT05525884
2363 Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease Recruiting NCT05513729 Canagliflozin;Pioglitazone
2364 Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records. Recruiting NCT05218538
2365 Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse Active, not recruiting NCT02616094
2366 Norepinephrine Transporter Imaging in Addiction Disorders Active, not recruiting NCT01719458 (S,S)-[11C]MRB
2367 Nalmefene Hydrochloride Hydrate Tablets 10mg Specified Drug-use Results Survey (the Safety and the Prognosis After Achieving Reduced Alcohol Intake) Active, not recruiting NCT04107051 Nalmefene Hydrochloride Hydrate
2368 Individualized Assessment and Treatment for Alcoholism: Treatment and Mechanisms Active, not recruiting NCT03233802
2369 Pilot Study to Evaluate Impact and Transferability of an Alcohol Focused Harm Reduction Support System Based on Mental Health Recovery Named IACA! Active, not recruiting NCT04927455
2370 Tailored Adaptive Mobile Messaging to Reduce Problem Drinking Active, not recruiting NCT03695653
2371 Volitional Dysfunction in Self-control Failures and Addictive Behaviors Active, not recruiting NCT04498988
2372 eHealth Coping Skills Training for Women Whose Partner Has a Drinking Problem Active, not recruiting NCT02984241
2373 Emotion Regulation Interventions for Preventing Collegiate Escalations in Drinking: A Randomized Controlled Trial to Establish Acceptability, Feasibility and Preliminary Efficacy Active, not recruiting NCT04492982
2374 Pilot: Randomized Controlled Trial of an Digital Therapeutic Versus Education for the Management of Problematic Substance Use Active, not recruiting NCT04974645
2375 An Economic and Relationship-strengthening Intervention for HIV-affected Couples Who Drink Alcohol in Malawi Active, not recruiting NCT04906616
2376 Testing the Feasibility of Pragmatic Case Finding and a Supplemental Digital Intervention for Alcohol-related Health Problems in General Practice Active, not recruiting NCT04725552
2377 The Impact of Modifiable Psychosocial Factors on Veterans' Long-term Trajectories of Functioning and Quality of Life: Promoting Recovery by Targeting Mindfulness and Psychological Flexibility Active, not recruiting NCT03615222
2378 Effects of Training Combined With a Small Financial Incentive on Reducing Alcohol Consumption: Study Protocol for a Cluster-randomized Controlled Trial Active, not recruiting NCT04999371
2379 Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach Active, not recruiting NCT03980873
2380 Pilot Test of a Substance Use Treatment and Recovery Team (START) for Medical Inpatients With Opioid and Alcohol Use Disorders Active, not recruiting NCT04314648
2381 Adapting and Implementing the Blended Collaborative Care Model in CBOCs Active, not recruiting NCT02713217
2382 Community Reinforcement and Family Training (CRAFT) Active, not recruiting NCT03281057
2383 Phosphatidylethanol-Based Contingency Management to Reduce Alcohol Use and Improve Housing Outcomes Active, not recruiting NCT04038021
2384 Stress Sensitivity, Emotion Processing and Cue-reactivity: the Influence of Adverse Childhood Experiences in Substance-related Disorders Active, not recruiting NCT03758053
2385 The STUN (STop UNhealthy) Alcohol Use Now! Project: Using Practice Facilitation to Disseminate and Implement Patient-Centered Outcomes Research (PCOR) Evidence on Screening and Management of Unhealthy Alcohol Use in Primary Care Active, not recruiting NCT04317989
2386 Validation of a Computer-based Training Program for Patients With Alcohol Use Disorder Active, not recruiting NCT03765476
2387 Online Intervention to Prevent Risky Behaviors During College Student Study Abroad Experiences Active, not recruiting NCT03928067
2388 Development and Testing of a Just-in-Time Adaptive Smart Phone Intervention Active, not recruiting NCT03746808
2389 Individual Differences in the Effects of Alcohol (IDEA) Study Active, not recruiting NCT03736343 Early Phase 1 Alcohol
2390 Blended Treatment for Alcohol Use Disorder - The BLEND-A Study Evaluation of a Blended Treatment Intervention for Alcohol Use Disorder in Denmark Active, not recruiting NCT04535258
2391 Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care Active, not recruiting NCT01621711
2392 Internet-delivered Therapy for Alcohol Misuse: Engagement, Outcomes and Satisfaction When Patients Select Preference for Self-guided or Guided Treatment Active, not recruiting NCT04611854
2393 Enhancing the Efficacy and Duration of a Brief Alcohol Intervention Using Self-Affirmation Active, not recruiting NCT03247647
2394 Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure Active, not recruiting NCT02299921
2395 The Australian Parental Supply of Alcohol Longitudinal Study (APSALS) Active, not recruiting NCT02280551
2396 Developing and Evaluating a Fully Integrated Treatment Program for Comorbid Social Anxiety and Alcohol Use Disorders Active, not recruiting NCT03428490
2397 Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH Active, not recruiting NCT05357248
2398 Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota - a Randomized Controlled Clinical Trial Active, not recruiting NCT03863730
2399 In-depth Studies of Glucagon Resistance on Hepatic Glucose, Fatty Acid and Triglyceride Kinetics and Generation of Toxic Lipid Intermediates in NAFLD and NASH. Active, not recruiting NCT04042142
2400 Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease Active, not recruiting NCT04882644
2401 Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease Active, not recruiting NCT02031913
2402 Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease Active, not recruiting NCT02568605
2403 Study of Quality of Life in Patients With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT03613480
2404 A Randomized, Double - Blind Study With Two Parallel Arms for 4 Months (20 Weeks), Evaluating the Effectiveness of the Prebiotics in Patients With Non-alcoholic Liver Disease. Active, not recruiting NCT02642172
2405 Effects of Bariatric Surgery on Non-Alcoholic Steatohepatitis Active, not recruiting NCT04043585
2406 Role of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Pre and Post bAriatric Surgery Active, not recruiting NCT01856465
2407 Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD) Active, not recruiting NCT03113929
2408 Effects of High-Intensity Interval Training Exercise in Adolescents With Hepatosteatosis Active, not recruiting NCT04342390
2409 The Effect of Acute Nutritional Challenges on FGF21 Levels in Humans Active, not recruiting NCT00968747
2410 Effects of Short Term Intermittent Fasting on Insulin Resistance in Type 2 Diabetes Active, not recruiting NCT02420054
2411 Nonalcoholic Fatty Liver Disease (NAFLD), Insulin Resistance and Dyslipidemia in Adolescents and Young Adults With Polycystic Ovary Syndrome (PCOS) Active, not recruiting NCT02506946
2412 Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study Active, not recruiting NCT02344680 Anti-HIV Agents
2413 Chronic Hepatitis B Virus Infection in Zambia: a Prospective Clinical Cohort Study Active, not recruiting NCT03158818
2414 The YMCA's Diabetes Prevention Program (YMCA's DPP) for the Treatment of Nonalcoholic Fatty Liver Disease Active, not recruiting NCT03512184
2415 Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD Active, not recruiting NCT05359471
2416 Prevalence of NASH in Subjects With Different Classes of Obesity Active, not recruiting NCT04653103